

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
DP.1	005-0167-0042761 - 821
DP.2	001-0005-0001420 - 28
DP.3	WVDEP000609-12
DP.4	WVDEP Final Ammonium Perfluorooctanoate (C8) Assessment of Toxicity Team (CATT) Report, August 2002
DP.5	CATT report signature pages
DP.6	003-0230-0000062-66
DP.7	EID079096-100; RJZ009213-18
DP.8	EID951509; RJZ009907
DP.9	RJZ005098
DP.10	EID072205-6
DP.11	EID136502-5; RCG0000104-17
DP.12	EID171605-34; RK000567-96
DP.13	Shin, et al.; Supplemental Material, Retrospective Exposure Estimation and Predicted versus Observed Serum Perfluorooctanoic Acid Concentrations for Participants in the C8 Health Project.
DP.14	West Virginia Department of Environmental Protection Final Decision and Response to Comments, July 2015
D.1	EID107173-75
D.2	EID083457-61
D.3	EID510221-26
D.4	EID137839-908
D.5	EID510258
D.6	RESERVED
D.7	EID079491
D.8	EID079493
D.9	Remarks of West Virginia Department of Environmental Protection (WVDEP) Ground Water Program Manager, D. Watkins, Little Hocking Water Ass'n Meeting
D.10	266036
D.11	002-2001-0003118-20
D.12	EID072186
D.13	EID096458-59
D.14	EID080548-64
D.15	EID079096-97
D.16	EID079098-99
D.17	EID072207-12

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.18	EID137839-908
D.19	GHS005332-77
D.20	GK012123-30
D.21	RESERVED
D.22	EID079491
D.23	LUB000934-35
D.24	WVDEP000609-12
D.25	003-0030-0001706- 003-0030-0001706.0002
D.26	EID079399-418
D.27	EID079287-92
D.28	EID096449-50
D.29	EID602999-3010
D.30	EID602956
D.31	EID181068-71
D.32	EID556309
D.33	Answer to First Amended Complaint and Request for Hearing TSCA-HQ-2004-0016; RCRA-HQ-2004-0016
D.34	Order Denying Motions for Accelerated Decision on Counts II and III; Order Setting Prehearing Exchange Schedule for Counts II, III, and IV; TSCA-HQ-2004-0016, RCRA-HQ- 2004-0016, TSCA-HQ-2005-5001
D.35	Consent Agreement and Final Order; TSCA-HQ-2004-0016, RCRA-HQ-2004-0016, TSCA- HQ-2005-5001
D.36	Leach Settlement Agreement
D.37	Bilott Letter to C8 Science Panel; Re: probable link standard
D.38	Bilott Letter to C8 Science Panel; Re: clarification of 1/22/2010 letter
D.39	C8 Science Panel's Probable Link Evaluation of Cancer
D.40	The C8 Health Project: Design, Methods, and Participants; Frisbee, Stephanie J., et al.; Environmental Health Perspectives
D.41	C8 Science Panel Probable Link Evaluation of Autoimmune Disease
D.42	Ulcerative Colitis and Perfluorooctanoic Acid (PFOA) in a Highly Exposed Population of Community Residents and Workers in the Mid-Ohio Valley; Steenland, Kyle, et al.; Environmental Health Perspectives
D.43	Design, Methods, and Population for a Study of PFOA Health Effects among Highly Exposed Mid-Ohio Valley Community Residents and Workers; Winqvist, et al.; Environmental Health Perspectives

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.44-53	RESERVED
D.54	Expert Report of Graham
D.55	RESERVED
D.56	Expert Report of Robert W. Rickard, Ph.D., D.A.B.T.
D.57	Expert Report of Shane A. Snyder, Ph.D.
D.58	Expert Report of Greg P. Sykes
D.59	Expert Report of Thomas C. Voltaggio
D.60	Expert Report of Douglas L. Weed, M.D., M.P.H., Ph.D.
D.61	EID727016-23
D.62	EID584775-77
D.63	EID131837-38
D.64	EID648234
D.65	EID521404-05
D.66	EID134354
D.67	EID167955
D.68	Employee Responsible Care Team Meeting Minutes
D.69	WV Bureau for Public Health - Public Health Guidance Advice for Reducing PFOA Exposures
D.70	EID510246
D.71	EID071913-15
D.72	LUB000086-89
D.73	030-0172-0005819
D.74	EID939552-54
D.75	EID078829-31
D.76	EID076014-23
D.77	001-0005-0001407
D.78	Epidemiologic Evidence on the Health Effects of Perfluorooctanoic Acid (PFOA); Steenland, Fletcher, Savitz
D.79	EID079198
D.80	EID079200
D.81	EID072032-33
D.82	040-0073-0000879
D.83	EID078719
D.84	PJB003379
D.85	LUB000079
D.86	EID185285

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.87	CF012479-531
D.88	EID078779-80
D.89	EID556287-89
D.90	EID718858-61
D.91	EID072968
D.92	EID231520-32 3M 0001-0014
D.93	EID107145-54
D.94	EID151938-52
D.95	EID521382-83
D.96	EID151937-52
D.97-99	RESERVED
D.100	EID521393-401
D.101	EID728036-38
D.102	EID107130-32
D.103	EID096523-25
D.104	EID134605-11
D.105	003-0001-0021278
D.106	EID498316-19
D.107	EID079086
D.108	EID078091-94
D.109	EID077758
D.110	EID079090
D.111	EID079089
D.112	EID079087
D.113	EID079124
D.114	EID080168-9
D.115	EID076010
D.116	EID080172-4
D.117	EID080175-8
D.118	EID073124-9
D.119	EID081915-7
D.120	EID072698
D.121	EID080341
D.122	EID076894
D.123-135	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.136	Steenland Study on Ulcerative Colitis
D.137	EID137316
D.138	EID071797-839
D.139	EID071855
D.140	EID107196
D.141	EID080214-17
D.142	EID510227-32
D.143	EID099433-34
D.144	EID713536-40
D.145	EID079427
D.146	EID715290-91 DHP000028-30
D.147	EID584346-48
D.148	EID079177 RJZ009794
D.149	EID079439-69
D.150	EID079497
D.151	EID079219
D.152	EID079471-75
D.153	EID128130-31 AJP002924-5
D.154	EID090078-80
D.155	EID128132-36 AJP002926-30
D.156	EID079486-87 AJP002656-7
D.157	EID079585-600
D.158	EID079494-96
D.159	EID079362-63
D.160	EID079360-61
D.161	EID079547-50
D.162	EID510252-3
D.163	EID079544-46
D.164	EID079521
D.165	EID079520
D.166	060-0002-0001517-18

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.167	EID071527, EID071660-75
D.168	EID079501
D.169	EID09740-54
D.170	EID080612-13
D.171	EID079099-100
D.172	EID107350-55
D.173	EID079141-42
D.174	EID076118-19
D.175	EID477206-13
D.176	EID136635-43
D.177	EID097177-85
D.178	EID713612-13
D.179	EID079134-39
D.180	EID128096
D.181	EID943616-27
D.182	EID459511-12
D.183	EID713759-60
D.184	EID107066-71
D.185	EID928492-94
D.186	LUB001932-35
D.187	EID076922-24
D.188	EID076918-21
D.189	EID073151-52
D.190	EDD0025536-38
D.191	LUB001874-78
D.192	BEL003508
D.193	EDD0051015-17
D.194	003-0001-0025123-24
D.195	Seixas 00473-4
D.196	006-0133-0135637.0000-11
D.197	Rickard Exh 24 LHWA
D.198	EID085-0199-0005015.0014-49; EID152937-72
D.199	030-0002-0001311-20
D.200	085-0199-0005015.0012
D.201	EID718019-21
D.202	000123-137

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.203	004635-51
D.204	EID510223-26
D.205	EID510222
D.206	Exh 3 to Karrh Depo
D.207	EID107194-95
D.208	EID927292-95
D.209	EID083373-74
D.210	EID072009-13
D.211	077-2009-0003729
D.212	079-2009-0025984
D.213	EID137217-20
D.213(S)	EID089382-402
D.214	USEPA004997
D.215	EID161876
D.216	077-2009-0005441-51
D.217	USEPA004998-99
D.218	USEPA005000-01
D.219	USEPA005002-03
D.220	USEPA005006-07
D.221	USEPA005004
D.222	USEPA005005
D.223	USEPA005008-09
D.224	USEPA004996
D.225	USEPA004995
D.226	179-2009-0005854
D.227	EID184228-31
D.228	000003-21
D.229	000312-18
D.230	000001-105
D.231	LE002357-59
D.232	EID827921-23
D.233	032-2009-0000664
D.234	060-2008-0002178-87
D.235	EID775401-59
D.236	EPA TSCA Complaint
D.237	DuPont's Answer and Req to EPA TSCA Complaint

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.238	Leach Settlement Agreement
D.239-40	RESERVED
D.241	Letter from R. Bilott
D.242	Letter from R. Bilott
D.243	EID735719-37
D.244	RESERVED
D.245	EID647950-3; WVDEP000609-12
D.246	3M 1303-8
D.247	003-0030-0001706-003-0030-0001706.0002
D.248-49	RESERVED
D.250	Boothe Ex. 5
D.251	EID137839-908
D.252	EID510258-60
D.253	RESERVED
D.254	EID556287-9
D.255	EID086187-9
D.256	EID079930
D.257	RESERVED
D.258	GK(p)001386
D.259	GK(p)001376-89
D.260	EID221796-820
D.261	Rickard Exh 27 MDL
D.262	ACGIH Ammonium Perfluorooctanoate
D.263	ACGIH Adopted Appendices Appendix A: Carcinogenicity
D.264	ACGIH Statement Of Position Regarding The TLVs and BEIs
D.265	EID104752-3
D.266	EID136506-14
D.267	EID107159
D.268	EID107158
D.269	EID123183-4
D.270	EID136550-9
D.271	EID122923-8
D.272	EID072158-9
D.273	GK(p)001219-24
D.274	RESERVED
D.275	EID134607-8



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.276	EID136502-5
D.277	EID080548-55
D.278	EID521382-92
D.279	EID477126-35
D.280	EID477125
D.281	RESERVED
D.282	EID079128-33
D.283-84	RESERVED
D.285	EID924123-5
D.286	EID510279-89
D.287	EID363408-9
D.288	EID645647-65
D.289	EDD0091332-4
D.290	EID107160 RL001727
D.291	EID464011-28
D.292	Kirkland, Susan, Epidemiology - Relative And Attributable Risk <a href="http://medicine.jrank.org/pages/583/Epidemiology-Relative-attributable-risk.html">http://medicine.jrank.org/pages/583/Epidemiology-Relative-attributable-risk.html</a>
D.293	EID076003-4
D.294	EID128121
D.295	EID078834-43
D.296	EID076014-5
D.297	EID116835-8
D.298	EID073382-85
D.299	EID131837-39
D.300	EID131891
D.301	EID871517-20
D.302	002-0218-0001881-002-0218-0001881.0006
D.303	003-0001-0025156-7
D.304	109-0001-0004890
D.305	003-0001-0025161-2
D.306	061-0001-0005333-40
D.307	002-0001-0000909-12
D.308	002-0001-0009136
D.309	002-0001-0009137-8
D.310	002-0001-0009139-77

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.311	015-0002-0005874-5 WITH 021-0158-0017384-87.0002 WITH 021-0158-0017390
D.312	015-0002-0005874 OR 13062500057573
D.313	021-0158-0017384-5
D.314	021-0158-0017386
D.315	021-0158-0017387-021-0158-0017387.0002
D.316	021-0158-0017390
D.317	1.30625E+13
D.318	063-0151-0046965-7
D.319	063-0151-0046974-6
D.320	003-0001-0025119
D.321	004-0193-0002103-004-0193-0002106.0002
D.322	004-0193-0002103
D.323	004-0193-0002104-004-0193-0002104.0001
D.324	004-0193-0002106-004-0193-0002106.0002
D.325	002-0001-0000740
D.326	002-0001-0000723-5
D.327	138-0244-0000513-138-0244-0000513.0002
D.328	004-0219-0005819-004-0219-0005819.0001
D.329	004-0134-0002078-004-0134-0002078.0001
D.330	002-0131-0015506-002-0131-0015506.0024
D.331	138-0261-0000105-138-0261-0000105.0001
D.332	138-0244-0001625
D.333	EID675933-77; WVDEP 8799-845
D.334	063-0001-0005553-063-0001-0005555
D.335	002-0001-0009136-77
D.336	EID071859-60; 000212815-6; 000239859
D.337	EID107111-29
D.338	RL001743-5
D.339	EID107198-200
D.340	EID071444
D.341	EID071842
D.342	AJP001406
D.343	EID071444; EID071842; AJP001406
D.344	EID107158
D.345	EID071439-40
D.346	CHW000014-5

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.347	AJP002552-71
D.348	AVM010647
D.349	EID123321-2
D.350	EID071529
D.351	EID071528
D.352	EID071527
D.353	EID071530
D.354	DPL000215
D.355	JW000109-10
D.356	RESERVED
D.357	EID166246-7
D.358	LE 2894-8
D.359	RESERVED
D.360	EDD0037347
D.361	EID801003-28
D.362	GK007334-45
D.363	RESERVED
D.364	040-0073-0000879-82
D.365	AJP002270-1
D.366	EID076001-2
D.367	EID079654-6
D.368	EID168311-3
D.369	EID024272-5
D.370	EID109417-22
D.371	EID118964-70
D.372	EID160011-25
D.373	JJP012454
D.374-75	RESERVED
D.376	EID072207
D.377	EID556287-9
D.378	EID079930
D.379	EID221817
D.380	EID136523-30
D.381	EID123110-2
D.382	EID072027-8
D.383	EID136531-40

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.384	EID123183-4
D.385	RCG000064-73
D.386	RCG000077-83
D.387	EID072205-6
D.388	EID079034
D.389	RCG000088-93
D.390	EID136580-5
D.391	EID071913-18
D.392	EID071913-5
D.393	BLD000009-13
D.394	PJB003383
D.395	RCG000149-57
D.396	AVM000124-8
D.397	RCG000181-91
D.398	C8 Toxicity Summary
D.399	RCG000014-17
D.400-599	RESERVED
D.600	EID569993-8
D.601	EDD0051198-206
D.602	EID677724-30
D.603	EID900586
D.604	EID097177
D.605	EID943617-27
D.606	AVM010433-40
D.607	DDJ001665-6
D.608	ROWE006696-701
D.609	003-00131-0000984-1031
D.610	ACGIH 2014 TLVs and BEIs
D.610(S)	ACGIH 2011 TLVs and BEIs
D.611	EID477087
D.612	003-0001-0019742
D.613	RWR004085-130
D.614	WVDEP000609-12
D.615	AVM010342-4
D.616	006-0131-0008921-73
D.617	002-0002-0000902

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.618	EID080214-15
D.619	DDJ001695-6
D.620	002-0002-0000916; 002-0002-0000764; 002-0002-0000905-6
D.621	EID523012-21
D.622	EID523012-3
D.623	EID523009-10
D.624	EID523011
D.625	EID523012-3
D.626	EID523014
D.627	EID523015
D.628	EID523016
D.629	EID523017-21
D.630	002-0002-0000907-9
D.631	002-0002-0000903
D.632	Correspondence from J. Walrath to Y. Power
D.633	RWR000883-92
D.634	RWR000882
D.635	AJP010008-9
D.636	EID072968 EID148070
D.637	EID072968
D.638	EID148070
D.639	AJP000596-8
D.640-69	RESERVED
D.670	RL002146-61
D.671	RL003145-63
D.672	RL000133
D.673	EID079372-4
D.674	EID123084
D.675	AJP000749-50
D.676	EID163688-9
D.677	AJP000752
D.678	AJP000753
D.679	EID096510-1
D.680	016-0280-0000001-016-0280-0000001.0008
D.681	003-0001-0006259-61

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.682	RESERVED
D.683	003-0230-0000062-6
D.684	AJP003622-31
D.685	AJP002900-10
D.686	EID079740-54
D.687	RJZ005099-100 RWR000996-9
D.688	WVDEP 14300-11
D.688(S)	STB006795-806
D.689	EID128090-92
D.690	RLR002889
D.691	US Drinking Water Standards
D.692	BEL003504-7
D.693	RESERVED
D.694	EID602999-3010
D.695	EID602999-3000
D.696	RJZ009215-6
D.697	RJZ009213-8
D.698	LUB000927-8
D.699	EID076014-23
D.700	RJZ009711-2
D.701	AVM011203-6
D.702	GK000385
D.703	DDJ001690
D.704	RL001722-3
D.705	RP001239-43
D.706	RJZ009835
D.707	AJP002919-20
D.708	AJP001342-54
D.709	AJP002664-6
D.710	AJP002500-01
D.711	AJP002498-9
D.712	AJP001212
D.713	AJP001148-RJZ009011-26
D.714	AJP001148; RJZ009011-17
D.715	RJZ009018-25

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.717	RJZ009815
D.718	RL001777; EID107196
D.719	RJZ009817
D.720	RESERVED
D.721	EID099433-4
D.722	AJP002919-21; EID090078-80
D.723	040-0073-0000879-82
D.724	RJZ005098
D.725	RL001771
D.726	DDJ001689-94
D.727	DDJ001690-4
D.728	RJZ009817
D.729	AJP002597-603
D.730	AJP002612-3
D.731	AJP002609-39
D.732	EID079462-3
D.733	AJP002650-4
D.734	DDJ001720-1
D.735	DDJ001722
D.736	EID071913-5
D.737	DDJ001726
D.738	GK001642-3 FS000258-63
D.739	EID357640-2
D.740	LUB000086-9
D.741	LUB000079
D.742	EDD0051013-4
D.743	DDJ008748
D.744	002-0131-0000640-002-0131-0000640.0013
D.745	AJP002660-1
D.746	AJP002671
D.747	AVM010662-4
D.748	EID076014-23
D.749	LUB000930-1
D.750	CF009625-8
D.751	WVDHHR000018

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.752	AJP001620
D.753	CF027371
D.754	CF008987-9
D.755	EID087421-37
D.756	LUB001932
D.757	EID156469
D.758	West Virginia Department of Environmental Protection website: C-8 Investigation Reports
D.759	USEPA000087
D.760	CF016942
D.760(S)	CF016941-8
D.761	RJZ033413
D.762	CF024954
D.763	076-0154-0008986-076-0154-0008986.0007
D.764	DDJ001441-2
D.765	DDJ001758-9
D.766	DDJ001463
D.767	LUB000080-5
D.768	LUB000072-7
D.769	LUB000067-71
D.770	LUB000061-66
D.771	LUB000037-9
D.772	LUB000029-6
D.773	LUB000018-23
D.774	076-0154-0000995
D.775	DDJ007141-5
D.776	030-0172-0005614-030-0172-0005614.0009
D.777	DDJ008662-9
D.778	030-0172-0005624-030-0172-0005624.0003
D.779	DDJ009328-32
D.780	DDJ009335-41
D.781	CKC000400-1
D.782	DDJ001342-3
D.783	EID277955-8
D.784	EID278173-5
D.785	DDJ001335



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.786	DDJ001331
D.786(S)	DDJ001331-3
D.787	EID263484-6
D.788	EID263490-2
D.789	EID271668-70
D.790	EID223201-3
D.791	EDD0039670-3
D.792	DDJ008653-5
D.793	DDJ008656-7
D.794	DDJ008658-60
D.795	CKC000396-7
D.796	CKC000398-9
D.797	030-0172-0007146-030-0172-0007146.0002
D.798	030-0172-0010183-030-0172-0010183.0001
D.799	031-0149-0005271-031-0149-0005271.0002
D.800	006-0231-0001937-8
D.801	DuPont News Release: DuPont Disagrees With Science Advisory Board Draft Report on PFOA
D.802	115-0050-0000542.0003-115-0050-0000542.0004
D.803	001-0229-0000727-001-0229-0000727.0005
D.804	West Virginia Bureau for Public Health: Public Health Guidance: Advice for Reducing PFOA Exposures
D.805	AJP002634-9
D.806	AJP002655-7
D.807	Bossert depo exh. 1
D.808	006-0010-0001255.0037-006-0010-0001255.0041
D.809	Communication from K. Steenland to M. Aiello, D. Savitz and T. Fletcher
D.810	Hill Peterson website
D.811	Hill Peterson website
D.812	EID174384-7
D.813	OEPA001859-62
D.814	AJP002642-5
D.815	AJP002641-6
D.816	EID713793-801
D.817	EID769939-50
D.818	EID769958-9

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.819	002-0214-0004150-002-0214-0004150.0001
D.820	002-0131-0015399.0012
D.821	EID769969-71
D.822	EID739143-4
D.823	EID772151-2
D.824	056-0205-0002282-056-0205-0002282.0011
D.825	002-0001-0005109-11
D.826	002-0001-0011846-7
D.827	002-0131-0011455-6
D.828	002-0131-0008834-002-0131-0008834.0001
D.829	002-0001-0011493-6
D.830	054-0002-0000534-4
D.831	002-0132-0004470
D.832	002-0001-0000977-9
D.833	002-0131-0020560
D.834	002-0001-0000893-4
D.835	066-0002-0000853-4
D.836	P000028285-319
D.837	002-0001-0009602-4
D.838	002-0001-0009602
D.839	002-0001-0009603-4
D.840	002-0001-0000674
D.841	056-0147-0010350-056-0147-0010350.0004
D.842	002-0001-0011438
D.843	002-0001-0000488-510
D.844	002-0001-0000481-7
D.845	054-0001-0000228-67
D.846	054-0001-0000228
D.847	054-0001-0000229-30
D.848	054-0001-0000231-67
D.849	002-0131-0013818-20
D.850	002-0131-0008836
D.851	002-0131-0015704-8
D.852	002-0131-0002749-822
D.853	003-0029-0001549-53
D.854	022-0045-0000435-022-0045-0000435.0003

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.855	022-2001-0000103-104
D.856	003-0029-0001538-003-0029-0001538.0001
D.857	003-0029-0001556-7
D.858	004-0219-0003702-9
D.859	002-0007-0000026-002-0007-0000026.0006
D.860	023-0135-0020981-023-0135-0020981.0002
D.861	004-0219-0005819-004-0219-0005819.0001
D.862	006.0133.0141944
D.862(S)	006.0133.0141944-5
D.863	002-0132-0010301-002-0132-0010301.0078
D.864	024-0245-0011101-024-0245-0011101.0002
D.865	022-2001-0006592-936
D.866	AJP000321-439
D.867	LWB004536-44
D.868	MDA043903-29
D.869	RESERVED
D.870	EID949378
D.871	EID460310
D.872	EID941063
D.873	EID127915
D.874	EID181677
D.875	EID181911
D.876	EID127893
D.877	EID127810
D.878	EID127896-917
D.879	RJZ009220
D.880	EID079099-100
D.881	RJZ009213-4
D.882	RJZ009211
D.883	RJZ009209-10
D.884	RJZ009208
D.885	EID091388
D.886	EID091378-401
D.887	RJZ009207
D.888	JRW000015-6
D.889	RJZ009206

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.890	RJZ009205
D.891	DE000236-75
D.892	RJZ009617
D.893	EID556237-40; AJP001615-8
D.894	RJZ010002-9
D.895	GAA000016
D.896	RJZ009247
D.897	DE000245-60
D.898	DE000245-6
D.899	GLK002519-33
D.900	HLG001080
D.901	RJZ014430
D.902	RJZ014442
D.903	RLR002889-92
D.904	BSL000248-9
D.905	RJZ014952
D.906	RJZ014453-5
D.907	MDA043396
D.908	RJZ032691-6; EID185155-60
D.909	LUB000565
D.910	RJZ032702-7
D.911	RJZ032708-17
D.912	HLG001006-7
D.913	EID150345-EID150177-234
D.914	EID311919-20
D.915	JSO006827
D.916	MAK002744-53
D.917	RJZ032722
D.918	RLR002893-4; HDR002872
D.919	EID071527
D.920	EID637891; OTC006233
D.921	EID603162-74
D.922	Table 3.1 Fluoropolymer Manufacturing Processes - DuPont Washington Works Data Assessment Report
D.923	AJP002924-5
D.924	AJP002929-30

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.925	DPL000057-8
D.926	YAA000101-3
D.927	Tennant Farm Herd Health Investigation Cattle Team Report
D.928	EID079544-6
D.929	AJP002849
D.930	EID096503
D.931	EID096492
D.932	EID924547
D.933	EID924548-9
D.934	EID924546
D.935	AJP002919-21
D.936	EID090076-7
D.937	EID090078-80
D.938	EID090081-2
D.939	EID096465-72
D.940	EID131670-2
D.941	EID106181-90
D.942	EID102437
D.943	Notice of Deposition of Lubeck Public Service District representative James Cox
D.944	Lubeck Public Service District's Responses to Interrogatories in Leach
D.945	LUB007172-230
D.946	Lubeck PSD Groundwater Vulnerability (Susceptability) Assessment
D.947	LUB007852-961
D.948	LUB003579
D.949	LUB000794-5
D.950	LUB006515-6
D.951	LUB006273-5
D.952	LUB002603-13
D.953	LUB000809-17
D.954	LUB004393
D.955	LUB001553
D.956	The County Commission of Wood County, Homewood Road Water Storage Facility and Water Transmission Main
D.957	Lubeck PSD map
D.958	Lubeck PSD, Water Storage Facilities
D.959	Lubeck PSD, Boundary Line

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.960	LUB000458
D.961	LUB000518-9
D.962	LUB000459
D.963	LUB000445-53
D.964	LUB000935-49
D.965	LUB000929-31
D.966	LUB000507-8
D.967	LUB000504-6
D.968	LUB000455-7
D.969	LUB000495-7
D.970	LUB001933-40
D.971	LUB001874-6
D.972-74	RESERVED
D.975	Fluoropolymer Applications
D.976-77	RESERVED
D.978	Dervilla McCann CV
D.979	AJP002646
D.980	EID071660-75
D.981	EID097178-85
D.982	AJP001620; EID500594-605; EID147939-52
D.983	EID500594-605
D.984	EID147939-52
D.985	EID943621-7
D.986	EID107066
D.986(R)	EID107066
D.987	EID157083
D.988	EID077623-4
D.989	EID107111-29
D.990	EID080253-4
D.991	GK000378-80
D.992	EID080236-40
D.993	EID080236
D.994	EID080237
D.995	EID080238
D.996	EID080239-40
D.997	RL001770-3

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.998	Karrh depo exhibit 22
D.999	EID102508-34
D.1000	EID117451
D.1001	EID096494-5
D.1002	EID079607-12
D.1003	EID071705-6
D.1004	EID951548-49 RJZ009949-50
D.1005	EID079682-4
D.1006	EID951505-6
D.1007	EID079256-7
D.1008	EID951507-11
D.1009	EID924240-59
D.1010	EID951584-91
D.1011	DE000245-56
D.1012	EID147883-923
D.1013	Staats depo exhibit #2
D.1014	Staats depo exhibit #3
D.1015	Staats depo exhibit #4
D.1016	Staats depo exhibit #5
D.1017	EID173849-53
D.1018	EID197786-804
D.1019	EID197765-8
D.1020	WVDEP 10299
D.1021	Staats depo exhibit # 14
D.1022	Staats depo exhibit # 21
D.1023	Staats depo exhibit #23; EID152937-73; STB000315-51
D.1024	EID152937-72
D.1025	Staats depo exhibit #25
D.1026	WVDEP 11341-55
D.1027	WVDEP 11342-3
D.1028	WVDEP 11344-53
D.1029	WVDEP 11354-5
D.1030	WVDEP 11563-6
D.1031	Staats exhibit # 36
D.1032	LE 1755-89

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1033	STB004300-1, STB004315, STB004318, STB004372, STB004377, STB004382, STB004384, STB004468, STB004350, Staats exhibit #39
D.1034	ASH018117-41
D.1035	WVDEP 9892-900; Staats exhibit # 43
D.1036	EID172110-20; RLR003875-85
D.1037	EID097177-85; RAM000001-9
D.1038	DDJ007384-416
D.1039	EID166246-7
D.1040	Probable Link Report: Birth Defects
D.1041	Probable Link Report: Diabetes
D.1042	Probable Link Report: Heart Disease
D.1043	Probable Link Report: Infectious Disease
D.1044	Probable Link Report: Chronic Kidney Disease
D.1045	Probable Link Report: Liver Disease
D.1046	Probable Link Report: Miscarriage and Stillbirths
D.1047	Probable Link Report: Neurodevelopmental Disorders in Children
D.1048	Probable Link Report: Osteoarthritis
D.1049	Probable Link Report: Parkinson's Disease
D.1050	Probable Link Report: Pregnancy Induced Hypertension and Preeclampsia
D.1051	Probable Link Report: Preterm Birth and Low Birthweight
D.1052	Probable Link Report: Non-infectious Lung Disease
D.1053	Probable Link Report: Stroke
D.1054	Probable Link Report: Thyroid Disease
D.1055	EID713720-2
D.1056	Tinker, T. L. et al., Communicating Risk in a Changing World. Ch. 21 Panelist Reaction: Right to Know. Pp 159-160
D.1057	EID171605-34; RK000567-96
D.1058	John M. Flaherty Curriculum Vitae
D.1059	Michael L. Dourson Curriculum Vitae
D.1060	EID083406-7
D.1061	EID134492-500
D.1062	003-0030-0003526
D.1063	S18T Hazard Determination Process
D.1064	LE004180-2
D.1065	EID104794-839
D.1066	EID077118-20; AJP003639-41



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1067	EID951513-4
D.1068	EID128038-44
D.1069	EID477214-20
D.1070	EID477218-23; RWR001004-9
D.1071	EID128013-6; AJP000243-6
D.1072	EID079832-6
D.1073	006-0008-0000965-006-0008-0000965.0001
D.1074	006-0009-0002371-006-0009-0002371.0001
D.1075	008-0228-0001310-008-0228-0001310.0001
D.1076	EID157578-83
D.1077	EID157578
D.1078	EID157579
D.1079	EID157580-3
D.1080	EID157920
D.1081	EID157837-44
D.1082	EID157837
D.1083	EID157838-41
D.1084	EID157842-44
D.1085	EID167224
D.1086	EID222910
D.1087	EID388474-6
D.1088	EID435532-5
D.1089	EID446211
D.1090	EID158077-8
D.1091	EDD0039895-8
D.1092	EDD0039967; EID683177-8
D.1093	109-0194-0000069
D.1094	EDD0040293-4
D.1095	EDD0040293
D.1096	EDD0040294
D.1097	061-0001-0007527-8
D.1098	DDJ009092-107
D.1099	OEPA001668-9
D.1100	OEPA001675-6
D.1101	OEPA001696
D.1102	BLH000537-62

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1103	AEL000599-600
D.1104	GHS007817-9
D.1105	EID864646-7
D.1106	AEL000573
D.1107	PJB004072-3
D.1108	AEL000576-7
D.1109	AEL000574-5
D.1110	MAC002236
D.1111	024-0134-0062561-024-0134-0062561.0001
D.1112	013-0015-0002587
D.1113	013-0015-0002585; 013-0015-0002585.0001
D.1114	006-0236-0001660
D.1115	022-0044-0001294-022-0044-0001294.0003
D.1116	GKP002529-42
D.1117	GKP001219-24
D.1118	A. Hartten presentation: Water Treatment for PFOA and PFOS
D.1119	Communication from T. Samples re 2010/15 Stewardship Program Report
D.1120	Correspondence from W. Wentworth to A. Hartten re Approval of RCRA Facility Investigation Report
D.1121	Oral Teratology Study of T-2998CoC in Rats
D.1122	EID122709-91
D.1123	EID135388-437
D.1124	EID575123-33
D.1125	EID271434
D.1126	EID128151
D.1127	EID147439
D.1128	EDD0039893-4
D.1129	Water Treatment for PFOA and PFOS. Photo of GAC System for Private Well/Residential Application
D.1130	Water Treatment for PFOA and PFOS. Photo of 1.5 MGD GAC Facility
D.1131	Water Treatment for PFOA and PFOS. Photo of 1.0 MGD GAC Facility with Equilization Tank
D.1132	Water Treatment for PFOA and PFOS. Photo of 1.5 MGD GAC Facility Under Construction
D.1133	Communication from G. Kennedy to C. Auer with enclosure
D.1134	EPA Complaint (TSCA)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1135	EPA First Amended Complaint and Notice of Opportunity for Hearing (TSCA)
D.1136	EPA TSCA Consent Agreement and Final Order
D.1137	Andersen, M.E. et al., Perfluoroalkyl Acids and Related Chemistries - Toxicokinetics and Modes of Action. Toxicological Sciences 102(1), 3-14 (2008).
D.1138	Presentation by R. Rickard to US EPA: Overview of APFO/Telomer Active DuPont/DuPont-Sponsored Projects
D.1139	Correspondence from R. Rickard to C. Auer
D.1140	G. Kennedy presentation: APFO: Lactational and Transplacental Transport Study in Rats
D.1141	R. Leonard presentation: Results to Date From the PFOA Worker Study
D.1142	G. Kennedy presentation: Comparative Responses of Rats and Mice Given Oral Doses of Linear/Branched, Linear, or Branched APFO
D.1143	R. Leonard presentation: Results to Date From the PFOA Worker Study
D.1144	Presentation to Health Canada: Update PFOA Human Health and Hazard Assessment
D.1145	FDA Presentation: Developing a "Molecular Context" for the Biological Effects of PFOA
D.1146	FDA Presentation: Developing a "Molecular Context" for the Biological Effects of PFOA - Single page: Test Ligands
D.1147	EID639853-40150
D.1148	Presentation to US EPA Office of Water: Risk Assessment Approaches
D.1149	"Weight of the Evidence" Evaluation
D.1150	Geometric Mean (95%CI) Concentrations, CDC NHANES and American Red Cross Studies, 1999-2006
D.1151	Community Studies: Washington County, Minnesota
D.1152	General Distribution of PFCs in the Southeast Metro
D.1153	Median Perfluorochemical Concentrations (ng/mL) of Municipal and Well Water Users, MDH East Metro Biomonitoring Study
D.1154	Approximate Average PFOA Concentrations (ng/mL)
D.1155	Occupational Studies Pancreatic Cancer
D.1156	Occupational Studies Prostate Cancer
D.1157	Occupational Studies, Ischemic Heart Disease
D.1158	Occupational Studies (continued) Ischemic Heart Disease
D.1159	Approximate Average PFOA Concentrations (ng/mL)
D.1160	Comparison of Human PFOA Biomonitoring Data to Benchmark Lower Bound Internal Concentrations from Toxicological Study Endpoints

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1161	EID620777-833
D.1162	Data Assessment DuPont Washington Works (OPPT-2004-0113 PFOA Site Related Environmental Assessment Program)
D.1163	Environ: Screening Level Exposure Assessment for DuPont Washington Works Facility, Washington West Virginia
D.1164	EID209554-61
D.1165	Environ: Revised Final Amended Screening Level Exposure Assessment for DuPont Washington Works Facility, Washington West Virginia
D.1166	MOU Phase III - Future Work Plan Data Assessment DuPont Washington Works, Washington, West Virginia, PFOA Site Related Environmental Assessment Program (OPPT-2004-0113 PFOA)
D.1167	Information on the C-8 (PFOA) Medical Monitoring Program Screening Results Prepared by the Medical Panel for C-8 Class Members (Nov. 18, 2013)
D.1168	WVDEP Statement of Basis Washington Works
D.1169	Emerging Contaminate Fact Sheet - PFOS and PFOA
D.1170	2012 Edition of the Drinking Water Standards and Health Advisories
D.1171	EPA: The Third Unregulated Contaminant Monitoring Rule (UCMR 3): Data Summary
D.1172	EPA Press Release: DuPont Agrees to Lower Limit of PFOA in Drinking Water
D.1173	CDC FactSheet: Perfluorooctanoic Acid (PFOA)
D.1174	ECHA PFOA Report
D.1175	Commentary: Class Action Lawsuits: Can They Advance Epidemiological Research.
D.1176	Letter from D. Duncan to S. Johnson enclosing letter of intent
D.1177	Letter from T. Samples to Document Control Office with Stewardship Program Report
D.1178	External Peer Review of EPA's Draft Health Effects Documents for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)
D.1179	Preliminary Risk Assessment of the Developmental Toxicity Associated with Exposure to Perfluorooctanoic Acid and its Salts (OPPT-2003-0012-0002)
D.1180	Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perfluorooctanoic Acid and its Salts
D.1181	Provisional Health Advisories for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS)
D.1182	EPA: Health Effects Document for Perfluorooctanoic Acid (PFOA)
D.1183	Letter to S. Johnson re SAB Review of EPA's Draft Risk Assessment of Potential Health Effects Associated with PFOA and Its Salts

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1184	Response from S. Johnson re SAB Review of EPA's Draft Risk Assessment of Potential Health Effects Associated with PFOA and Its Salts
D.1185	Correspondence from G.B. van der Voet to R. Bilott
D.1186	Response from R. Bilott to G.B. van der Voet
D.1187	Maximum Exposure Guideline for Perfluorooctanoic Acid in Drinking Water. CAS Registry Number (Free Acid):335-67-1
D.1188	Minnesota Department of Health Health Risk Limits for Perfluorochemicals. Report to the Minnesota Legislature 2008
D.1189	NCSAB Recommendation Pending Review by North Carolina Division of Water Quality. Recommendation to the Division of Water Quality for an Interim Maximum Allowable Concentration for PFOA in Groundwater
D.1190	006-0131-0005841-006-0131-0005841.0043
D.1191	DuPont Sponsored Studies
D.1192	Letter from D. Boothe to Chemical Control Division regarding PCP and Phase III Work Plan
D.1193	EID080548-55
D.1194	AJP009986-7
D.1195	EID477126-35
D.1196	EID477125
D.1197	RJZ005098
D.1198	AJP000563
D.1199	RL001483-8
D.1200	EID924123-5
D.1201	EID363408-9
D.1202	EID645647-65
D.1203	AJP009997-10005
D.1204	EID151937-52
D.1205	EID510279-89
D.1206	EID123419-60
D.1207	EID104752-3
D.1208	EID160011-25
D.1209	EID727016
D.1210	EID601267
D.1211	EID134607-8
D.1212	ATSDR, Draft Toxicological Profile For Perfluoroalkyls, May 2009.
D.1213	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1214	EDD0074140-1
D.1215-16	RESERVED
D.1217	EID136506-14
D.1218	EID136523-30
D.1219	EID136531-40
D.1220	EID136550-9
D.1221	EID136574-9
D.1222	EID072158-9
D.1223	EID136580-5
D.1224	EID136627-34
D.1225	EID136635-43
D.1226	EID136667-77
D.1227	EDD0051198-206
D.1228	EID677724-30
D.1229	EID507401
D.1230	RJZ009217-8
D.1231	EID501603-6
D.1232	EID071913-5
D.1233	EID136502-5
D.1234	EID123183-4
D.1235	Minnesota Department of Health — Health Risk Limits, 2008.
D.1236	AJP001212
D.1237	EID072205-6
D.1238	EID078779-80
D.1239	EID122923-8
D.1240	EID107350-5
D.1241	EID209458-62
D.1242	EID072207-12
D.1243	AJP000243-50
D.1244	EID102749-53
D.1245	EID079930
D.1246	EID569993-8
D.1247	DuPont Risk Assessment Approaches — Presented to the U.S. EPA Department of Water, October 16, 2009.
D.1248	EID510258
D.1249	RJZ009705

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1250	EID644173-219
D.1251	Environment Canada, Health Canada — Screening Assessment, 2012.
D.1252	RESERVED
D.1253	EID718745-7
D.1254	Health Council of the Netherlands — Evaluation of carcinogenicity and genotoxicity, 2013.
D.1255	Lancet - Carcinogenicity of PFOA, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone, thelancet.com, July 11, 2014.
D.1256	Maine Center for Disease Control and Prevention — Maximum Exposure Guideline, 2014
D.1257	New Jersey Department of Environmental Protection. Guidance for PFOA in Drinking Water at Pennsgrove Water Supply Company. State of New Jersey Department of Environmental Protection, Division of Science, Research and Technology. Memorandum. <a href="http://www.nj.gov/dep/watersupply/dwc_quality_pfoa.html">http://www.nj.gov/dep/watersupply/dwc_quality_pfoa.html</a> .
D.1258	NIOSH, Letter from Elana H. Page (NIOSH) to Brian Lewis (Pace International Union), July 31, 2001
D.1259	North Carolina Science Advisory Board — Recommendation for an Interim Maximum Allowable Concentration, 2013.
D.1260	AJP002926-30
D.1261-62	RESERVED
D.1263	EID544159-61
D.1264	RESERVED
D.1265	EID556287-9
D.1266	U.S. EPA - Preliminary Risk Assessment of Developmental Toxicity, 2003.
D.1267	U.S. EPA— Draft Risk Assessment of Potential Human Health Effects, 2005.
D.1268	U.S. EPA— SAB Review of EPA's Draft Risk assessment of Potential Health Effects Associated with PFOA and its Salts (May 30, 2006).
D.1269	U.S. EPA— web page <a href="http://www.epa.gov/oppt/pfoa/pfoarisk.htm">www.epa.gov/oppt/pfoa/pfoarisk.htm</a> , accessed June 1, 2006.
D.1270	006-0133-0111757 to 006-0133-0111757.0003
D.1271	U.S. EPA— Memorandum from Christopher P. Weis, 2006.
D.1272	U.S. EPA— Memorandum - The Toxicity of PFOA and PFOS, 2009.
D.1273	U.S. EPA— Draft Health Effects Document for Perfluorooctanoic Acid (PFOA) (Draft), February 2014.
D.1274	U.S. EPA— Draft Health Effects Document for Perfluorooctane Sulfonate (PFOS) (Draft), February 2014.
D.1275	011-0002-0000143; GPK000803-11
D.1276	RESERVED

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1277	000266036
D.1278	034-0002-0004219-27
D.1279	EID127793-811
D.1280	EID071251-71
D.1281	EID127896-915
D.1282	EID949357-380
D.1283	AJP002920
D.1284	CF008987-89
D.1285	CF016692-95
D.1286	EID181866-916
D.1287	EID181657-678
D.1288	CF018634
D.1289	EID181994-182011
D.1290	CF029219
D.1291	CF036249-52
D.1292	DDJ001665-73
D.1293	EDD0029933-60
D.1294	EDD0074005-6
D.1295	EID071188-207
D.1296	EID071270
D.1297	EID072029-31
D.1298	EID072727-845
D.1299	EID079088-100
D.1300	EID079124
D.1301	EID079096-7
D.1302	EID086188-9
D.1303	EID090329-30
D.1304	EID091378-401
D.1305	EID091388
D.1306	EID099567-695
D.1307	EID099865-72
D.1308	EID099873-8
D.1309	EID103018-23
D.1310	EID109509-11
D.1311	EID109642-787
D.1312	EID124568-93



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1313	EID127793-811
D.1314	RJZ079006
D.1315	EID127896-915
D.1316	EID134486-91
D.1317	EID136026-7
D.1318	EID136033-4
D.1319	EID136970
D.1320	EID136972-5
D.1321	EID138137-58
D.1322	EID143356-7
D.1323	EID149334-90
D.1324	EID149381-96
D.1325	EID149401-11
D.1326	EID149417-29
D.1327	EID149448-58
D.1328	EID149509-50
D.1329	EID149552-604
D.1330	EID149605-25
D.1331	EID149626-739
D.1332	EID150093-285
D.1333	EID150114-26
D.1334	EID150131-47
D.1335	EID150177-234
D.1336	EID150281-6
D.1337	EID150345
D.1338	EID150407
D.1339	EID150414-5
D.1340	EID150418
D.1341	EID156383-86
D.1342	EID177167-75
D.1343	EID180799-802
D.1344	EID181657-78
D.1345	EID181885-87
D.1346	EID181866-916
D.1347	EID181994-182011
D.1348	EID185019-152

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1349	EID185155-60
D.1350	EID185166-71
D.1351	EID185172-81
D.1352	EID185434-38
D.1353	EID195208
D.1354	EID195965-68
D.1355	EID211377-834
D.1356	EID252953-253071
D.1357	EID256133-62
D.1358	EID311919-20
D.1359	EID460310
D.1360	EID500111-14
D.1361	EID514519-22
D.1362	EID525770-801
D.1363	EID525935-71
D.1364	EID541273
D.1365	EID545330
D.1366	EID545492-500
D.1367	EID545530
D.1368	EID546037-63
D.1369	EID556287-9
D.1370	EID563489-92
D.1371	EID598321-43
D.1372	EID598330-7
D.1373	EID718144-49
D.1374	EID718858-61
D.1375	EID909790-810
D.1376	EID909811-19
D.1377	EID924197-217
D.1378	EID924229-34
D.1379	EID928299-347
D.1380	EID935144
D.1381	EID935149
D.1382	EID936853
D.1383	EID936951
D.1384	EID939381-3

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1385	EID941041-66
D.1386	EID949357-80
D.1387	EID949449
D.1388	EID949490-91
D.1389	EID949493-517
D.1390	EID950228-42
D.1391	GW007544
D.1392	HLG001008-66
D.1393	JMM008139-42
D.1394	LE 00251
D.1395	LUB001874-79
D.1396	RLR002889-92
D.1397	RJZ009213-16; EID079096-99
D.1398	RJZ009215-6; EID079098-99
D.1399	RJZ009217-8; EID079099-100
D.1400	EID941041-66
D.1401-02	RESERVED
D.1403	Memo from Bower to Haskell Liaison Committee re Workplace Limits for DuPont
D.1404-06	RESERVED
D.1407	Expert Report of David L. MacIntosh, ScD, CIH in re: E. I. du Pont de Nemours & Co. C-8 Personal Injury Litigation, MDL 2433. Case No. 2:13-md-2433 (S.D. Ohio). December 8, 2014.
D.1408	RESERVED
D.1409	Letter from Laurence F. Janssen to Drs. Fletcher, Steenland, and Savitz. January 22, 2010. Re: Jack W. Leach et al. v. E. I. du Pont de Nemours and Company.
D.1410	RESERVED
D.1411	Reference Manual on Scientific Evidence. Federal Judicial Center. Washington DC: National Academies Press, 2011.
D.1412	RESERVED
D.1413	Consent Order Issued Pursuant to Articles 5 and 12, Chapter 22 and Article 1, Chapter 16 of the West Virginia Code, Order No. GWR-2001 (Nov. 14, 2001)
D.1414	EID478252-3
D.1415	National Pollutant Discharge Elimination Permit, Water Pollution Control Permit No. WV0001279 (Aug. 4, 2003)
D.1416	WVDEP, Letter from Scott G. Mandirola to David F. Altman regarding WV/NPDES Permit No. WV0001279 Wood County (12/23/2014)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1417	EID480934-481002
D.1418	EID083372-083407
D.1419	EID094265-926
D.1420	EID481623-27
D.1421	EID087421-35
D.1422	EID624915-71
D.1423	EID919853-55
D.1424	EID911312
D.1425	EID090347-730
D.1426	EID778894-937
D.1427	Letter from A. Hartten (DuPont) to W. Wentworth (EPA Region III) enclosing revised Corrective Measures Study Report
D.1428	EID128121
D.1429	EID097178-85
D.1430	EID078779-80
D.1431	EID072158-9
D.1432	EID136627-136634
D.1433	EID160011-25
D.1434	EID104752-3
D.1435	EID483641-51
D.1436	EID079427-38
D.1437	EID079493
D.1438	AVM010662-4
D.1439	EID078834-43
D.1440	EID078041-82
D.1441	EID131837-8
D.1442	EID079685-709
D.1443	EID951471
D.1443(S)	EID951469-72
D.1444	EID637891
D.1445	In the Matter of E. I. du Pont de Nemours and Company, SDWA-03-2007-019, SDWA-05-2002-0002, Order on Consent (3/7/02)
D.1446	006-0133-0012924
D.1447	006-0133-0135637
D.1448	In the Matter of E. I. du Pont de Nemours and Company, SDWA-03-2007-0039, SDWA-05-2007-0001, Order on Consent (11/17/06)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1449	001-0229-0000727
D.1450	In the Matter of E. I. du Pont de Nemours and Company, SDWA-03-200-0127, SDWA-05-2009-0001, Order on Consent (3/10/09)
D.1451	024-0263-0000010
D.1452	EPA Office of Water Provisional Health Advisory
D.1453	007-0148-0130579
D.1454	EID 080271-75
D.1455	EID 107198-200
D.1456	EID080241-46
D.1457	RESERVED
D.1458	EID122791
D.1459	EID071717
D.1460	EID108045
D.1461	CV of Dr. S. Cohen
D.1462	CV of Dr. D. Weed
D.1463	CV of S. Washburn
D.1464	CV of Dr. S. Snyder
D.1465	CV of Dr. G. Sykes
D.1466	CV of Dr. J. Graham
D.1467	CV of T. Voltaggio
D.1468	CV of Dr. S. Hanauer
D.1469	CV of Dr. R. Rickard
D.1470	ACGIH— Ammonium Perfluorooctanoate, 2001.
D.1471	RESERVED
D.1472	Sampling Precautions
D.1473	APCA - DuPont Company Experience with the CMA Air Toxics Policy
D.1474	Deposition Transcript of Steven Amter
D.1475	Amter Deposition Exh No. 1
D.1476	Amter Deposition Exh No. 2
D.1477	Amter Deposition Exh No. 3
D.1478	Amter Deposition Exh No. 4
D.1479	Amter Deposition Exh No. 5
D.1480	Amter Deposition Exh No. 6
D.1481	Amter Deposition Exh No. 7
D.1482	Amter Deposition Exh No. 8
D.1483	Amter Deposition Exh No. 9

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1484-1509	RESERVED
D.1484-1491	RESERVED
D.1492	A. Boobis, S. Cohen, V. Dellarco, et al.; Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. <i>Regulatory Toxicology and Pharmacology</i> , 82 (2016) 158-166
D.1493	A. Fredrich, K. Olenjniczak; Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009). <i>Reg. Tox. And Pharm.</i> 60; 225-248 (2011)
D.1494	S. Cohen, A. Boobis, V. Dellarco, et al.; Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. <i>Reg. Tox. And Pharm.</i> 103; 100-105 (2019)
D.1495	B. Ames, M. Profet, L. Gold; Dietary pesticides (99.99% all natural). <i>Proc. Natl. Acad. Sci. USA</i> , 87; 7777-7781 (1990)
D.1496	B. Ames, L. Gold; Chemical carcinogenesis: Too many rodent carcinogens. <i>Pro. Natl. Acad. Sci. USA</i> , 87; 7772-7776 (1990)
D.1497	B. Ames, M. Profet, L. Gold; Nature's chemicals and synthetic chemicals: Comparative toxicology. <i>Proc. Natl. Acad. Sci. USA</i> , 87; 7782-7786 (1990)
D.1498	S. Cohen; Human Carcinogenic Risk Evaluation: An Alternative Approach to the Two-Year Rodent Bioassay. <i>Toxicol. Sciences</i> , 80; 225-229 (2004)
D.1499	D. Armbruster, T. Pry; Limit of Blank, Limit of Detection and Limit of Quantitation. <i>Clin. Biochem Rev</i> , 29; 49-52 (2008)
D.1500	J. Holzer, O. Midasch, K. Rauchfuss, et al.; Biomonitoring of Perfluorinated Compounds in Children and Adults Exposed to Perfluorooctanoate-Contaminated Drinking Water. <i>Environmental Health Perspective</i> , 116(5); 651-657 (2008)
D.1501	EPA Reaches Agreement with DuPont to Protect Drinking Water Near W.Va Plant, (2006)
D.1502	Chemours Quarterly Progress Report No. 6
D.1503-D.1509	RESERVED
D.1510	Deposition Transcript of Robert W. Johnson
D.1511	Johnson Deposition Exh No. 1
D.1512	Johnson Deposition Exh No. 2
D.1513	Johnson Deposition Exh No. 3
D.1514	Johnson Deposition Exh No. 4
D.1515	Johnson Deposition Exh No. 5
D.1516	Johnson Deposition Exh No. 6
D.1517	Deposition Transcript of Barry S. Levy

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1518	Levy Deposition Exh. No. 1
D.1519	Levy Deposition Exh. No. 2
D.1520	Levy Deposition Exh. No. 3
D.1521	Levy Deposition Exh. No. 4
D.1522	Levy Deposition Exh. No. 5
D.1523	Levy Deposition Exh. No. 6
D.1524	Levy Deposition Exh. No. 7
D.1525	Levy Deposition Exh. No. 8
D.1526	Levy Deposition Exh. No. 9
D.1527	Deposition Transcript of David MacIntosh
D.1528	MacIntosh Deposition Exh. No. 1
D.1529	MacIntosh Deposition Exh. No. 2
D.1530	MacIntosh Deposition Exh. No. 3
D.1531	MacIntosh Deposition Exh. No. 4
D.1532	MacIntosh Deposition Exh. No. 5
D.1533	MacIntosh Deposition Exh. No. 6
D.1534	MacIntosh Deposition Exh. No. 7
D.1535	MacIntosh Deposition Exh. No. 8
D.1536	MacIntosh Deposition Exh. No. 9
D.1537	MacIntosh Deposition Exh. No. 10
D.1538	MacIntosh Deposition Exh. No. 11
D.1539	MacIntosh Deposition Exh. No. 12
D.1540	MacIntosh Deposition Exh. No. 13
D.1541	MacIntosh Deposition Exh. No. 14
D.1542	MacIntosh Deposition Exh. No. 15
D.1543	MacIntosh Deposition Exh. No. 16
D.1544	MacIntosh Deposition Exh. No. 17
D.1545	MacIntosh Deposition Exh. No. 18
D.1546-65	RESERVED
D.1566	Deposition Transcript of Stephen E. Petty
D.1567	Petty Deposition Exh. No. 1
D.1568	Petty Deposition Exh. No. 2
D.1569	Deposition Transcript of Michael B. Siegel
D.1570	Siegel Deposition Exh. No. 1
D.1571	Siegel Deposition Exh. No. 2
D.1572	Siegel Deposition Exh. No. 3

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1573	Siegel Deposition Exh. No. 4
D.1574	Siegel Deposition Exh. No. 5
D.1575	Siegel Deposition Exh. No. 6
D.1576	Siegel Deposition Exh. No. 7
D.1577	Siegel Deposition Exh. No. 8
D.1578	Siegel Deposition Exh. No. 9
D.1579	Siegel Deposition Exh. No. 10
D.1580	Siegel Deposition Exh. No. 11
D.1581	Siegel Deposition Exh. No. 12
D.1582	Siegel Deposition Exh. No. 13
D.1583	Siegel Deposition Exh. No. 14
D.1584	Deposition Transcript of James S. Smith
D.1585	Smith Deposition Exh. No. 1
D.1586	Smith Deposition Exh. No. 2
D.1587	Smith Deposition Exh. No. 3
D.1588	Smith Deposition Exh. No. 4
D.1589	Smith Deposition Exh. No. 5
D.1590	Smith Deposition Exh. No. 6
D.1591	Smith Deposition Exh. No. 7
D.1592	Smith Deposition Exh. No. 8
D.1593	Smith Deposition Exh. No. 9
D.1594	Smith Deposition Exh. No. 10
D.1595	Smith Deposition Exh. No. 11
D.1596	Smith Deposition Exh. No. 12
D.1597	Smith Deposition Exh. No. 13
D.1598	Smith Deposition Exh. No. 14
D.1599	Smith Deposition Exh. No. 15
D.1600	Smith Deposition Exh. No. 16
D.1601	Smith Deposition Exh. No. 17
D.1602-21	RESERVED
D.1622	LUB000072-7
D.1623	022-0049-0001532
D.1624	022-0049-0001532- 022-0049-0001532.0108
D.1625	022-0049-0001532.0084
D.1626	GK007348-65



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1627	GKP000660
D.1628	GKP000660-1
D.1629	003-0135-0001263
D.1630	109-0194-0000069
D.1631	053-0001-0010931-47
D.1632	053-0001-0010942
D.1633	Communication from D. Jackson re Employee Responsible Care Team
D.1634	LUB000078
D.1635	JHH002997
D.1636	061-0001-0007543-4
D.1637	AJP002340-1
D.1638	EID257130
D.1639	EID257130-1
D.1640	EID387202-7
D.1641	EDD0017397-8
D.1642	EID614241-2
D.1643	EID614243-5
D.1644	EID515127
D.1645	EID194385-90; CF021550-5
D.1646	EID042170; GPS000984
D.1647	EID042172-5; GPS000986-9
D.1648	EID042184-5; GPS000999-1000
D.1649	EID042282; GPS001103
D.1650	053-0215-0001017-8
D.1651	USGS Toxic Substances Hydrology Program <a href="http://toxics.usgs.gov/regional/est_errata.html">http://toxics.usgs.gov/regional/est_errata.html</a>
D.1652	Shoemaker, J.A. and Bassett, M.V. Method 535. Measurement of Chloroacetanilide and Other Acetamide Herbicide Degradates in Drinking Water By Solid Phase Extraction And Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS). EPA Document #: EPA/600/R-05/053
D.1653	Shoemaker, J.A. et al, Method 537. Determination of Selected Perfluorinated Alkyl Acids in Drinking Water By Solid Phase Extraction And Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
D.1654	Kolpin, Dana et al., Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A National Reconnaissance. Environ. Sci. Technol. 2002, 36, 1202-1211

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1655	EID112965-9; DDJ001809-13
D.1656	EDD0076050-1
D.1657	EDD0039893-8
D.1658	085-0199-0005015-085-0199-0005015.0001
D.1659	009-0139-0003404-009-0139-0003404.0002
D.1660	022-0045-0002304-022-0045-0002304.0001
D.1661	022-0047-0000577
D.1662	LH265337-8
D.1663	DuPont Haskell Global Centers for Health & Environmental Sciences. Celebrating 75 years of Excellence
D.1664	Haskell Laboratory 50 Years of Research and Service
D.1665	Danese, M. and Fiocchi, C. Ulcerative Colitis, The New England Journal of Medicine 365; 18 1713-25.
D.1666	Beynen, A.C. et al, Abstract: A Mathematical relationship between the fatty acid composition of the diet and that of the adipose tissue in man. Am. J. Clin. Nutr. Vol. 33 no. 1 81-85
D.1667	90-Day Feeding Study in Rats
D.1668	Certificate of Analysis
D.1669	USEPA Final Permit For Corrective Action Permit No. WVD 04 587 5291
D.1670	PFOA Draft Data Package Review
D.1671	Sampling Precautions
D.1672	EID159983
D.1673	EID147440-1
D.1674	EID803300-22
D.1675	EID803300-8
D.1676	EID123138-40
D.1677	EID101656-62; GK001607-13
D.1678	EID575362-81
D.1679	EID900586-704
D.1680	EID797573-87 GK012871-85
D.1681	AJCC Cancer Staging Manual
D.1682	033-0204-0001551-033-0204-0001551.0008
D.1683	EID072062-4
D.1684	EID714209-11
D.1685	EID071707

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1686	EID072053-5
D.1687	EID072058
D.1688	EID072052
D.1689	EID713821-2
D.1690	EID072168
D.1691	Color cover of Cattle Team Data Workbook
D.1692	EID150694-6
D.1693	EID194474-5
D.1694	EID042286-7
D.1695	Ohio EPA Drinking Water Standards for Ohio Public Water Systems
D.1696	EPA Health Effects for PFOS
D.1697	EPA: The Third Unregulated Contaminant Monitoring Rule (UCMR 3): Data Summary
D.1698	EID096486
D.1699	AJP002942-3
D.1700	Ollis-Stemple Deposition Exhibit No 92
D.1701	Bailey Exhibit No 1
D.1702	Bailey Exhibit No 2
D.1703	Bailey Exhibit No 3 Robinson Exhibit No 2
D.1704	Bailey Exhibit No 4 Robinson Exhibit No 3
D.1705	Bailey Exhibit No 5 Robinson Exhibit No 4
D.1706	Bailey Exhibit No 6 Robinson Exhibit No 5
D.1707	Bailey Exhibit No 7
D.1708	Bailey Exhibit No 8
D.1709	Bailey Exhibit No 9
D.1710	Robinson Exhibit No 1
D.1711	Robinson Exhibit No 6
D.1712	Robinson Exhibit No 7
D.1713	Robinson Exhibit No 8
D.1714	EID096481
D.1715	Luebker, D.J. et al., Two generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. <i>Toxicology</i> 215 (2005) 126-148

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1716	Luebker, D.J. et al., Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: Dose-respons, and biochemical and pharamcokinetic parameters. <i>Toxicology</i> 215 (2005) 149-169
D.1717	Seacat, Andrew, et al., Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. <i>Toxicological Sciences</i> 68, 249-264 (2002)
D.1718	Cook, J.C. et al., Induction of Leydig Cell Adenomas by Ammonium Perfluorooctanoate: A Possible Endocrine-Relataed Mechanism. <i>Toxicology and Applied Pharmacology</i> 113, 209-217 (1992)
D.1719	Fourth National Exposure Report, Updated Tables, Serum Perfluorooctanoic acid (PFOA) (1999-2010)
D.1720	Fourth National Exposure Report, Updated Tables, Serum Perfluorooctanoic acid (PFOA) (2011-2012)
D.1721	Correspondence form S. Stalneck to S. Johnson
D.1722	Correspondence from K. McCord to S. Johnson
D.1722(S)	Correspondence from K. McCord to S. Johnson
D.1723	Correspondence from K. McCord to S. Johnson
D.1724	Correspondence from D. Boothe to L. Jackson
D.1725	Correspondence from T. Samples to OPPT Document Control Office
D.1726	Figure 4.1 2008 Data Assessment
D.1727	EID127813-31
D.1728	EID127833-53
D.1729	EID131842-5
D.1730	EID127876-94
D.1731	Leonard Exhibit 1
D.1732	Leonard Exhibit 2
D.1733	Leonard Exhibit 4
D.1734	Leonard Exhibit 8
D.1735	Leonard Exhibit 15
D.1736	Leonard Exhibit 16
D.1737	Leonard Exhibit 18
D.1738	Leonard Exhibit 21
D.1739	Leonard Exhibit 22
D.1740	Leonard Exhibit 28
D.1741	Leonard Exhibit 31
D.1742	Leonard Exhibit 32
D.1743	Leonard Exhibit 38

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1744	Walrath Exhibit 1
D.1745	Walrath Exhibit 2
D.1746	Walrath Exhibit 3
D.1747	Walrath Exhibit 4
D.1748	Walrath Exhibit 9
D.1749	Walrath Exhibit 10
D.1750	Walrath Exhibit 15
D.1751	Walrath Exhibit 16
D.1752	Walrath Exhibit 17
D.1753	Walrath Exhibit 18
D.1754	Walrath Exhibit 21
D.1755	Walrath Exhibit 23
D.1756	Walrath Exhibit 24
D.1757	Walrath Exhibit 27
D.1758	EID769132
D.1759	Correspondence from APFO Users to S. Johnson
D.1760	Correspondence from TRP Member Companies to S. Johnson
D.1761	Future Data Needs Assessment
D.1762	European Food Safety Authority (EFSA) — Scientific Opinion on PFOS and PFOA, 2008.
D.1763	EID077871-906
D.1764	EID077871
D.1765	EID077872-3
D.1766	EID077874
D.1767	EID077875-906
D.1768	2008 West Virginia University School of Medicine. Population Results for C8 and C8 Sulfonate Plasma Concentrations
D.1769	2009 West Virginia University School of Medicine. Population Results for C8 and C8 Sulfonate Plasma Concentrations Stratified by Participant's Qualifying Water District
D.1770	Memorandum of Understanding EPA-HQ-OPPT-2004-0113-0002
D.1771	Communication from G. Kennedy to C. Auer
D.1772	Communication from G. Kennedy to C. Auer
D.1773	Communication from C. Auer to G. Kennedy
D.1774	Communication from C. Auer to G. Kennedy
D.1775	Communication from G. Kennedy to C. Auer
D.1776	Communication from G. Kennedy to C. Auer

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1777	Communication from G. Kennedy to C. Auer
D.1778	Communication from G. Kennedy to C. Auer
D.1779	Communication from R. Hefter to G. Kennedy
D.1780	Communication from G. Kennedy to OPPT
D.1781	Communication from R. Hefter to G. Kennedy
D.1782	Communication from G. Kennedy to OPPT
D.1783	MOU Phase III - Future Work Plan Data Assessment DuPont Washington Works, Washington, West Virginia, PFOA Site Related Environmental Assessment Program (OPPT-2004-0113 PFOA)
D.1784	S18T Hazard Determination Process
D.1785	S18T Hazard Determination Process
D.1786	S18T Hazard Determination Process
D.1787	S18T Hazard Determination Process
D.1788	S18T Hazard Determination Process
D.1789	Fayerweather Deposition Exhibit 1
D.1790	Fayerweather Deposition Exhibit 2
D.1791	Fayerweather Deposition Exhibit 5
D.1792	Fayerweather Deposition Exhibit 6
D.1793	Fayerweather Deposition Exhibit 7
D.1794	Fayerweather Deposition Exhibit 9
D.1795	EID102508
D.1796	Fayerweather Deposition Exhibit 16
D.1797	RESERVED
D.1798	Fayerweather Deposition Exhibit 17
D.1799	Fayerweather Deposition Exhibit 19
D.1800	Fayerweather Deposition Exhibit 20
D.1801	Fayerweather Deposition Exhibit 24
D.1802	Fayerweather Deposition Exhibit 26
D.1803	Fayerweather Deposition Exhibit 27
D.1804	Fayerweather Deposition Exhibit 31
D.1805	Fayerweather Deposition Exhibit 32
D.1806	Fayerweather Deposition Exhibit 33
D.1807	Fayerweather Deposition Exhibit 35
D.1808	Fayerweather Deposition Exhibit 40
D.1809	EID079396-98
D.1810	WVDEP1880-98

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1811	EID501021-33
D.1812	CATT report signature pages
D.1813	Letter from R. Bilott with attachments
D.1814	EID109642
D.1815	RCRA Facility Investigation Report
D.1816	Letter from R. Bilott with attachments
D.1817	Letter from R. Bilott with attachments
D.1818	WVDEP C8 Investigation reports
D.1819	WV/NPDES Permit Dry Run Landfill Report
D.1820	WV/NPDES Permit Dry Run Landfill Report
D.1821	WV/NPDES Permit Dry Run Landfill Report
D.1822	WV/NPDES Permit Dry Run Landfill Report
D.1823	WV/NPDES Permit Dry Run Landfill Report
D.1824	WV/NPDES Permit Dry Run Landfill Report
D.1825	WV/NPDES Permit Dry Run Landfill Report
D.1826	WV/NPDES Permit Dry Run Landfill Report
D.1827	WV/NPDES Permit Dry Run Landfill Report
D.1828	WV/NPDES Permit Dry Run Landfill Report
D.1829	WV/NPDES Permit Dry Run Landfill Report
D.1830	EID136627-34
D.1831	EDD0074140-47
D.1832	EID079394
D.1833	EID079396
D.1834	EID924499-501
D.1835	EID080612-3
D.1836	EID076005-6
D.1837	EID718339-40, EID076005
D.1838	EID078041-82
D.1839	EID459511-2
D.1840	EID911247-51
D.1841	EID134354
D.1842	EID134355
D.1843	EID134356-62
D.1844	EID134354-62
D.1845	EID510252-3

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1846	EID181074-6 CF018865-7
D.1847	EID170810-1
D.1848	DDJ002289
D.1849	ASH010161-4
D.1850	C-8 Blood Samples
D.1851	Work histories
D.1852	Kidney Cases 1989
D.1853	Kidney Cases 1992
D.1854	Kidney Cases 1997
D.1855	Kidney Work History 1989
D.1856	Kidney Work History 1992
D.1857	Kidney Work History 1997
D.1858	Testis Cases 1989
D.1859	Testis Cases 1992
D.1860	Testis Cases 1997
D.1861	Testis Work History 1989
D.1862	Testis Work History 1992
D.1863	Testis Work History 1997
D.1864	Orsanco Award
D.1865	Yazaki North America Award
D.1866	Yazaki North America Award 2011
D.1867	BVC Award
D.1868	Orsanco Award 2011
D.1869	EID131699-701
D.1870	EID131702
D.1871	EID037271-341
D.1872	EID078844-7
D.1873	EID076048; ATSDR 403
D.1874	EID086681-2
D.1875	SEP Completion Report
D.1876	SEP Q3 Progress Report
D.1877	Permit to Operate
D.1878	Permit to Operate 2013 Modification
D.1879	Permit to Operate December 2014 Modification
D.1880	Permit to Operate July 2014 Modification



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1881	Permit to Operate June 2014 Modification
D.1882	Permit to Operate January 2015 Modification
D.1883	EID082984-90
D.1884	Permit to Operate
D.1885	EID228021-6
D.1886	EID075666-72
D.1887	EID076235-391
D.1888	EID077782-840
D.1889	WVDEP Air Permit
D.1890	WVDEP Air Permit
D.1891	WVDEP Air Permit
D.1892	WVDEP Air Permit to Modify
D.1893	WVDEP Air Permit to Modify
D.1894	Permit to Operate
D.1895	Permit to Operate
D.1896	Newspaper article
D.1897	Newspaper article
D.1898	Newspaper article
D.1899	Newspaper article
D.1900	Newspaper article
D.1901	Newspaper article
D.1902	Newspaper article
D.1903	Newspaper article
D.1904	Newspaper article
D.1905	Newspaper article
D.1906	Newspaper article
D.1907	Newspaper article
D.1908	Newspaper article
D.1909	Newspaper article
D.1910	Program: Celebrating a Day of Purpose, People, and Peace
D.1911	Newspaper article
D.1912	Newspaper article
D.1913	Newspaper article
D.1914	Newspaper article
D.1915	EPA Docket OPPT-2004-0133
D.1916	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1917	History 1
D.1918	History 2
D.1919	History 3
D.1920	History 4
D.1921	History 5
D.1922-25	RESERVED
D.1926	EID072009-13
D.1927	EID075542-4
D.1928	EID718745-7
D.1929	EID102509-34
D.1930	EID584159-204
D.1931	EID479207
D.1932	EID134981-5
D.1933	13062500089464-72; RJZ009254-61
D.1934	EID129700-2
D.1935	EID134371
D.1936	058-0078-0000651.0004-5
D.1937	EID079356-9
D.1938	EID079372-4
D.1939	EID079310
D.1940	EID083438
D.1940(S)	EID083438-441
D.1941	EID079277-8
D.1942	EID082855-7
D.1943	EID083351-2
D.1944	EID082821
D.1945	EID083065-8
D.1946	EID082761
D.1946(S)	EID082761-774
D.1947	EID083431
D.1948	EID083475-7
D.1949	EID083024-5
D.1950	EID083342-5
D.1951	EID131868
D.1952	EID137215
D.1953	EID083363-6

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.1954	EID083368-71
D.1955	EID072034-45
D.1956	008-0018-0002252-008-0018-0002252.0014
D.1957	LUB004393
D.1958	LUB00459
D.1959	LUB001553
D.1960	S2Z The DuPont Commitment
D.1961	S18T Hazard Determination Process
D.1962	EID950228-31
D.1963	EID079095
D.1964	EID124682-90
D.1965	EID156383-6
D.1966	EDD0053978-81
D.1967	EID072182
D.1968	EID073467-525
D.1969	Leach Fairness Hearing
D.1970	EID951550-1
D.1971	EID079740
D.1972	EID072234
D.1972(S)	EID072234-5
D.1973	EID112799-830
D.1974	EID077720-3
D.1975	EID575362-81
D.1976-99	RESERVED
D.2000	Riker Experiment No. 0281CR0012, Two Year Oral (Diet) Toxicity / Carcinogenicity Study of Fluorochemical FM-3924 in Rats. Riker Laboratories, EPA Public Docket AR-226-0437, 1987
D.2001	Butenhoff et al., <i>Toxicology</i> , 298: 1-13, 2012
D.2002	Cook et al., <i>Toxicol. Appl. Pharmacol.</i> , 113: 209-217, 1992
D.2003	Klaunig et al., <i>Crit. Rev. Toxicol.</i> , 33:655-780, 2003
D.2004	Ubel et al., <i>Am. Ind. Hyg. Assoc. J.</i> , 41: 584-589, 1980
D.2005	Gilliland and Mandel, Mortality Among Employees of a Perfluorooctanoic Acid Production Plant. <i>J. Occup. Med.</i> , 35 950-954, 1993
D.2006	Olsen et al., An Epidemiologic Investigation of Reproductive Hormones in Men with Occupational Exposure to Perfluorooctanoic Acid. <i>J. Occup. Environ. Med.</i> , 40: 614-622, 1998

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2007	Lundin et al., Ammonium Perfluorooctanoate and Occupational Mortality. <i>Epidemiology</i> , 20: 921-928, Nov. 2009
D.2008	Raleigh et al., Mortality and cancer incidence in ammonium perfluorooctanoate acid production workers. <i>Occup. Environ. Med.</i> , in press, 2014 (available online)
D.2009	Leonard et al., Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. <i>Ann. Epidemiol.</i> , 18: 15-22, 2008
D.2010	Steenland and Woksie, Cohort mortality study of workers exposed to perfluorooctanoic acid. <i>Am. J. Epidemiol.</i> , 176: 909-917, 2012
D.2011	Steenland et al., <i>Occup. Environ. Med.</i> , in press, 2015
D.2012	Consonni et al., Cancer Risk Among Tetrafluoroethylene Synthesis and Polymerization Workers. <i>Am. J. Epidemiol.</i> , 178: 350-358, 2012
D.2013	Barry et al., Perfluorooctanoic acid (PFOA) and incident cancers among adults living near a chemical plant. <i>Env. Health Persp.</i> , 121: 113-1318, 2013
D.2014	VM Vieira et al., Perfluorooctanoic acid and cancer outcomes in a contaminated community: a geographic analysis. <i>Env. Health Persp.</i> , 121: 318-323, 2013
D.2015	Frisbee et al., The C-8 Health Project: Design, Methods and Participants. <i>Env. Health Persp.</i> , 117: 1873-1882, Dec. 2009
D.2016	Chang et al., <i>Crit. Rev. Toxicol.</i> , available online, 2014
D.2017	Johansson and Cohen, Epidemiology and Etiology of Bladder Cancer. <i>Sem. Surg. Oncol.</i> , 13: 291-298, 1997
D.2018	RESERVED
D.2019	RESERVED
D.2020	RESERVED
D.2021	RESERVED
D.2022	RESERVED
D.2023	RESERVED
D.2024	Ames et al., Nature's chemicals and synthetic chemicals: Comparative toxicology. <i>PNAS</i> , 87: 7782-7786, Oct. 1990
D.2025	Adams et al., Body size and renal cell cancer in a large US Cohort study. <i>Am. J. Epidemiol.</i> , 168: 268-277, 2008
D.2026	RESERVED
D.2027	RESERVED
D.2028	Dobbins et al., <i>ISRN Prev. Med.</i> , article ID 680536, 2013
D.2029	RESERVED
D.2030	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2031	RESERVED
D.2032	RESERVED
D.2033	RESERVED
D.2034	RESERVED
D.2035	Cohen and Arnold, Chemical Carcinogenesis. <i>Toxicol. Sci.</i> , 120: 76-92, 2011
D.2036	Greenfield et al., A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. <i>Carcinogenesis</i> , 5: 437-445, 1984
D.2037	Moolgavkar and Knudson, Mutation and Cancer: A Model for Human Carcinogenesis. <i>JNCI</i> , 66: 1037-1052, 1981
D.2038	Knudson, Mutation and Cancer: Statistical Study of Retinoblastoma. <i>PNAS</i> , 68: 820-823, 1971
D.2039	Tomasetti and Vogelstein, Variation in cancer risk among tissues can be explained by the number of stem cell divisions. <i>Science</i> , 347: 78-81, 2015
D.2040	Cohen and Ellwein, Cell Proliferation in Carcinogenesis. <i>Science</i> , 249: 1007-1011, 1990
D.2041	Lawlor, Study No. 17073-0-409, Mutagenicity Test with T-6342 in the Salmonella-Excherichia Coli/Mammalian-Microsome Reverse Mutation Assay. Corning Hazleton, Vienna, VA, 1995
D.2042	Sadhu, Report No. 01-7019, CHO/HGPRT Forward Mutation Assay - ISO (T-6889.7). Toxicon Corp., 2002
D.2043	Murli, Report No. 17073-0-437CO, Measuring Chromosomal Aberrations in Chinese Hamster Ovary (CHO) Cells: with a Confirmatory Assay with Multiple Harvests. Corning Hazleton, Vienna, VA, 1996
D.2044	Eriksen et al., <i>Mutat. Res.</i> , 700: 39-43, 2010
D.2045	Klaunig et al., Mode of Action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and Human Relevance. <i>Reproductive Toxicol.</i> , 33: 410-418, 2012
D.2046	Cohen, Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays: The Two-Year Bioassay Is No Longer Necessary. <i>Toxicol. Pathol.</i> , 38:487-501, 2010
D.2047	Holsapple et al., Mode of Action in Relevance of Rodent Liver Tumors to Human Cancer Risk. <i>Toxicol. Sci.</i> , 89: 51-56, 2006
D.2048	Meek et al., A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action. <i>Crit. Rev. Toxicol.</i> , 33: 591-653, 2003
D.2049	Seed et al., Overview: Using Mode of Action and Life Stage Information to Evaluate the Human Relevance of Animal Toxicity Data. <i>Crit. Rev. Toxicol.</i> , 35: 663-672, 2005

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2050	Boobis et al., IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans. <i>Crit. Rev. Toxicol.</i> , 38: 87-96, 2008
D.2051	Boobis et al., IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans. <i>Crit. Rev. Toxicol.</i> , 36: 781-792, 2006
D.2052	Simon et al., The use of mode of action information in risk assessment: Quantitative key events/dos-response framework for modeling the dose-response for key events. <i>Crit Rev Toxicol</i> 44(S3): 17-43, 2014
D.2053	Kirsch-Volders et al., Risk assessment of genotoxic mutagens with thresholds: A brief introduction. <i>Mutat. Res.</i> , 678:72-72, 2009
D.2054	Sonich-Mullin et al., IPCS Conceptual Framework for Evaluating a Mode of Action for Chemical Carcinogenesis. <i>Reg. Toxicol. Pharmacol.</i> , 34: 146-152, 2001
D.2055	Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis. IARC, Int. Agency for Research on Cancer Scientific Pubs., 147: 1-32, 1999
D.2056	Brambilla et al., Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals. <i>Mutat. Res.</i> , 750: 1-51, 2011
D.2057	Betton et al., Gastric ECL-Cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-Antagonists SK&F 93479 and Oxmetidine and Omeprazole. <i>Toxicol. Pathol.</i> , 16: 288-298, 1988
D.2058	Hakanson and Sundler, Proposed mechanism of induction of gastric carcinoids: the gastrin hypothesis. <i>Europ. J. Clin. Invest.</i> , 20(S1): 65-71, 1990
D.2059	Ames et al., Dietary pesticides (99.99% all natural). <i>PNAS</i> , 87: 7777-7781, Oct. 1990
D.2060	Ames and Gold, Chemical carcinogenesis: Too many rodent carcinogens. <i>PNAS</i> , 87: 7772-7776, Oct. 1990
D.2061	Clayson and Cooper, Cancer of the Urinary Tract. <i>Adv. Cancer Res.</i> , 13: 271-381, 1970
D.2062	Cohen et al., 4-Aminobiphenyl and DNA Reactivity: Case Study Within the Context of the 2006 IPCS Human Relevance Framework for Analysis of a Cancer Mode of Action for Humans. <i>Crit. Rev. Toxicol.</i> , 36: 803-819, 2006
D.2063	Andersen et al., Lessons Learned in Applying the U.S. EPA Proposed Cancer Guidelines to Specific Compounds. <i>Toxicol. Sci.</i> , 53: 159-172, 1999
D.2064	Chlorine Chemical Council v. EPA, Citation: 30 ELR 20473; No. No. 98-1627, 206F.3d 1286/(D.C. Cir., 03/31/2000)
D.2065	MacDonald and Halleck, The Toxicology of HMG-CoA Reductase Inhibitors: Prediction of Human Risk. <i>Toxicol. Pathol.</i> , 32(S2): 26-41, 2004
D.2066	Chiu et al., Stain Use and the Risk of Liver Cancer: A Population-Based Case-Control Study. <i>Am. J. Gastroenterol.</i> , 106: 894-898, 2011

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2067	Nielsen et al., Stain Use and Reduced Cancer-Related Mortality. <i>New Engl. J. Med.</i> , 367: 1792-1802, 2012
D.2068	Corton et al., Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) as a case study. <i>Crit. Rev. Toxicol.</i> , 44: 1-49, 2014
D.2069	Tateno et al., Chimeric Mice with Hepatocyte-humanized Liver as an Appropriate Model to Study Human Peroxisome Proliferator-activated Receptor-X. <i>Toxicol. Pathol.</i> , available on line, 2014
D.2070	Yamada et al., Human Hepatocytes Support the Hypertrophic but not the Hyperplastic Response to the Murine Nongenotoxic Hepatocarcinogen Sodium Phenobarbital in and <i>In Vivo</i> Study Using a Chimeric Mouse with Humanized Liver. <i>Toxicol. Sci.</i> , 142: 137-157, 2014
D.2071	Rosen et al., Toxicogenomic Dissentation of the Perfluorooctanoic Acid Transcript Profile in Mouse Liver: Evidence for the Involvement of Nuclear Receptors PPAR and CAR. <i>Toxicol. Sci.</i> , 103: 46-56, 2008
D.2072	Rosen et al., Gene Profiling in the Livers of Wild-type and PPAR-Null Mice Exposed to Perfluorooctanoic Acid. <i>Toxicol. Pathol.</i> , 36: 592-607, 2008
D.2073	Cheng and Klaassen, Perfluorocarboxylic Acids Induce Cytochrome P450 Enzymes in Mouse Liver through Activation of PPAR and CAR Transcription Factors. <i>Toxicol. Sci.</i> , 106: 29-36, 2008
D.2074	Elcombe et al., Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPAR and CAR/PXR. <i>Toxicology</i> , 293: 16-29, 2011
D.2075	Elcombe et al., Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. <i>Crit. Rev. Toxicol.</i> , 44: 64-82, 2014
D.2076	Phenobarbital and its Sodium Salt. IARC, Int. Agency for Research on Cancer Monographs, 79: 161-288, 2001
D.2077	Rusiecki et al., Cancer Incidence among Pesticide Applicators Exposed to Permethin in the Agricultural Health Study. <i>Env. Health Persp.</i> , 117: 581-586, Apr. 2009
D.2078	Rao and Haseman, Influence of Corn Oil and Diet on Body Weight, Survival, and Tumor Incidences in F344/N Rats. <i>Nutr. Cancer</i> , 19: 21-30, 1993
D.2079	Obourn et al., <i>Toxicol. Appl. Pharmacol.</i> , 145: 425-436, 1997
D.2080	Cook et al., <i>Crit. Rev. Toxicol.</i> , 29: 169-261, 1999



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2081	Cohen and Ellwein, Genetic Errors, Cell Proliferation and Carcinogenesis. <i>Cancer Res.</i> , 51: 6493-6505, 1991
D.2082	Brent, R.L. and Beckman, D.A., Prescribed Drugs, Therapeutic Agents, and Fetal Teratogens, in <i>Medicine of the Fetus and Mother</i> (2nd Ed.), 1999
D.2083	RESERVED
D.2084	Babkina N, Graham JM, Jr: New genetic testing in prenatal diagnosis. <i>Seminars in Fetal and Neonatal Medicine</i> , 19: 214- 219, 2014.
D.2085	Brent R.L. 2004. Environmental causes of human malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and Genetic factors. <i>Pediatrics</i> 113:957-968.
D.2086	Mortier G., Graham J.M. Jr. and Rimoin D.L.: Chapter 17: Short Stature Syndromes. In: Kelnar C. J. H., Savage M.O., Saenger P., and Cowell C.T. (Eds.), <i>Growth Disorders</i> (2nd Edition), London, UK, Hodder Arnold Press, pp 261-282, 2007.
D.2087	Graham JM Jr., Burkardt DD, and Rimoin D.L.: Chapter 38: Abnormal body size and proportion. In: Rimoin D.L., Pyeritz R.E., Korf B.R. (Eds.), <i>Emery and Rimoin's Principles and Practice of Medical Genetics</i> (6th Edition), New York NY, Churchill Livingstone, 1022-1045, 2013.
D.2088	Moh W., Graham Jr. J.M., Isha Wadhawan I, Sanchez-Lara Pa: Extrinsic factors influencing fetal deformations and intrauterine growth restriction. <i>Journal of Pregnancy</i> , 2012:750485. Epub 2012 Jul 19.
D.2089	Barton Et. Al., Charectarizing Perfluorooctanoate in Ambient Air near the Fence Line of a Manufacturing Facility: Comparing Modeled and Monitored Values. <i>Air &amp; Waste Mangement</i> 56:48-55
D.2090	Opitz J.M., Mendez H.M., Hall J.G.: Growth analysis in clinical genetics. <i>Prog Clin Biol Res</i> 200:33-63, 1985.
D.2091	Cogswell M.E., Yip R.: The influence of fetal and maternal factors on the distribution of birth weight. <i>Semin Perinatol</i> 19(3):222-240, 1995.
D.2092	Drooger J.C, Troe J.W., Borsboom G.J. et al.: Ethnic differences in prenatal growth and the association with fetal and maternal characteristics. <i>Ultrasound Obstet Gynecol</i> 26:115-122, 2005.
D.2093	Nelson K, Holmes LB: Malformations due to presumed spontaneous mutations in newborn infants. <i>N Engl J Med</i> 320:19-23, 1989.
D.2094	Winther JF, Olsen JH, Wu H, et al.: Genetic disease in the children of Danish survivors of childhood and adolescent cancer. <i>J Clin Oncol.</i> 30:27---33, 2012.
D.2095	Crow J.F. Age and sex effects on human mutation rates: an old problem with new complexities. <i>J Radiat Res.</i> 47(Suppl):B75-B82, 2006.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2096	Kong A., Frigge M.L., Masson G., et al.: Rate of de novo mutations and the importance of father's age to disease risk. <i>Nature</i> 488:471-475, 2012.
D.2097	Case M.T., York R.G., Christian M.S. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. <i>Int J Toxicol</i> 20:101-109, 2001.
D.2098	Thibodeaux J.R., Hanson R.G., Rogers J.M., et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. <i>Toxicol Sci</i> 74:369-381. Erratum in: <i>Toxicol Sci</i> 2004; 82:359, 2003.
D.2099	Butenhoff J.L., Kennedy G.L. Jr., Frame S.R., O'Connor J.C., York R.G. 2004. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. <i>Toxicology</i> 196:95-116.
D.2100	Kennedy G.L. Jr., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., et al. The toxicology of perfluorooctanoate. <i>Crit Rev Toxicol</i> 34:351-384, 2004.
D.2101	Lau C., Thibodeaux J.R., Hanson R.G., et al. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. <i>Toxicol Sci</i> 90:510-518, 2006.
D.2102	Graham J.M., Jr., Lee J.: Bosma arhinia microphthalmia syndrome. <i>American Journal of Medical Genetics</i> , 140A:189-193, 2006.
D.2103	Stein CR, Savitz DA, Bellinger DC: Perfluorooctanoate exposure in a highly exposed community and parent and teacher reports of behavior in 6-12-year-old children. <i>Paediatr Perinat Epidemiol.</i> 28:146-156, 2014.
D.2104	Darrow LA, Howards PP, Winquist A, Steenland K: PFOA and PFOS serum levels and miscarriage risk. <i>Epidemiology.</i> 25: 505-512, 2014.
D.2105	Savitz DA, Stein CR, Bartell SM, et al.: Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. <i>Epidemiology.</i> 23:386-892, 2012a.
D.2106	Savitz DA, Stein CR, Elston B, et al.: Relationship of perfluorooctanoic acid exposure to pregnancy outcome based on birth records in the mid-Ohio Valley. <i>Environ Health Perspect.</i> 120:1201-1207, 2012b.
D.2107	Nolan LA, Nolan JM, Shofer FS, et al.: The relationship between birth weight gestational age and perfluorooctanoic acid (PFOA)-contaminated public drinking water. <i>Reprod Toxicol.</i> 27:231-238, 2009.
D.2108	Nolan LA, Nolan JM, Shofer FS, et al.: Congenital anomalies, labor/delivery complications, maternal risk factors and their relationship with perfluorooctanoic acid (PFOA)-contaminated public drinking water. <i>Reprod Toxicol.</i> 29:147-155, 2010.
D.2109	Stein CR, Savitz DA, Dougan M: Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. <i>Am J Epidemiol.</i> 170:837-846, 2009.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2110	Stein CR, Savitz DA: Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age. <i>Environ Health Perspect.</i> 119:1466-1471, 2011.
D.2111	Stein CR, Savitz DA, Bellinger DC: Perfluorooctanoate and neuropsychological outcomes in children. <i>Epidemiology.</i> 24:590-599, 2013.
D.2112	Stein CR, Savitz DA, Elston B, et al.: Perfluorooctanoate exposure and major birth defects. <i>Reprod Toxicol.</i> 47:15-20, 2014.
D.2113	Lau C., Thibodeaux J.R., Hanson R.G., et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings, <i>Toxicological Sci.</i> 2, 366-394 (2007)
D.2114	Grice M.M., Alexander B.H., Hoffbeck R., and Kampa D.M: Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. <i>Journal of Occupational and Environmental Medicine</i> 49:722-729, 2007.
D.2115	Olsen G.W., Burlew MM, Marshall JC, et al.: Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facility. <i>Journal of Occupational and Environmental Medicine</i> 46:837-846, 2004.
D.2116	Fei, C., McLaughlin K., Tarone R.E., Olsen J.: Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort, <i>Envtl. Health Perspectives</i> 41:1677-1682, 2007.
D.2117	Monroy R., Morrion K., Teo K., et al.: Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. <i>Environ Res.</i> 108:56-62, 2008.
D.2118	Washino N, Saijo Y, Sasaki S, et al.: Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. <i>Environ Health Perspect.</i> 117:660--667, 2009.
D.2119	Chen MH, Ha EH, Wen TW, et al.: Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. <i>PLoS One.</i> 7:e42474, 2012.
D.2120	Fei, C., McLaughlin K., Tarone R.E., Olsen J.: Fetal growth indicators and perfluorinated chemicals: a study within the Danish National Birth Cohort, <i>Am J Epidemiol.</i> 168:66-72, 2008.
D.2121	Andersen CS, Fei C, Gamborg M, et al.: Prenatal exposures to perfluorinated chemicals and anthropometry at 7 years of age. <i>Am J Epidemiol.</i> 178:921-927, 2013.
D.2122	Frisbee SJ, Brooks AP, Maher A et al.: The C8 Health Project: design, methods, and participants. <i>Environ Health Perspect</i> 117:1873-1882, 2009.
D.2123	Abbott B.D., Wolf C.J., Schmid J.E. et al., Perfluorooctanoic acid-induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferators-activated receptor-alpha. <i>Toxicological Sciences</i> 98:571-581, 2007.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2124	RESERVED
D.2125	RESERVED
D.2126	Woskie, S.R., et al. 2012. Retrospective Exposure Assessment of Perfluorooctanoic Acid Serum Concentrations at a Fluoropolymer Manufacturing Plant. <i>Ann. Occup. Hyg.</i> 56(9): 1025–1037
D.2127	Bartell, S., et al. 2010. Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia. 118.2:222-228. February.
D.2128	Bartell, S., et al. 2010. Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia. 118.2:222-228. February.
D.2129	Costa, G.C., et al. 2009. Thirty Years of Medical Surveillance in Perfluorooctanoic Acid Production Workers. <i>Journal of Occupational and Environmental Medicine.</i> 51(3): 1-9.
D.2130	Olsen, G.W., et al. 2003c. An Occupational Exposure Assessment of a Perfluorooctanesulfonyl Fluoride Production Site: Biomonitoring. <i>AIHA Journal.</i> 64:651-659.
D.2131	Olsen, G.W. and Zobel, L.R. 2007. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. <i>Int. Arch. Occup. Environ. Health.</i> 81(2):231-246.
D.2132	Calafat, A.M., et al. 2007b. Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and Comparisons with NHANES 1999-2000. <i>Environmental Health Perspectives.</i> 115(11):1596-1602.
D.2133	Olsen, G.W., et al. 2008. Decline in Perfluorooctanesulfonate and Other Polyfluoroalkyl Chemicals in American Red Cross Adult Blood Donors, 2000 – 2006. <i>Environmental Science and Technology.</i> 42(13): 4989-4995.
D.2134	Olsen, G.W., et al. 2003b . Perfluorooctanesulfonate and Other Fluorochemicals in the Serum of American Red Cross Adult Blood Donors. <i>Environmental Health Perspectives.</i> 111(16):1892-1901.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2135	Calafat, A.M., et al. 2007a. Serum Concentrations of 11 Polyfluoroalkyl Compounds in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. <i>Environ. Sci. Technol.</i> 41:2237-2242.
D.2136	Emmett, E.A., et al. 2006. Community Exposure to Perfluorooctanoate: Relationships between Serum Concentrations and Exposure Sources. <i>J. Occup. Environ. Med.</i> 48(8):759-779.
D.2137	West Virginia University School of Medicine. 2008. Population Results for C8 and C8 Sulfonate Plasma Concentrations Stratified by Participant's Qualifying Water District. <a href="http://www.hsc.wvu.edu/ResOff/C8/Home">http://www.hsc.wvu.edu/ResOff/C8/Home</a>
D.2138	Steenland, K., et al. 2009. Predictors of PFOA Levels in a Community Surrounding a Chemical Plant. 117.7:1083-1088. July.
D.2139	Olsen, G.W., et al. 2007a. Half-Life of Serum Elimination of Perfluorooctanesulfonate, Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers. <i>Environmental Health Perspectives.</i> 115(9):1298-1305.
D.2140	Shin et al. 2011b. Shin, H., et al. 2011. Retrospective Exposure Estimation and Predicted versus Observed Serum Perfluorooctanoic Acid Concentrations for Participants in the C8 Health Project. 119.12:1760-1765. December.
D.2141	Shin et al. 2014. Biomarker-Based Calibration of Retrospective Exposure Predictions of Perfluorooctanoic Acid. <i>Environmental Science and Technology</i> 48(10): 5636-5642.
D.2142	Shin et al. 2011a. Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works facility in West Virginia. <i>Environmental Science and Technology</i> 45(4):1435-1442.
D.2143	RESERVED
D.2144	Biegel, L.B., Liu, R.C.M., Hurtt, M.E., Cook, J.C., Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. <i>Toxicol Appl Pharmacol</i> 134:18-25:1995.
D.2145	Biegel, L. B., Hurtt, M. E., Frame, S. R., O'Connor, J. C., Cook, J.C.. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male rats. <i>Toxicol Sci</i> 60:44-55:2001.
D.2146	Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G. Lieder, P., Olsen, G., Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. <i>Toxicol Sci</i> 69:244-257:2002.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2147	Butenhoff, J.L., Kennedy, G.L.Jr., Frame, S.R., O'Connor, J.C., York, R.G., The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. <i>Toxicology</i> 196:95-116:2004.
D.2148	Butenhoff, J.L., Gaylor, D.W., Moore, J.A., Olsen, G.W., Rodricks, J., Mandel, J.H., Zobel, L.R., Characterization of risk for general population exposure to perfluorooctanoate. <i>Reg. Toxicol. Pharmacology</i> 39:363-380:2004.
D.2149	Butenhoff, J.L., Kennedy, G.L., Jung, R., Chang, S-C., Evaluation of perfluorooctanoate for potential geotoxicity. <i>Toxicol Reports</i> 1:252-270:2014.
D.2150	RESERVED
D.2151	RESERVED
D.2152	Corsini, E., Sangiovanni, E., Avagadro, A., Galbiati, V., Viviani, B., Marinovich, M., Galli, C.L., Dell'Agli, M., Germolec, D.R., In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). <i>Toxicol Appl Pharmacol</i> 258:2448-255:2011.
D.2153	David, R.M., Moore, M.R., Finney, D.C., Guest, D., Chronic toxicity of di(2-ethylhexyl)phthalate in rats. <i>Toxicol Sci</i> 55:433-443:2000.
D.2154	DeWitt, J.C., Peden-Adams, M.M., Keller, J.M., Gerolec, D.R., Immunotoxicity of perfluorinated compounds: recent developments. <i>Toxicol. Pathology</i> 40:300-311:2012.
D.2155	Elcombe, C.R., Wolf, C.R., and Westwood, A.L. (15 August 2011) International Patent No. WO 2011/101643 A1. World International Patent Organization.
D.2156	Endo, O., Ohkubo, M., Tsunoda, Watanabe, I., Yamashita, N., Mutagenicity of perfluorooctane sulfonate (PFOS) and related compounds (abstract TOX005) in FLUOROS Conference, Toronto, August 19-20, 2005. <a href="http://www.chem.utoronto.ca/symposium/fluoros/Fluorosabstractbook.pdf">http://www.chem.utoronto.ca/symposium/fluoros/Fluorosabstractbook.pdf</a> . 2005.
D.2157	Florentin, A., Deblonde T., Diguio, N., Hautemaniere, A., Hartemann, P., Impacts of two perfluorinated compounds (PFOS and PFOA) on human hepatoma cells: cytotoxicity but no genotoxicity? <i>Intern J Hyg Environ Health</i> 214:493-499:2011.
D.2158	Freire, F.P.F., Martin, P.J.M., Herrero, O., Peropadre, A., de la Pena, E., Hazen, M.J., In vitro assessment of the cytotoxic and mutagenic potential of perfluorooctanoic acid. <i>Toxicol In Vitro</i> 22:1228-1233:2008.
D.2159	Griffith, F.D., Long, J.E., Animal toxicity studies with ammonium perfluorooctanoate (APFO). <i>Am Ind Hyg Assoc J.</i> 41:576-583:1980.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2160	Grunewald,D.A., Hess,D.L., Wilkinson,C.W., Matsumoto,A.M., Excessive testicular progesterone secretion in aged male Fischer 344 rats: a potential cause of age-related gonadotropin suppression and confounding variable in aging studies. J Genontol 47:164-170:1992.
D.2161	Han,X., Snow,T.A., Kemper,R.A., Jepson,G.W., Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem Res Toxicol 16:775-781:2003.
D.2162	Han,X., Nabb,D.L., Russell,M.H., Kennedy,G.L.Jr.,Rickard,R.W., Renal elimination of perfluorocarboxylates (PFCAs). Chem Res Tox 25:35-46:2012.
D.2163	Hardisty,J. F., Willson,G. A., Brown,W.R., McConnell,E. E., Frame,S. R., Gaylor,D.W., Kennedy,G.L., Butenhoff,J. L., Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem Toxicol 33:131-137:2010.
D.2164	Holzer,J., Goen,T., Rauchfuss,K., Kraft,M., Angerer,J., Kleeschulte,P., Wilhelm,M., One-year follow-up of perfluorinated compounds in plasma of German residents from Arneberg formerly exposed to PFOA-contaminated drinking water. Int. J. Hyg. Environ. Health 212:494-505:2009.
D.2165	Hu,X.Z., Hu,D.C., Effects of perfluorooctanoate and perfluorooctane sulfonate exposure on hepatoma Hep G2 cells. Arch Toxicol 83:851-861:2009.
D.2166	Jacquet,N., Maire,M.A., Rast,C., Bonnard,M., Vasseur,P., Perfluorooctanoic acid (PFOA) acts as a tumor promotor on Syrian hamster embryo (SHE) cells. Environ Sci Pollut Res Int 19:2537-2549:2012.
D.2167	Kato, K., Wong, L-Y, Jia, L.T., Kuklenyik, Z, Calafat, A.M., Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ. Sci. Technology 45:8037-8045:2011.
D.2168	Kawashima,Y., Kobayashi,H., Miura,H., Kozuka,H., Characterization of hepatic response of rats to administration of perfluorooctanoic acid and perfluorodecanoic acid at low levels. Toxicol 99:169-178:1995.
D.2169	Kennedy,G.L.Jr., Hall,C.T., Brittelli,M.R., Barnes,J.R., Chen,H.C., Inhalation toxicology of ammonium perfluorooctanoate. Food Chem Toxicol 24:1325-1329:1986.
D.2170	Liu,R.C., Hahn,C., Hurtt,M.E. The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro., Fundam Appl Toxicol 30:102-108:1996.
D.2171	Loccisano,A.E., Campbell,J.L.Jr., Andersen,M.E., Clewell,H.J.III., Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol 59:157-175:2011.
D.2172	RESERVED



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2173	Longnecker,D.S., Interface between adaptive and neoplastic growth in the pancreas. Gut 28:253-258:1987.
D.2174	Longnecker,D.S., Sumi,C., Effects of sex hormones on pancreatic cancer in the rat. Intern J Pancreatol 7:159-165:1990.
D.2175	Loveless,S.E, Hoban,D., Sykes,G., Frame,S.R., Everds,N.E. Evaluation of the immune system in rats and mice administered linear ammonium perfluorooctanoate. Toxicol Sci 105:86-96:2008.
D.2176	Mac Pherson,J.R., Bissett,D., Petty,R.D., Tait,B., Samuel,L.M., MacDonald,J., Smith,M., Birse-Archbold,J.A., Barnett,A.L., Wolf,C.R., Elcombe,C.R., Jeynes-Ellis,A., Evans,T.R.J., A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. J Clin Oncol 29:suppl abstr 3063:2011.
D.2177	Malley,L.A., Carakostas,M., Hansen,J.F., Rusch,G.M., Kelly,D.P., Trochimowicz,H.J., Two-year inhalation toxicity study in rats with hydrochlorofluorocarbon 123, Fundam Appl Toxicol 25:101-114:1995.
D.2178	Maloney,E.K., Waxman,D.J., Transactivation of PPAR $\alpha$ and PPAR $\gamma$ by structurally diverse chemicals. Toxicol Appl Pharmacol 161:2009-218:1999.
D.2179	Oda,Y., Nakayama,S., Harada,K., Koizumi,A., Negative results of umu genotoxicity test of fluorotelomer alcohols and perfluoroalkyl acids. Environ Health Prev Med 12:217-219:2007.
D.2180	Olsen,G.W., Church,T.R., Larson,E.B., van Belle, G., Lundberg,J.K., Hansen,K.J., Burris,J.M., Mandel,J.H., Zobel,L.R., Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere 54:1599-1611:2004.
D.2181	Olsen,G.W., Huang,H-Y, Helzesouer,K.J., Hansen,K.J., Butenhoff,J.L., Mandel,J.H., Historical comparison of perfluorooctanesulfonate, perfluorooctanoate and other fluorochemicals in human blood. Environ Health Perspectives 113:539-545:2005.
D.2182	Pastoor,T.P., Lee,K.P., Perri,M.A., Gillies,P.J., Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exper Molec Pathol 47:98-109:1987.
D.2183	Perkins.,R.G., Butenhoff,J.L., Kennedy,G.L.Jr., Palazzolo,M.J., 13-week toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem Toxicol 27:361-378:2004.
D.2184	Peters,J.M., Gonzales,F.J. Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. Chem Res Toxicol 24:1601-1609:2011.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2185	Rosen,M.B., Tribodeaux,J.R., Wood,C.R., Zehr,R.D., Schmid,J.E., Lau,C., Gene expression profiling in the lung and liver of PFOA-exposed mouse fetuses. <i>Toxicology</i> 239:15-33:2007.
D.2186	Sakr,C.J., Kreckmann,K.H., Green,J.W., Gillies,P.J., Reynolds,J.L., Leonard,R.C., Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or PFOA) as part of a general health survey in a cohort of occupationally exposed workers., <i>J. Occup. Environ. Med.</i> 49:1086-1096:2007.
D.2187	Scialli,A.R., Iannucci,A., Turim,J. Combining perfluoroalkane acid exposure levels for risk assessment. <i>Regul Toxicol Pharmacol</i> 49:195-202:2007.
D.2188	Svoboda,D.J., Azarnoff,D.L., Tumors in male rats fed ethylchlorophenoxyisobutyrate, a hypolipidemic drug. <i>Cancer Res</i> 39:3419-3428:1979.
D.2189	Tardiff, R.G., Carson, M.L., Sweeney, L.M., Kirman, C.R., Tan, Y., Andersen, M. Bevan, C., Gargas, M.L. Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound, <i>Food and Chemical Toxicology</i> , Volume 47, Issue 10, October 2009,
D.2190	Lancet on behalf of the International Agency for Research on Cancer Monograph Working Group, <a href="http://thelancet.com/oncology">thelancet.com/oncology</a> , July 11, 2014
D.2191	Vanden Heuvel,J.P., Thompson,J.T., Frame,S.R., Gillies,P.J., Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor- $\alpha$ , $\beta$ , and $\gamma$ , liver X receptor- $\beta$ , and retinoid X receptor- $\alpha$ . <i>Toxicol Sci</i> 92:476-489:2006.
D.2192	Voss,C., Zerban,H., Bannasch,P., Berger,M.R. ,Lifelong exposure to di(2-ethylhexyl)phthalate induces tumors in liver and testes of Sprague-Dawley rats. <i>Toxicology</i> 206:359-371:2005.
D.2193	Wu,L.-L., Gao,H.-W., Gao,N.-Y., Chen,F.-F., Chen,L., Interaction of perfluorooctanoic acid with human serum albumin. <i>BMC Struct Biol</i> 9:31-8:2009.
D.2194	Yang,Q, Xie,Y., DiPierre,J.W., Effects of peroxisome proliferators on the thymus and spleen of mice. <i>Exp Immunol</i> 122:219-226:2000.
D.2195	Yang,Q., Xie,Y., Ericksson,A.M., Nelson,B.D., DiPierre,J.W., Further evidence for the involvement of inhibitors of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluorooctanoic acid in mice. <i>Biochem Pharmacol</i> 62:1133-1140:2001.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2196	Yang,Q., Abedi-Valuggerdi,M., Zie,Y., Zhao,X., Moller,G., Nelson,B.D., DiPierre,J.W., Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. <i>Int Immunopharmacol</i> 2:389-397:2002
D.2197	Yao.X., Zhong,L., Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. <i>Mutat Res</i> 587:38-44:2005.
D.2198	York,R.G., Kennedy,G.L.Jr., Olsen,G.W., Butenhoff,J.L., Male reproductive system parameters in a two-generation study of ammonium perfluorooctanoate in rats and human relevance. <i>Toxicology</i> 271:64-72:2010.2010.
D.2199	Alexander DD, Weed DL, Mink PJ, et al. A weight-of-evidence review of epidemiologic studies of colorectal cancer in pesticide applicators. <i>Int Arch Occup Environ Health</i> 2012;85:715-45.
D.2200	Alexander DD, Weed DL, Chang ET, et al. A systematic review of multivitamin-multimineral use and cardiovascular disease and cancer incidence and total mortality. <i>J Amer Coll Nutr</i> 2013;32:339-54.
D.2201	Althuis MD, Weed DL, Frankenfeld CL. Evidence-based mapping of design heterogeneity prior to meta-analysis: a systematic review and evidence synthesis. <i>Systematic Reviews</i> 2014;3:80.
D.2202	American College of Epidemiology Ethics Guidelines. <i>Ann Epidemiol</i> 2000;10:487-97.
D.2203	Aschengrau A, Seage GR. Bias. Chapter 10 in: <i>Essentials of Epidemiology in Public Health</i> . Sudbury, MA:Jones and Bartlett, 2003;251-79.
D.2204	Aschengrau A, Seage GR. Confounding. Chapter 11 in: <i>Essentials of Epidemiology in Public Health</i> . Sudbury, MA:Jones and Bartlett, 2003;281-98.
D.2205	Aschengrau A, Seage GR. The Epidemiologic Approach to Causation. Chapter 15 in: <i>Essentials of Epidemiology in Public Health</i> . Sudbury, MA:Jones and Bartlett, 2003;375-401.
D.2206	Beaglehole R, Bonita R, Kjellstrom T. Causation in Epidemiology. Chapter 5 in: <i>Basic Epidemiology</i> . Geneva:World Health Organization, 1993;71-81.
D.2207	Bhandari M, Deverequeux PJ, Montori V, et al. Users' guide to the surgical literature: how to use a systematic literature review and meta-analysis. <i>J Can Chir</i> 2004;47:60-7.
D.2208	Bhopal R. Cause and effect: The epidemiological approach. Chapter 5 in: <i>Concepts of Epidemiology</i> . New York:Oxford University Press, 2002;98-132.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2209	Boffetta P, McLaughlin JK, La Vecchia C, et al. False-positive results in cancer epidemiology: a plea for epistemological modesty. <i>J Natl Cancer Inst</i> 2008;100:988-95.
D.2210	Bramwell VHC, Williams CJ. Do authors of review articles use systematic methods to identify, assess, and synthesize information? <i>Ann Oncol</i> 1997;8:1185-95.
D.2211	Breslow RA, Ross SA, Weed DL. Quality of reviews in epidemiology. <i>Am J Pub Health</i> 1998;88(3):475-7.
D.2212	Checkoway C, Pearce N, Kriebel D. Overview of study designs. Chapter 3 in: <i>Research Methods in Occupational Epidemiology</i> . 2nd Ed. Oxford:University Press, 2004;59-81.
D.2213	Cogliano VJ, Baan RA, Straif K, et al. The science and practice of carcinogen identification and evaluation. <i>Environ Health Perspect</i> 2004;112:1269-74.
D.2214	Crowther MA, Cook DJ. Trials and tribulations of systematic reviews and meta-analyses. <i>Hematology</i> 2007;493-7.
D.2215	Crystal S, Akincigil A, Bilder S, et al. Study prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. <i>Med Care</i> 2007;45:s58-s65.
D.2216	Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. <i>J Epidemiol Commun Health</i> 1998;52:377-84.
D.2217	Dufault B and Klar N. The quality of modern cross-sectional ecologic studies: a bibliometric review. <i>Am J Epidemiol</i> 2011;174:1101-7.
D.2218	Goldman SA. Limitations and strengths of spontaneous reports data. <i>Clin Ther</i> 1998;20:C40-C44.
D.2219	Goodman SN. Introduction to Bayesian methods. I: Measuring the strength of evidence. <i>Clin Trials</i> 2005;2:282-90.
D.2220	Goodman SN, Samet JM. Cause and Cancer Epidemiology. In: Schottenfeld D, Fraumeni JF. (eds). <i>Cancer Epidemiology and Prevention</i> . New York:Oxford, 2006, 3-9.
D.2221	Gordis L. From Association to Causation: Deriving Inferences from Epidemiologic Studies. Chapter 13 in: <i>Epidemiology</i> , 2nd ed. Philadelphia:W.B. Saunders, 2000;184-203.
D.2222	Gray-Donald K, Kramer MS. Causality inference in observational vs. experimental studies: an empirical comparison. <i>Amer J Epidemiol</i> 1988;127:885-92.
D.2223	Greenhalgh T. How to read a paper: Papers that summarise other papers (systematic reviews and meta-analyses). <i>BMJ</i> 1997;315:672-5.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2224	Higgins JT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. <i>Brit Med J</i> 2003;327:557-60.
D.2225	Hill AB. The environment and disease: association or causation? <i>Proc Roy Soc Med</i> 1965;58:295-300.
D.2226	Hill AB. Statistical evidence and inference. Chapter 24 in: <i>A Short Textbook of Medical Statistics</i> . London:Hodder and Stoughton 1971:283-96.
D.2227	Hutchison BG. Critical appraisal of review articles. <i>Can Fam Physician</i> 1993;39:1097-102.
D.2228	Jick H. The discovery of drug-induced illness. <i>New Engl J Med</i> 1977;296:481-5.
D.2229	Kelsey JL, Pettiti DB, King AC. Key Methodologic Concepts and Issues. Chapter 2 in: <i>Brownson RR, Pettiti DB. Applied Epidemiology: Theory to Practice</i> . New York:Oxford University Press, 1998;35-69.
D.2230	RESERVED
D.2231	Koopman JS, Weed DL. Epigenesis theory: A mathematical model relating causal concepts of pathogenesis in individuals to disease patterns in populations. <i>Am J Epidemiol.</i> 1990;132:366-390.
D.2232	Krimsky S. The weight of evidence in policy and law. <i>Am J Pub Health</i> 2005;95(Suppl 1):S129-S136.
D.2233	Lancashire RJ, Cheng K, Langman MJS. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. <i>Aliment Pharmacol Ther</i> 2003;17:887-93.
D.2234	Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. <i>Ann Int Med</i> 2009;151:65-94.
D.2235	Lichtenstein AH, Yetley EA, Lau J. Application of systematic review methodology to the field of nutrition. <i>J Nutrition</i> 2008;138:2297-306.
D.2236	Lundh A, Knijnenburg SL, Jorgensen AW, et al. Quality of systematic reviews in pediatric oncology—a systematic review. <i>Cancer Treat Rev</i> 2009;35:645-52.
D.2237	MacMahon B, Pugh TF. Concepts of Cause. Chapter 2 in: <i>Epidemiology: Principles and Methods</i> . Boston:Little, Brown, 1970.
D.2238	Mausner JD, Bahn AK. The Search for Causal Relations: Observational Studies. Chapter 5 in: <i>Epidemiology: An Introductory Text</i> . Philadelphia:W.B. Saunders. 1974;91-111.
D.2239	Mignini LE, Khan KS. Methodological quality of systematic reviews of animal studies: a survey of reviews of basic research. <i>BMC Med Research Methodology</i> 2006, 6:10. doi:10.1186/1471-2288-6-10.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2240	Milne R, Chambers L. Assessing the scientific quality of review articles. J Epidemiol Commun Health 1993;47:169-70.
D.2241	Moher D, Tsertsvadze A, Tricco AC, et al. When and how to update systematic reviews. Cochrane Database Syst Rev 2008;23(1):MR000023.
D.2242	Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med 2007;4(3): e78. doi:10.1371/journal.pmed.0040078.
D.2243	Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6:e1000097.
D.2244	Montori VM, Swiontkowski MF, Cook DJ, et al. Methodologic issues in systematic reviews and meta-analyses. Clin Orthop Rel Rsch 2003;413:43-54.
D.2245	Muir Gray JA. Two classes of creativity—improving systematic reviews. J Epidemiol Commun Health 1994;48:4-5.
D.2246	Mullen PD, Ramirez G. The promise and pitfalls of systematic reviews. Annu Rev Public Health 2006;27:81-102.
D.2247	RESERVED
D.2248	Mulrow CD. Rationale for systematic reviews. BMJ 1994;309:597-599.
D.2249	Naranjo CA, Busto U, Seller EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
D.2250	Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992;32:897-904.
D.2251	National Research Council (NRC). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academy of Sciences, 2007.
D.2252	Noordzij M, Hooft L, Dekker FW et al. Systematic reviews and meta-analyses: when they are useful and when to be careful. Kidney Int 2009;76:1130-6.
D.2253	Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J 1988;138:697-703.
D.2254	RESERVED
D.2255	Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence. Health Research Policy and Systems 2006, 4:20. doi:10.1186/1478-4505-4-20.
D.2256	Parascandola M, Weed DL, Dasgupta A. The Surgeon General's Reports on Smoking and Cancer: a historical investigation of the practice of causal inference. Emerg Themes Epidemiol. 2006;3:1-11.
D.2257	Petticrew M. Systematic reviews from astronomy to zoology: myths and misconceptions. Brit Med J. 2001;322:98-101.
D.2258	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2259	Rochon PA, Bero LA, Bay AM, et al. Comparison of review articles published in peer-reviewed and throwaway journals. JAMA 2002;287:2853-6.
D.2260	RESERVED
D.2261	Rothman KJ. What is Causation? Chapter 2 in: Epidemiology: an Introduction. New York:Oxford University Press, 2002;8-23.
D.2262	Rothman KJ, Greenland S. Causation and Causal Inference. Chapter 2 in: Modern Epidemiology, 2nd ed. Philadelphia:Lippincott, Raven. 1998.
D.2263	Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986;81:49-55.
D.2264	Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Research Methodology 2007, 7:10. doi:10.1186/1471-2288-7-10.
D.2265	Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. Brit Med J 2004;329:44-7.
D.2266	Stroup DF, Berlin JA, Morton SC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. J Am Med Assoc 2000;283:2008-12
D.2267	Susser M. Rules of inference in epidemiology. Reg Tox Pharm 1986;6:116-28.
D.2268	Surgeon General's Advisory Committee on Smoking and Health. Smoking and health: 1964. Rockville MD: U.S. Public Health Service, 1964 (DHEW Publication no. (PHS) 1103).
D.2269	Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. Brit Med J 1994;309:1351-5.
D.2270	United States Environmental Protection Agency (EPA). Guidelines for Carcinogen Risk Assessment. Risk Assessment Forum U.S. Environmental Protection Agency, Washington, DC. EPA/630/P-03/001F March, 2005.
D.2271	United States Preventive Services Task Force (USPSTF). Procedure Manual. Section 4: Evidence Report Development. AHRQ Publication #08-05118-EF, July, 2008.
D.2272	Vandenbroucke JP. Case reports in an evidence-based world. J Roy Soc Med 1999;92:159-63.
D.2273	Venning GR. Identification of adverse reactions to new drugs. III. Alerting process and early warning systems. Brit Med J 1983;286:458-60.
D.2274	Weed DL. On the logic of causal inference. Am J Epidemiol 1986;123:965-79.
D.2275	Weed DL, Tyroler H, Shy CM. The healthy worker effect in actively-working communications workers. J Occup Med. 1987;29:335-9.
D.2276	Weed DL. Causal and Preventive Inference. Chapter 17 in: Greenwald P, Kramer BS, Weed DL. Cancer Prevention and Control. New York:Marcel Dekker, 1995;285-302.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2277	Weed DL, Gorelic LS. The practice of causal inference in cancer epidemiology. <i>Cancer Epidemiol Biomark Prev</i> 1996;5:303-11.
D.2278	Weed DL. Methodological guidelines for review papers. <i>J Natl Cancer Inst</i> 1997;89:6-7.
D.2279	Weed DL, Hursting SD. Biologic plausibility in causal inference: current method and practice. <i>Am J Epidemiol</i> 1998;147:415-25.
D.2280	Weed DL. Preventing scientific misconduct. <i>Am J Public Health</i> 1998;88:125-129.
D.2281	Weed DL. Interpreting epidemiological evidence: how meta-analysis and causal inference methods are related. <i>Int J Epidemiol</i> 2000;29:387-90.
D.2282	Weed DL. Epidemiological evidence and causal inference. <i>Hemat/Oncol Clin N Amer</i> 2000;14:797-807.
D.2283	Weed DL. Methods in epidemiology and public health: does practice match theory? <i>J Epidemiol Commun Health</i> 2001;55:104-10.
D.2284	Weed DL, McKeown RE. Ethics in epidemiology and public health I. Technical terms. <i>J Epidemiol Commun Health</i> 2001;55:855-7.
D.2285	Weed DL. Environmental epidemiology: basics and proof of cause-effect. <i>Toxicology</i> 2002; 181-182:399-403.
D.2286	Weed DL. Weight of evidence: review of concept and methods. <i>Risk Anal</i> 2005;25:1545-57.
D.2287	Weed DL. Evidence synthesis and general causation: key methods and an assessment of reliability. <i>Drake Law Review</i> 2006;54:639-50.
D.2288	Weed DL. The nature and necessity of scientific judgment. <i>J Law Policy</i> 2007;15:135-64.
D.2289	Weed DL. Meta-analysis and causal inference: a case study of PFOA and non-Hodgkin's lymphoma. <i>Ann Epidemiol</i> 2010;20:347-55.
D.2290	Weed DL, Althuis MA, Mink PJ. Quality of reviews on sugar-sweetened beverages and health outcomes. <i>Am J Clin Nutr</i> 2011;94:1340-7.
D.2291	Alexander BH, Olsen GW, Burris JM, et al. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. <i>Occup Environ Med</i> 2003;60:722-9.
D.2292	Andersen V, Olsen A, Carbonnel F, et al. Diet and risk of inflammatory bowel disease. <i>Dig Liver Dis</i> 2012;44:185-94.
D.2293	Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. <i>Lancet</i> 2007;369:1627-40.
D.2294	Bernstein CN. Why and where to look in the environment with regard to the etiology of inflammatory bowel disease. <i>Dig Dis</i> 2012;30(Suppl 3):28-32.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2295	Brede E, Wilhelm M, Goen T, et al. Two-year follow-up biomonitoring pilot study of residents' and controls' PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. <i>Int J Hyg Environ Health</i> 2010;213:217-23.
D.2296	Cairns P. Renal cell carcinoma. <i>Cancer Biomark</i> 2011;9:461-73.
D.2297	Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. <i>New Engl J Med</i> 2003;348:1625-38.
D.2298	Castiglione F, Diaferia M, Morace F, et al. Risk factors for inflammatory bowel disease according to the "hygiene hypothesis": a case-control, multi-centre prospective study in Southern Italy. <i>J Crohns Colitis</i> 2012;6:324-9.
D.2299	Centers for Disease Control and Prevention (CDC). Defining overweight and obesity. At: <a href="http://www.cdc.gov/obesity/adult/defining.html">www.cdc.gov/obesity/adult/defining.html</a> . Last reviewed: April, 2012. Accessed: December, 2014.
D.2300	Chang ET, Adami HO, Boffetta P, et al. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. <i>Crit Rev Tox</i> 2014;doi:10.3109/10408444.2014.905767.
D.2301	Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. <i>JAMA</i> 1999;281:1628-31.
D.2302	Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. <i>Nat Rev Urol</i> 2010;7:245-57.
D.2302	Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. <i>Nat Rev Urol</i> 2010;7:245-57.
D.2303	Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. <i>Cancer Epidemiol Biomarkers Prev</i> 2009;18:801-7.
D.2303	Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. <i>Cancer Epidemiol Biomarkers Prev</i> 2009;18:801-7, 2009
D.2304	Costa G, Sartori S, Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. <i>J Occup Environ Med</i> 2009;51:364-72.
D.2304	Costa G, Sartori S, Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. <i>J Occup Environ Med</i> 2009;51:364-72, 2009
D.2305	De Vroey B, Cassan CD, Gower-Rousseau C, et al. Antibiotics earlier, IBD later? <i>Am J Gastroenterol</i> 2010;105:2693-6.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2305	De Vroey B, Cassan CD, Gower-Rousseau C, et al. Antibiotics earlier, IBD later? Am J Gastroenterol 2010;105:2693-6.
D.2306	DeWitt JC, Shnyra A, Badr MZ, et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol 2009;39:76-94.
D.2307	Dobbins M, Decorby K, Choi BCK. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013;doi/10.5402/2013/680536.
D.2308	Dubeau MF, Iacucci M, Beck PL, et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 2013;19:445-56.
D.2309	Eriksen KT, Sorensen M, McLaughlin JK, et al. Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J Natl Cancer Inst 2009;101:605-9.
D.2310	Frisbee SJ, Brooks AP, Maher A, et al. The C8 Health Project: Design, Methods, and Participants. Environ Health Perspect 2009;117:1873-82. (including Supplemental Material)
D.2311	Fromme H, Tittlemier SA, Volkel W, et al. Perfluorinated compounds—exposure assessment for the general population in Western countries. Int J Hyg Environ Health 2009;212:239-70.
D.2312	Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid plant. J Occup Med 1993;950-4.
D.2313	Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009;9:88. doi:10.1186/1471-2458-9-88.
D.2314	Hou JK, Abraham B, El-Serag H, et al. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011;106:563-73, 2011
D.2315	RESERVED
D.2316	International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 83: Tobacco smoke and involuntary smoking. Lyon:IARC Press, 2004.
D.2317	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49, Aug. 2009



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2318	Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9.
D.2319	Karami S, Schwartz K, Purdue MP, et al. Family history of cancer and renal cell cancer in Caucasians and African Americans. Br J Cancer 2010;102:1676-80.
D.2320	Kaur N, Chen CC, Luther J, et al. Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2011;2:4,211-6.
D.2321	Kerger BD, Copeland TL, DeCaprio AP. Tenuous dose-response correlations for common disease states: case study of cholesterol and perfluorooctanoate sulfonate (PFOA/PFOS) in the C8 Health Project. Drug Chem Toxicol 2011;34:396-404.
D.2322	Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 2012;130:e794-e803.
D.2323	Lau C, Anitole K, Hodes C, et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Tox Sci 2007;99:366-94.
D.2324	Lindstrom AB, Strynar MJ, Libelo EL. Polyfluorinated compounds: past, present, and future. Environ Sci Technol 2011;45:7954-61.
D.2325	Margolis DJ, Fanelli M, Hoffstad O, et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010; doi: 10.1038/ajg.2010.303.
D.2326	McLaughlin JK, Lipworth L, Tarone RE, et al. Renal cancer. Chapter 57 in: Schottenfeld D, Fraumeni JF Jr. (eds). Cancer Epidemiology and Prevention. New York:Oxford University Press, 2006:1087-100.
D.2327	Miller FW, Alfredsson L, Costenbader KH, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 2012;39:259-71.
D.2328	National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK). What Causes UC? @ <a href="http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/#causes">http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/#causes</a> . Accessed: 8.30.2014.
D.2329	Ohio Cancer Incidence Surveillance System. County Cancer Profile (Athens, Gallia, Meigs, Morgan, and Washington Counties). 2008. Ohio Department of Health.
D.2330	Olsen GW, Burris JM, Burlew MM, et al. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 2003;45:260-70.
D.2331	Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012;dx.doi.org/10.1016/S0140-6736(12)60150-0.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2332	Pischon T, Nothlings U, Boeing H. Obesity and cancer. <i>Proc Nutr Soc</i> 2008;67:128-45.
D.2333	Prevedouros K, Cousins IT, Buck RC, et al. Sources, fate and transport of perfluorocarboxylates. <i>Environ Sci Technol</i> 2006;40:32-44.
D.2334	Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. <i>Br Med J</i> 2007;doi:10.1136/bmj/39367.495995.AE.
D.2335	Seals R, Bartell SM, Steenland K. Accumulation and clearance of perfluorooctanoic acid (PFOA) in current and former residents of an exposed community. <i>Environ Health Perspect</i> 2011;119:119-24.
D.2336	Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. <i>Am J Gastroenterol</i> 2011; doi: 10.1038/ajg.2011.304.
D.2337	Shin HM, Ryan PB, Vieira VM, et al. Modeling the air-soil transport pathway of perfluorooctanoic acid in the mid-Ohio Valley using linked air dispersion and vadose zone models. <i>Atmospheric Environ</i> 2012;51:67-74.
D.2338	Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). <i>Environ Health Perspect</i> 2010;118:1100-8.
D.2339	Steenland K, Zhao L, Winkquist A, et al. Ulcerative colitis and perfluorooctanoic (PFOA) in a highly exposed population of community residents and workers in the Mid-Ohio Valley. <i>Environ Health Perspect</i> 2013;121:900-5.
D.2340	Strynar MJ, Lindstrom AB. Perfluorinated compounds in house dust in Ohio and North Carolina, USA. <i>Environ Sci Technol</i> 2008;42:3751-6.
D.2341	Sung MK, Park MY. Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view. <i>World J Gastroenterol</i> 2013;19:994-1004.
D.2342	Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. <i>Ann NY Acad Sci</i> 2012;1271:37-43.
D.2343	West Virginia Cancer Registry (1993 to 2007). Cancer Incidence in West Virginia: 2009. West Virginia Department of Health and Human Resources. Bureau for Public Health, Charleston, West Virginia.
D.2344	Winkquist A, Lally C, Shin HM, et al. Design, methods, and population for a study of PFOA health effects among highly exposed mid-Ohio Valley community residents and workers. <i>Environ Health Perspect</i> 2013;121:893-9.
D.2345	World Health Organization (WHO). Fact Sheet No. 311, "Obesity and overweight." At: <a href="http://www.who.int/mediacentre/factsheets/fs311/en">http://www.who.int/mediacentre/factsheets/fs311/en</a> . Updated: August, 2014. Accessed: December, 2014.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2346	Woskie SR, Gore R, Steenland K. Retrospective exposure assessment of perfluorooctanoic acid serum concentrations at a fluoropolymer manufacturing plant. <i>Ann Occup Hyg</i> 2012;56:1025-37.
D.2347	Centers for Disease Control (CDC). 2014. Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, August 2014.
D.2348	DeSilva, A.O. and Mabury, S.A. 2006. Isomer Distribution of Perfluorocarboxylates in Human Blood: Potential Correlation to Source. <i>Environ. Sci. Technol.</i> 40: 2903-2909.
D.2349	Ehresman, D.J., et al. 2007. Comparison of whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOA), perfluorooctanoate (PFOA), and other fluorochemicals. <i>Environmental Research.</i> 103:176-184.
D.2350	Kannan, K., et al. 2004. Perfluorooctanesulfonate and Related Fluorochemicals in Human Blood from Several Countries. <i>Envtl. Sci. Technology.</i> 38:4489-4495.
D.2351	U.S. Environmental Protection Agency (USEPA). 2009. National Drinking Water Regulations. EPA 816-F-09-004. May.
D.2352	U.S. Geological Survey. (USGS). 2015. National Water Web Interface. USGS 03114306 Ohio River above Sardis, OH. <a href="http://nwis.waterdata.usgs.gov/oh/nwis/inventory/?site_no=03114306&amp;agency_cd=USGS">http://nwis.waterdata.usgs.gov/oh/nwis/inventory/?site_no=03114306&amp;agency_cd=USGS</a>
D.2353	West Virginia University School of Medicine. 2008. Population Results for C8 and C8 Sulfonate Plasma Concentrations Stratified by Participant's Qualifying Water District. <a href="http://www.hsc.wvu.edu/ResOff/C8/Home">http://www.hsc.wvu.edu/ResOff/C8/Home</a>
D.2354	Butenhoff, J.L., Kennedy, G.L. Jr, Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J., Gorman, G.S., Noker, P.E., Thomford, P.J., Pharmacokinetics of Perfluorooctanoate (PFOA) in cynomolgus monkeys. <i>Toxicol.</i> 82:394-406:2004.
D.2355	RESERVED
D.2356	American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual, Seventh Edition Springer, New York, 2010. P. 479-489.
D.2357	Cohen and Ellwein, <i>Toxicol. Appl. Pharmacol.</i> , 104: 79-93, 1990a
D.2358	Cohen et al., <i>Crit. Rev. Toxicol.</i> , 33: 581-590, 2003
D.2359	Cohen et al., <i>Toxicol. Sci.</i> , 78: 181-186, 2004
D.2360	Embry et al., <i>Crit. Rev. Toxicol.</i> , 44(S3): 6-16, 2014
D.2361	IARC, Int. Agency for Research on Cancer Monographs, 66: 391-426, 1996
D.2362	IARC, Int. Agency for Research on Cancer Monographs, 100A: 377-398, 2012
D.2363	IARC, Int. Agency for Research on Cancer Monographs, 106: 35-217, 2014
D.2364	Pastoor et al., <i>Crit. Rev. Toxicol.</i> , 44(S3): 1-5, 2014
D.2365	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2366	Winqvist and Steenland, Env. Health Persp., 122: 1299-1305, 2014
D.2367	Benotti, M., R. A. Trenholm, et al. (2009). "Pharmaceuticals and endocrine disrupting compounds in U.S. drinking waters." <i>Environmental Science &amp; Technology</i> 43(3): 597-603.
D.2368	Snyder, S., T. L. Keith, et al. (1999). "Analytical methods for detection of selected estrogenic compounds in aqueous mixtures." <i>Environmental Science and Technology</i> 33(16): 2814-2820.
D.2369	Snyder, S. A. (2014). "Emerging Chemical Contaminants: Looking for Better Harmony." <i>Journal American Water Works Association</i> 106(8): 38-52.
D.2370	Hallet, L. T. (1960). "SENSITIVITY OF ANALYTICAL METHODS." <i>Analytical Chemistry</i> 32(9): 1057-1057.
D.2371	Richardson, S. D. and T. A. Ternes (2014). "Water Analysis: Emerging Contaminants and Current Issues." <i>Analytical Chemistry</i> 86(6): 2813-2848.
D.2372	Armitage, J., I. T. Cousins, et al. (2006). "Modeling global-scale fate and transport of perfluorooctanoate emitted from direct sources." <i>Environmental Science &amp; Technology</i> 40(22): 6969-6975.
D.2373	Simcik, M. F. and K. J. Dorweiler (2005). "Ratio of perfluorochemical concentrations as a tracer of atmospheric deposition to surface waters." <i>Environmental Science &amp; Technology</i> 39(22): 8678-8683.
D.2374	Quiñones, O. and S. A. Snyder (2009). "Occurrence of perfluoroalkyl carboxylates and sulfonates in drinking water utilities and related waters from the United States." <i>Environmental Science and Technology</i> 43(24): 9089-9095.
D.2375	Appleman, T. D., C. P. Higgins, et al. (2014). "Treatment of poly- and perfluoroalkyl substances in US full-scale water treatment systems." <i>Water Research</i> 51: 246255.
D.2376	Boulanger, B., A. M. Peck, et al. (2005). "Mass budget of perfluorooctane surfactants in Lake Ontario." <i>Environmental Science &amp; Technology</i> 39(1): 74-79.
D.2377	Backe, W. J. and J. A. Field (2012). "Is SPE Necessary for Environmental Analysis? A Quantitative Comparison of Matrix Effects from Large-Volume Injection and Solid-Phase Extraction Based Methods." <i>Environmental Science &amp; Technology</i> 46(12): 6750-6758.
D.2378	Post, Gloria et al., PFOA: An Emerging Drinking Water Contaminant: A critical review of recent literature. <i>Environmental Research</i> 116 (2012) 93-117.
D.2379	de Voogt, P. and M. Saez (2006). "Analytical chemistry of perfluoroalkylated substances." <i>Trac-Trends in Analytical Chemistry</i> 25(4): 326-342.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2380	RESERVED
D.2381	Sweetser, P. B. (1956). "DECOMPOSITION OF ORGANIC FLUORINE COMPOUNDS BY WICKBOLD OXYHYDROGEN FLAME COMBUSTION METHOD." <i>Analytical Chemistry</i> 28(11): 1766-1768.
D.2382	Capka, V., C. P. Bowers, et al. (2004). "Determination of total fluorine in blood at trace concentration levels by the Wickbold decomposition method with direct potentiometric detection." <i>Talanta</i> 64(4): 869-878.
D.2383	Belisle, J. and D. F. Hagen (1980). "METHOD FOR THE DETERMINATION OF PERFLUOROOCTANOIC ACID IN BLOOD AND OTHER BIOLOGICAL SAMPLES." <i>Analytical Biochemistry</i> 101(2): 369-376.
D.2384	Lovelock, J. E. (1974). "The electron capture detector: Theory and practice." <i>Journal of Chromatography A</i> 99(0): 3-12.
D.2385	Lovelock, J. E., R. J. Maggs, et al. (1973). "Halogenated Hydrocarbons in and over the Atlantic." <i>Nature</i> 241(5386): 194-196.
D.2386	Koskinen, W. C., J. M. Otto, et al. (1992). "POTENTIAL INTERFERENCES IN THE ANALYSIS OF ATRAZINE AND DEETHYLATRAZINE IN SOIL AND WATER." <i>Journal of Environmental Science and Health Part B-Pesticides Food Contaminants and Agricultural Wastes</i> 27(3): 255-268.
D.2387	Ylinen, M., H. Hanhijarvi, et al. (1985). "QUANTITATIVE GAS-CHROMATOGRAPHIC DETERMINATION OF PERFLUOROOCTANOIC ACID AS THE BENZYL ESTER IN PLASMA AND URINE." <i>Archives of Environmental Contamination and Toxicology</i> 14(6): 713-717.
D.2388	Moody, C. A. F., Jennifer A. (1999). "Determination of Perfluorocarboxylates in Groundwater Impacted by Fire-Fighting Activity." <i>Environmental Science and Technology</i> 33: 2800-2806.
D.2389	Yost, R. A. and C. G. Enke (1978). "SELECTED ION FRAGMENTATION WITH A TANDEM QUADRUPOLE MASS-SPECTROMETER." <i>Journal of the American Chemical Society</i> 100(7): 2274-2275.
D.2390	Whitehouse, C. M., R. N. Dreyer, et al. (1985). "ELECTROSPRAY INTERFACE FOR LIQUID CHROMATOGRAPHS AND MASS SPECTROMETERS." <i>Analytical Chemistry</i> 57(3): 675-679.
D.2391	RESERVED

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2392	Bruins, A. P., T. R. Covey, et al. (1987). "ION SPRAY INTERFACE FOR COMBINED LIQUID CHROMATOGRAPHY/ATMOSPHERIC PRESSURE IONIZATION MASS-SPECTROMETRY." <i>Analytical Chemistry</i> 59(22): 2642-2646.
D.2393	Grayson, M. A. (2011). "John Bennett Fenn: A Curious Road to the Prize." <i>Journal of the American Society for Mass Spectrometry</i> 22(8): 1301-1308.
D.2394	Schultz, M. M., D. F. Barofsky, et al. (2003). "Fluorinated alkyl surfactants." <i>Environmental Engineering Science</i> 20(5): 487-501.
D.2395	Snyder, S. A., B. J. Vanderford, et al. (2003). "Analytical methods used to measure endocrine disrupting compounds in water." <i>Practice Periodical of Hazardous, Toxic, and Radioactive Waste Management</i> 7(4): 224-234.
D.2396	Vanderford, B. J., R. A. Pearson, et al. (2003). "Analysis of endocrine disruptors, pharmaceuticals, and personal care products in water using liquid chromatography/tandem mass spectrometry." <i>Analytical Chemistry</i> 75(22): 6265-6274.
D.2397	Snyder, S. A., B. J. Vanderford, et al. (2005). "Trace analysis of bromate, chlorate, iodate, and perchlorate in natural and bottled waters." <i>Environmental Science &amp; Technology</i> 39(12): 4586-4593.
D.2398	Gros, M., M. Petrovic, et al. (2006). "Multi-residue analytical methods using LC-tandem MS for the determination of pharmaceuticals in environmental and wastewater samples: a review." <i>Analytical and Bioanalytical Chemistry</i> 386(4): 941-952.
D.2399	Hansen, K. J., L. A. Clemen, et al. (2001). "Compound-specific, quantitative characterization of organic: Fluorochemicals in biological matrices." <i>Environmental Science &amp; Technology</i> 35(4): 766-770.
D.2400	Moody, C. A., W. C. Kwan, et al. (2001). "Determination of perfluorinated surfactants in surface water samples by two independent analytical techniques: Liquid chromatography/tandem mass spectrometry and F-19 NMR." <i>Analytical Chemistry</i> 73(10): 2200-2206.
D.2401	Yamashita, N., K. Kannan, et al. (2004). "Analysis of perfluorinated acids at parts-per-quadrillion levels in seawater using liquid chromatography-tandem mass spectrometry." <i>Environmental Science &amp; Technology</i> 38(21): 5522-5528.
D.2402	Flaherty, J. M., P. D. Connolly, et al. (2005). "Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry." <i>Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences</i> 819(2): 329-338.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2403	Kaiser, M. A., B. S. Larsen, et al. (2005). "Method for the determination of perfluorooctanoic acid in air samples using liquid chromatography with mass spectrometry." <i>Journal of Occupational and Environmental Hygiene</i> 2(6): 307313.
D.2404	Davis, K. L., M. D. Aucoin, et al. (2007). "Transport of ammonium perfluorooctanoate in environmental media near a fluoropolymer manufacturing facility." <i>Chemosphere</i> 67(10): 2011-2019.
D.2405	Soukup-Hein, R. J., J. W. Remsburg, et al. (2007). "A general, positive ion mode ESI-MS approach for the analysis of singly charged inorganic and organic anions using a dicationic reagent." <i>Analytical Chemistry</i> 79(19): 7346-7352.
D.2406	Anumol, T. and S. A. Snyder (2015). "Rapid analysis of trace organic compounds in water by automated online solid-phase extraction coupled to liquid chromatography–tandem mass spectrometry." <i>Talanta</i> 132(0): 77-86.
D.2407	Kennedy, G. L. (1985). "DERMAL TOXICITY OF AMMONIUM PERFLUOROOCTANOATE." <i>Toxicology and Applied Pharmacology</i> 81(2): 348-355.
D.2408	Veith, G. D., D. W. Kuehl, et al. (1981). "POLYCHLORINATED-BIPHENYLS AND OTHER ORGANIC-CHEMICAL RESIDUES IN FISH FROM MAJOR UNITED-STATES WATERSHEDS NEAR THE GREAT-LAKES, 1978." <i>Pesticides Monitoring Journal</i> 15(1): 1-8.
D.2409	Pereira, J. J., R. Mercaldo-Allen, et al. (1993). "Effect of cadmium accumulation on serum vitellogenin levels and hepatosomatic and gonadosomatic indices of winter flounder ( <i>Pleuronectes americanus</i> )." <i>Archives of Environmental Contamination and Toxicology</i> 24: 427-431.
D.2410	ORSANCO. (2015). "Ohio River Valley Water Sanitation Commission - Monitoring Data - PCBs." Retrieved January 24th, 2015, from <a href="http://www.orsanco.org/data-main/10-mainpages/orsanco-programs/202-monitoring-data">http://www.orsanco.org/data-main/10-mainpages/orsanco-programs/202-monitoring-data</a> .
D.2411	Vecchia, A. V., R. J. Gilliom, et al. (2009). "Trends in Concentrations and Use of Agricultural Herbicides for Corn Belt Rivers, 1996-2006." <i>Environmental Science &amp; Technology</i> 43(24): 9096-9102.
D.2412	Wang, N., B. Szostek, et al. (2005). "Fluorotelomer alcohol biodegradation-direct evidence that perfluorinated carbon chains breakdown." <i>Environmental Science &amp; Technology</i> 39(19): 7516-7528.
D.2413	Musijowski, J., M. Trojanowicz, et al. (2007). "Flow-injection determination of total organic fluorine with off-line defluorination reaction on a solid sorbent bed." <i>Analytica Chimica Acta</i> 600(1-2): 147-154.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2414	Powley, C. R., S. W. George, et al. (2008). "Polyfluorinated chemicals in a spatially and temporally integrated food web in the Western Arctic." <i>Chemosphere</i> 70(4): 664672.
D.2415	Wang, N., B. Szostek, et al. (2009). "8-2 Fluorotelomer alcohol aerobic soil biodegradation: Pathways, metabolites, and metabolite yields." <i>Chemosphere</i> 75(8): 1089-1096.
D.2416	Liou, J. S. C., B. Szostek, et al. (2010). "Investigating the biodegradability of perfluorooctanoic acid." <i>Chemosphere</i> 80(2): 176-183.
D.2417	Berger, U., M. A. Kaiser, et al. (2011). "Recent developments in trace analysis of poly- and perfluoroalkyl substances." <i>Analytical and Bioanalytical Chemistry</i> 400(6): 1625-1635.
D.2418	Benskin, J. P., L. W. Y. Yeung, et al. (2010). "Perfluorinated Acid Isomer Profiling in Water and Quantitative Assessment of Manufacturing Source." <i>Environmental Science &amp; Technology</i> 44(23): 9049-9054.
D.2419	Porter, P. S., R. C. Ward, et al. (1988). "THE DETECTION LIMIT." <i>Environmental Science &amp; Technology</i> 22(8): 856-861.
D.2420	EID157381-2
D.2421	EID221477
D.2422	EID160322
D.2423	EID163688-9
D.2424	RP006039-40
D.2425	006-0133-0135637-006-0133-0135637.0010
D.2426	Olsen, G. W., et al., Perfluorooctanesulfonate and Other Fluorochemicals in the Serum of American Red Cross Adult Blood Donors
D.2427	RJZ005099-100
D.2428	JW000078-93
D.2429	CF035346
D.2430	DE000267-75
D.2431	AJP001624-9
D.2432	RJZ012172-6
D.2433	SRP001466-74
D.2434	EID090329-30
D.2435	RCB000377-88
D.2436	RJZ015502-4
D.2437	GLK002614
D.2438	RJZ015529



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2439	Federal Register 44: 75028-75052 (1979)
D.2440	EID743739-48
D.2441	Barton, C.A., et al. (2007) Partitioning and removal of perfluorooctanoate during rain events: the importance of physical-chemical properties. <i>Journal of Environmental monitoring</i> 9(8):839-846.
D.2442	EPA (1996). Method 8151A Chlorinated Herbicides by GC Using Methylation or Pentafluorobenzoylation Derivatization. U. EPA: 31.
D.2443	EPA (2001). Contaminants Regulated Under The Safe Drinking Water Act
D.2444	EPA (unknown). Method 608 - Organochlorine Pesticides and PCBS.
D.2445	Fenn, J.B., et al. (1989). Electrospray Ionization for Mass Spectrometry. <i>Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences</i> 819(2): 329-338.
D.2446	Hansen, K. J., et al. (2002). Quantitative Characterization of Trace Levels of PFOS and PFOA in the Tennessee River. <i>Environmental Science &amp; Technology</i> 36(8): 1681-1685.
D.2447	Mawn, M.P. et al. (2005). Determination of Extractable PFOA in water, sweat simulant, saliva simulant, and methanol from textile and carpet samples by LC/MS/MS. <i>Analyst</i> 130(5): 670-678
D.2448	Powley, C. R., et al. (2005) Determination of PFOA extractable from the surface of commercial cookware under simulated cooking conditions by LC/MS/MS. <i>Analyst</i> 130(9): 1299-1302.
D.2449	Risha, K.L., et al. (2005) Method for Trace level analysis of C8, C9, C10, C11, and C13 perfluorocarbon carboxylic acids in water. <i>Analytical Chemistry</i> 77(5): 1503-1508
D.2450	Scott, B.F. et al. (2006). Analysis for Perfluorocarboxylic Acids/anions in surface waters and precipitation using GC-MS and analysis of PFOA from large-volume samples. <i>Environmental Science &amp; Technology</i> 40(20): 6405-6410.
D.2451	RESERVED
D.2452	Work histories
D.2453	Work histories
D.2454	AJP002079
D.2455	Dourson CV
D.2456	RESERVED
D.2457	RESERVED
D.2458	RESERVED
D.2459	Supplemental Report of Dr. Robert Rickard
D.2460	USEPA16157-61; HLAB000240-44

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2461	Haskell Laboratory Report No. 128-68. Acute Oral Test, June 13, 1968
D.2462	EID123419-22; HLAB003868-71
D.2463	EID924170-72
D.2464	EID123357; HLAB003803
D.2465	EID123365; ULAB003814
D.2466	EID102398-405; RF000299
D.2467	EID171605-7; RK000567-69
D.2468	EID008492-98
D.2469	Christopher, B., Marias, A.J. 28-day oral toxicity study with FC-143 in albino mice. Final report, Industrial Bio-Test Laboratories, Study No. 8532-10655, 3M reference No. T-1742CoC, Lot 269, AR 226-0444.1977
D.2470	K. McGlynn, M. Cook; Etiologic factors in testicular germ cell tumors; NIH-PA
D.2471	Deposition transcript of Carrie Redlich
D.2472	Redlich 2/10/2016 deposition exhibit 1
D.2473	Redlich 2/10/2016 deposition exhibit 2
D.2474	Redlich 2/10/2016 deposition exhibit 3
D.2475	Redlich 2/10/2016 deposition exhibit 4
D.2476	Redlich 2/10/2016 deposition exhibit 5
D.2477	Redlich 2/10/2016 deposition exhibit 6
D.2478	Redlich 2/10/2016 deposition exhibit 7
D.2479	Redlich 2/10/2016 deposition exhibit 8
D.2480	RESERVED
D.2481	Redlich 2/10/2016 deposition exhibit 10
D.2482	Redlich 2/10/2016 deposition exhibit 11
D.2483	Redlich 2/10/2016 deposition exhibit 12
D.2484	Redlich 2/10/2016 deposition exhibit 13
D.2485	Redlich 2/10/2016 deposition exhibit 14
D.2486	Redlich 2/10/2016 deposition exhibit 15
D.2487	Redlich 2/10/2016 deposition exhibit 16
D.2488	Redlich 2/10/2016 deposition exhibit 17
D.2489	EID101909-20
D.2490	EID714689-98
D.2491	EID751421-32
D.2492	EID714833-52
D.2493	EID714866-88
D.2494	079-2009-0029660-86; RP001586

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2495	EID472626-42
D.2496	EID715009-35
D.2497	EID714989-5008
D.2498	EID152159-201
D.2499	EID216959-79
D.2500	EID190539-66
D.2501	EID714966-88
D.2502	EID714925-65
D.2503	EID715036-69
D.2504	EID216847-73
D.2505	EID715097-118
D.2506	EID190215-38
D.2507	EID714520-42
D.2508	EID714506-19
D.2509	EID714492-505
D.2510	EID714547-58
D.2511	EID714559-64
D.2512	EID102770-71
D.2513	Health Consultation - Exposure Investigation Report
D.2514	Health Consultation - Exposure Investigation Report
D.2515	Deposition of Ta-Wei Fu
D.2516	Deposition Ex. 1 of Ta-Wei Fu
D.2517	Deposition Ex. 2 of Ta-Wei Fu
D.2518	Deposition Ex. 3 of Ta-Wei Fu
D.2519	EID839548-85
D.2520	Deposition Ex. 5 of Ta-Wei Fu
D.2521	Deposition Ex. 6 of Ta-Wei Fu
D.2522	Deposition Ex. 7 of Ta-Wei Fu
D.2523	ID079740-54
D.2524	Deposition Ex. 9 of Ta-Wei Fu
D.2525	AJP002312-39
D.2526	RJZ009116
D.2527	Deposition Ex. 12 of Ta-Wei Fu
D.2528	Deposition Ex. 13 of Ta-Wei Fu
D.2529	Deposition Ex. 14 of Ta-Wei Fu
D.2530	KGK001656-712

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2531	007-2009-001488
D.2532	007-2009-0026015-16
D.2533	016-0146-0011625
D.2534	TWF002008-10; 007-2009-0009012-14
D.2535	007-0148-0040276-94
D.2536	EID776673; GHS012635; 063-2008-0006127
D.2537	Deposition Ex. 22 of Ta-Wei Fu
D.2538	LE-EX06464-67
D.2539	EID257298-331
D.2540	EDD0092420-452
D.2541	Abstract 3566: Anti-tumor activity of CXR1002
D.2542	Long-term Surveillance Plan for the Parkersburg, West Virginia, Disposal Site
D.2543	EID731460-71
D.2544	RJZ009898-900
D.2545	EID548229-59
D.2546	EID148048-52
D.2547	RJZ004159-82
D.2548	RJZ004310-23
D.2549	EID735499
D.2550	EID727407-19
D.2551	EID498929
D.2552	EID498934
D.2553	MGM000117-8
D.2554	Monitoring data submitted from M. Santoro at 3M to US EPA OPPT AR-226
D.2555	3M stewardship submission
D.2556	3M stewardship submission
D.2557	3M stewardship submission
D.2558	3M stewardship submission
D.2559	3M stewardship submission
D.2560	3M stewardship submission
D.2561	3M stewardship submission
D.2562	3M stewardship submission
D.2563	EID936005-164
D.2564	EID936165-263
D.2565	CF006635-8
D.2566	EID559816-29

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2567	EID123606-64
D.2568	RJZ000403-9
D.2569	EID365115-262
D.2570	EID258452-89
D.2571	EID258197-256
D.2572	EID257956-8027
D.2573	EID258781-839
D.2574	EID423327-83
D.2575	EID313972-4015
D.2576	EDD0038308-95
D.2577	EID680260-98
D.2578	132-0227-0016342-132-0227-0016342.0033
D.2579	132-0227-0016379-132-0227-0016379.0026
D.2580	132-0227-0016688-132-0227-0016688.0028
D.2581	026-0206-0033892-026-0206-0033892.0045
D.2582	026-0206-0033982-026-0206-0033982.0030
D.2583	026-0206-0034013-026-0206-0034013.0041
D.2584	027-0203-0009157-027-0203-0009157.0050
D.2585	026-0206-0033938-026-0206-0033938.0043
D.2586	EID926569-81
D.2587	011-0001-0000042-45
D.2588	EID079654-56
D.2589	EID459261-62
D.2590	EID599980-85
D.2591	078-0157-0009737
D.2592	EID156030-37
D.2593	EID417814-27
D.2594	EID160026-40
D.2595	EID118964-70; MEM000306-312
D.2596	EID169807-13; CAF002941-47
D.2597	EID489497-511
D.2598	016-0169-00112252
D.2599	EID595618-24; JAW003489-95
D.2600	EID217091-93; LWB000737-739
D.2601	EID217089-90
D.2602	EID499091-97

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2603	Plaintiffs' Mediation Statement, Tennant, et al. v. DuPont; USDC Southern District of West Virginia; 6:99-0488
D.2604	N. Gillett, Sierra Biomedical, Pathology Peer Review Report
D.2605	3M advertisement / order form for Fluorad Surfactants sample kit
D.2606	LH273840
D.2607	LH273844
D.2608	LH273848
D.2609	LH273852
D.2610	LH273856
D.2611	LH273860
D.2612	LH273864
D.2613	LH273868
D.2614	LH273872
D.2615	LH273876
D.2616	LH273880
D.2617	EDD0025668-84
D.2618	3M 1981 Fluorad
D.2619	3M 1962 surfactants
D.2620	Fluoropolymer manufacturing area
D.2621	Fluoropolymer manufacturing area
D.2622	3M MSDS re ESPE Cavityshield sodium fluoride varnish
D.2623	Pfizer MSDS re Sudafed
D.2624	MSDS re Dextrose
D.2625	WhiteHill MSDS re oral lozenges
D.2626	BioLabs MSDS re Sodium Fluoride
D.2627	MSDS re Sucralose
D.2628	P&G MSDS re Cascade
D.2629	P&G MSDS re Mr. Clean
D.2630	Colgate-Palmolive Company MSDA re Colgate toothpaste
D.2631	Colgate-Palmolive Company MSDA re Palmolive dish and hand soap
D.2632	J&J MSDS re baby powder
D.2633	J&J MSDS re baby shampoo
D.2634	EID255242-712
D.2635	EID069515
D.2636	EID096493
D.2637	EID096487-88

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2638	EID096482-83
D.2639	EID096492
D.2640	EID131668
D.2641	060-0002-0001507-1
D.2642	EID123463-64
D.2643	EID11214649
D.2644	EID216813
D.2645	EID111306
D.2646	EID217062-69
D.2647	EID111685-87
D.2648	EID718331
D.2649	EID718414
D.2650	EID079760-61
D.2651	EID071718-19
D.2652	EID517188-91
D.2653	EID936265-424
D.2654	EID171704-832
D.2655	A. Secat, J. Butenhoff, et al.; Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. Toxic Sci 68, 249-264 (2002)
D.2656	58 FR 37735
D.2657	3M Voluntary Use and Exposure Information Profile
D.2658	EPA Assessing and Managing Chemicals under TSCA 2010/2015 PFOA Stewardship Program
D.2659	Report on Site Visit to Washington Works, August 30, 1985
D.2660	001-0229-0000537-001-0229-0000537.0040
D.2661	EID495234-49
D.2662	DeWitt, J.C. Editor, Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances, Humana Press, 2015
D.2663	Longnecker, D.S., Early morphologic markers of carcinogenicity in rat pancreas, In Application of Biological Markers to Carcinogen Testing (H. Milman and S. Sell Eds) pp 43-60. Plenum Press, New York, 1983
D.2664	MacPherson, J.R. et al. A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. J. Clin Oncol 29:suppl abstr 3063:2011
D.2665	RESERVED
D.2666	German Authorities - Chemical Safety Report, 2009

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2667	Report of the State Senate Environment Committee-Investigation of Perfluorochemical (PFC) Contamination in Minnesota Phase One
D.2668	F. Oliaei, D. Kriens, R. Weber, A. Watson; PFOS and PFC releases and associated pollution from a PFC production plant in Minnesota (USA), Environ Sci Pollut Res (2013) 20:1977-1992.
D.2669	Perfluorochemicals and the 3M Cottage Grove Facility, Minnesota Dept. of Health
D.2670	3M Cottage Grove Site Proposed cleanup plan for PFCs, Minnesota Pollution Control Agency
D.2671	2014 Pollution Report to the Legislature, Minnesota Pollution Control Agency
D.2672	EID078728-29
D.2673	EID090299-307
D.2674	EID935265-66
D.2675	EID936830-31
D.2676	EID936832-33
D.2677	EID078682-85
D.2678	EID090180-81
D.2679	EID358516-18
D.2680	EID086217-18
D.2681	EID090143
D.2682	EID090195-219
D.2683	EID090144-46
D.2684	EID936853
D.2685	EID358535-536
D.2686	EID358539-40
D.2687	EID358505-06
D.2688	EID936859-61
D.2689	EID936864
D.2690	EID090151-52
D.2691	EID090331-39
D.2692	EID350207
D.2693	EID090175-78
D.2694	EID932786-88
D.2695	EID936945-47
D.2696	EID932817-18
D.2697	EID358412-13
D.2698	EID937820



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2699	EID937851-52
D.2700	EID937853
D.2701	EID357988
D.2702	EID361867
D.2703	EID362687
D.2704	EID932886-87
D.2705	EID355328-29
D.2706	EID355403-11
D.2707	EID362946-49
D.2708	EID377179-80
D.2709	EID574468-476
D.2710	060-0002-0001507
D.2711	W. Pearlson letter to T. O'Bryan re: 3/12 meeeting
D.2712	EID071432
D.2713	Revised Addendum to the TSCA Section 8(e) CAP Agreement
D.2714	EID108040-43
D.2715	EID108048-87
D.2716	M. Christman letter to EPA re: 8ECAP-0025
D.2717	EID109428-30
D.2718	EID170007-32
D.2719	EID148315-330
D.2720	001-0004-0000724-756
D.2721	EID079628-36
D.2721(S)	EID072046-51
D.2722	EID168282-6
D.2723	EID685861-7
D.2724	EID585231-7
D.2725	EID635850-7
D.2726	030-0002-0004155-6
D.2727	Griffin Ex 22
D.2728	Griffin Ex 25
D.2729	EID116835-54
D.2730	EID939578-669
D.2731	Perfluoroalkyls - ToxFAQa
D.2732	WV/NPDES Permit WV0001279
D.2733	WVDEP Division of Air Quality Fact Sheet Permit Number: R30-10700001-2010

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2734	EID150612-
D.2735	EID131706-08
D.2736	EID135722
D.2737	EID131702
D.2738	West Virginia Dept. of Environmental Protection Division of Air Quality Fact Sheet
D.2739	West Virginia Dept. of Environmental Protection Division of Air Quality Permit to Operate
D.2740	E. Emmett, F. Shofer, H. Zhang, et al.; Community Exposure to Perfluorooctanoate: Relationships Between Serum Concentrations and Exposure Sources. J Occup Environ Med. 2006 August; 48(8): 759-770.
D.2741	E. Emmett, H. Zhang, F. Shofer, et al.; Community Exposure to Perfluorooctanoate: Relationships Between Serum Levels and Certain Health Parameters. J Occup Environ Med. 2006 August; 48(8): 771-779.
D.2742	E. Emmett, H. Zhang, S. Shofer, et al.; Development and Successful Application of a "Community-First" Communication Model for Community-Based Environmental Health Research. J Occup Environ Med. 2009 February; 51(2): 146-156.
D.2743	EID735342-45
D.2744	EID736941-45
D.2745	EID743616-18
D.2746	EID735473-75
D.2747	EID743698-715
D.2748	EID735477
D.2749	EID735476
D.2750	EID735387-88
D.2751	EID795537-39
D.2752	EID735594
D.2753	EID735557
D.2754	EID497184-205
D.2755	EID591884-85
D.2756	EID644222-23
D.2757	EID644522
D.2758	EID743693
D.2759	EID780404-408
D.2760	EID780399-400
D.2761	006-0133-0115146
D.2762	005-0243-0006181

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2763	US EPA Assessing and Managing Chemicals under TSCA-Guidance Documents on Substantial Risk Notifications under TSCA
D.2764	Federal Register Vol. 68, No. 106: 33129-33140
D.2765	Federal Register Vol. 70, No. 8: 2162-2164
D.2766	TRI Facility Report - Cytec Industries Inc. Air Releases 1987-2005 Graph
D.2767	TRI Facility Report - Cytec Industries Inc. Table of Air Releases 1987-2005
D.2768	TRI Facility Report - Cytec Industries Inc. All Release Types 1987-2005 Graph
D.2769	TRI Facility Report - Cytec Industries Inc. Table of All Release Types 1987-2005
D.2770	TRI Facility Report - Cytec Industries Inc. Releases by Media in Lbs. 1987-2005 Graph
D.2771	TRI Facility Report - Cytec Industries Inc. of Water Releases 1987-2005 Graph
D.2772	TRI Facility Report - Cytec Industries Inc. Table of Water Releases 1987-2005
D.2773	TRI Facility Report - Eramet Marietta Inc. Air Releases 1987-2005 Graph
D.2774	TRI Facility Report - Eramet Marietta Inc. Table of Air Releases 1987-2005
D.2775	TRI Facility Report - Eramet Marietta Inc. All Release Types 1987-2005 Graph
D.2776	TRI Facility Report - Eramet Marietta Inc. Table of All Release Types 1987-2005
D.2777	TRI Facility Report - Eramet Marietta Inc. Releases by Media in Lbs. 1987-2005 Graph
D.2778	TRI Facility Report - Eramet Marietta Inc. of Water Releases 1987-2005 Graph
D.2779	TRI Facility Report - Eramet Marietta Inc. Table of Water Releases 1987-2005
D.2780	TRI Facility Report - Kraton Polymers US LLC Air Releases 1987-2005 Graph
D.2781	TRI Facility Report - Kraton Polymers US LLC Table of Air Releases 1987-2005
D.2782	TRI Facility Report - Kraton Polymers US LLC All Release Types 1987-2005 Graph
D.2783	TRI Facility Report - Kraton Polymers US LLC Table of All Release Types 1987-2005
D.2784	TRI Facility Report - Kraton Polymers US LLC Releases by Media in Lbs. 1987-2005 Graph
D.2785	TRI Facility Report - Kraton Polymers US LLC of Water Releases 1987-2005 Graph
D.2786	TRI Facility Report - Kraton Polymers US LLC Table of Water Releases 1987-2005
D.2787	TRI Facility Report - Solvay Specialty Polymers USA LLC Air Releases 1987-2005 Graph
D.2788	TRI Facility Report - Solvay Specialty Polymers USA LLC Table of Air Releases 1987-2005
D.2789	TRI Facility Report - Solvay Specialty Polymers USA LLC All Release Types 1987-2005 Graph
D.2790	TRI Facility Report - Solvay Specialty Polymers USA LLC Table of All Release Types 1987-2005
D.2791	TRI Facility Report - Solvay Specialty Polymers USA LLC Releases by Media in Lbs. 1987-2005 Graph

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2792	TRI Facility Report - Solvay Specialty Polymers USA LLC of Water Releases 1987-2005 Graph
D.2793	TRI Facility Report - Solvay Specialty Polymers USA LLC Table of Water Releases 1987-2005
D.2794	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2795	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2796	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2797	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2798	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2799	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2800	Deposition transcript of Robert Griffin; The Little Hocking Water Association, Inc. v. E.I. DuPont De Nemours and Company, USDC, Southern District of Ohio, 2:09-CV-1081
D.2801	David Griffin Deposition Ex. 3
D.2802	David Griffin Deposition Ex. 8
D.2803	David Griffin Deposition Ex. 9
D.2804	David Griffin Deposition Ex. 11
D.2805	David Griffin Deposition Ex. 12
D.2806	David Griffin Deposition Ex. 13
D.2807	David Griffin Deposition Ex. 14
D.2808	David Griffin Deposition Ex. 15
D.2809	David Griffin Deposition Ex. 16
D.2810	David Griffin Deposition Ex. 23
D.2811	David Griffin Deposition Ex. 38

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2812	David Griffin Deposition Ex. 39
D.2813	David Griffin Deposition Ex. 44
D.2814	David Griffin Deposition Ex. 47
D.2815	David Griffin Deposition Ex. 56
D.2816	David Griffin Deposition Ex. 82
D.2817	David Griffin Deposition Ex. 83
D.2818	David Griffin Deposition Ex. 84
D.2819	David Griffin Deposition Ex. 98
D.2820	David Griffin Deposition Ex. 101
D.2821	David Griffin Deposition Ex. 102
D.2822	David Griffin Deposition Ex. 103
D.2823	Diesel Exhaust and Cancer (American Cancer Society)
D.2824	Automobile Emissions - An Overview (US EPA)
D.2825	Air Toxics from Motor Vehicles (US EPA)
D.2826	Polycyclic Organic Matter (POM)A (US EPA, Technology Transfer Network Toxics Web Site)
D.2827	Master List of Compounds Emitted by Mobil Sources-2006 (US EPA)
D.2828	WVDEP 12009
D.2829	WVDEP 11678
D.2830	WVDEP 11679-89
D.2831	LE-EX06000-14
D.2832	EID070219-20
D.2833	EID917954-59; GLK000699-704
D.2834	033-0154-0000537
D.2835	M. Eriksson, C. Catz, S. Yaffee; Drugs and Pregnancy, Clinical Obstetrics and Gynecology, Vol. 16, 199 (1973).
D.2836	B. Merkin; Maternal and fetal distribution of drugs in pregnancy; Clinical and Pharmacological Therapy, Vo. 14, 643 (1973).
D.2837	H. Nishimura, T. Tanimura; Clinical aspects of the teratogenicity of drugs. Amsterdam: Experpta Medica, p. 57 (1976)
D.2838	R. Harbison; Teratogens. Casarett and Doull's Toxicolgy, Doull J, Klaassen CD, Amdur MO (ed). New York: Macmillan, 158, 160 (1980).
D.2839	F. Griffith, J. Long; Animal toxicity studies with ammonium perfluorooctanoate. Am. Ind. Hyg. Assoc. J. (41) No. 8, 576-583 (August 1980).

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2840	F. Ubel, S. Sorenson, D. Roach; Health status of plant workers exposed to fluorochemicals-a preliminary report. Am. Ind. Hyg. Assoc. J. (41), 584-589) (August, 1980).
D.2841	C. Olson, M. Andersen; The Acute Toxicity of Perfluorooctanoic and Perfluorodecanoic Acids in Male Rats and Effects on Tissue Fatty Acids. Toxicology and Applied Pharmacology 70, 362-372 (1983)
D.2842	R. Staples, B. Burgess, W. Kerns; The Embryo-Fetal Toxicity and Teratogenic Potential of Ammonium Perfluorooctanoate (APFO) in the Rat. Fundamental and Applied Toxicolgy, Vol. 4, 429-40 (1984).
D.2843	G. Kennedy; Dermal Toxicity of Ammonium Perfluorooctanoate. Toxicolgy and Applied Pharmacology 81, 348-355 (1985)
D.2844	T. Pastoor, K. Lee, M. Perri, P. Gillies; Biochemical and Morphological Studies of Ammonium Perfluorooctanoate-Induced Hepatomegaly and Peroxisome Proliferation. Experimental Molecular Pathology, Vo. 47, 98-109 (1987).
D.2845	G. Kennedy, G. Hall, M. Brittelli, et al.; Inhalation Toxicity of Ammonium Perfluorooctanoate. Fd Chem Toxic Vol. 24, No. 12, 1325-1329 (1986).
D.2846	G. Kennedy; Increase in Mouse Liver Weight Following Feeding of Ammonium Perfluorooctanoate and Related Fluorochemicals. Toxicolgy Letters, 39, 295-300 (1987).
D.2847	L. Kinney, N. Chromey, G. Kennedy; Acute Inhalation Toxicity of Ammonium Perfluorononanoate. Fd Chem Toxic, Vol. 27, No. 7, 465-468 (1989).
D.2848	F. Gilliland, J. Mandel; Mortality Among Employees of a Perfluorooctanoic Acid Production Plant. JOM, Vol. 35, 950-954 (1993).
D.2849	Y. Kawashima, S. Suzuki, H. Kozuka, et al.; Effects of prolonged administration of perfluorooctanoic acid on hepatic activities of enzymes which detoxify peroxide and xenobiotic in the rat. Toxicology 93, 85-97 (1994).
D.2850	F. Gilliland, J. Mandel; Serum Perfluorooctanoic Acid and Hepatic Enzymes, Lopoproteins, and Cholesterol: A Study of Occupationally Exposed Men. American Journal of Industrial Medicine 29:560-568 (1996).
D.2851	J. Rogers, R. Kavlock; Developmental Toxicology. Casarett and Doull's Toxicology The Basic Science of Poisons, Fifth Edition, Chapter 10, 314 (1996).
D.2852	G. Olsen, F. Gilliland, M. Burlew, et al.; An Epidemiologyc Investigation of Reproductive Hormones in Men with Occupational Exposure to Perfluorooctanoic Acid. Journal of Occupational Medicine, Vol. 40, 614-622 (1998).

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2853	R. Staples; Improper Interpretation of Data Concerning Teratogenicity: A Case Report. Prevention of Physical and Mental Congenital Defects, Part C: Basic and Medical Science, Education, and Future Strategies, 161-163 (1985).
D.2854	E. Berman memo re: Report of Emergency Incidents under TSCA Section 8(e)
D.2855	EID209463-67
D.2856	EID071940-45
D.2857	F. Kover memo to J. Merenda re: Status Report
D.2858	F. Kover memo to J. Merenda re: Status Report
D.2859	F. Kover memo to J. Wiltse re: Perfluorinated Alkyl Mixtures
D.2860	V. Kimm letter to R. Sussman re: EPA's TSCA 8(e) reporting guidelines
D.2861	C. Reich letter to US EPA as 3M TSCA 8(e) notice re: Perfluorooctane Sulfonate
D.2862	C. Reich letter to US EPA re: TSCA 8(e) Substantial Risk Notice
D.2863	P. Robertson letter to C. Auer, US EPA re: Further DuPont Voluntary Response to 11/4/2004 Request for Submission
D.2864	K. Davis / B. Cuento AECOM memo to A. Hartten
D.2865	T. Pastoor, K. Lee, P. Gillies; Morphological and Biochemical Characteristics of Perfluorooctanoate-Induced Liver Enlargement. The Toxicologist, Vol. 5, 155 (Abstract 617) (1985)
D. 2866	EID461271-475
D.2867	Science Panel Initial Contract
D.2868	Amendment A to Science Panel Initial Contract of Dr. Steenland
D.2869	ORSANCO. (2015). Ohio River Valley Water Sanitation Commission - Ohio River Toxic Release Inventory Analysis (TRI), Reporting Year 2013 (Updated May 2015).
D.2870	EID630708-59
D.2871	003-0030-0001706-006-0030-0001706.0001
D.2872	EID598805-69
D.2873	EID736043-44
D.2874	EID644136
D.2875	EID644171
D.2876	EID644116-25
D.2877	EID644919
D.2878	EID644920-21
D.2879	EID736287
D.2880	EID718742-43
D.2881	OEPA001666; EID735396
D.2882	RJZ009907



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2883	RJZ005426-29
D.2884	119-2014-0000613-20
D.2885	001-2007-0005648
D.2886	RJZ009998-1000
D.2887	060-0002-0001718-21
D.2888	DPL000024-30; EID713579-85
D.2889	EID192481-82
D.2890	ASH014603-10; EID192473-80
D.2891	AJP002392
D.2892	LWB000682-87; EID217056-61
D.2893	LWB000757-58; EID217103-04
D.2894	0074049-50
D.2895	9/25/14 Declaration of Angela Hardesty
D.2896	EDD0037555
D.2897	EDD0037974-80
D.2898	EID317429-30
D.2899	DDJ009042
D.2900	EID509669-72
D.2901	EID648215-16
D.2902	EID565477-80
D.2903	EID599327-28
D.2904	5/17/02 S. Bruny e-mail to C. Jones
D.2905	EID644670
D.2906	EID816294-95
D.2907	EID644917
D.2908	EID795854-55
D.2909	EID653519-21
D.2910	EID644033-35
D.2911	EID605154-55
D.2912	EID644341-43
D.2913	Oliaei, Kriens, Weber; Discovery and Investigation of PFOS/PFCs Contamination from a PFC Manufacturing Facility in Minnesota-Environmental Releases and Exposure Risks
D.2914	EID932823
D.2915	EID355352
D.2916	EID362939, EID932940947



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2917	EID106752-54
D.2918	004-0134-0001660-004-0134-0001660.0002
D.2919	Casarett and Doull's Toxicology - The Basic Science of Poisons, Second Edition
D.2920	Bibliography of Key PFOA and PFOS Studies as of September 2009
D.2921	001-0001-0002884-2929
D.2922	2/5/14 Tide MSDS
D.2923	Demonstrative slide of Companies using C-8
D.2924	DE Pence, AW Miekles; A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man; Human & Experimental Toxicology (1995)
D.2925	6/5/16 article, Water that is safe to drink?; Parkersburg News and Sentinel
D.2926	EID131822-23
D.2927	7/11/91 Haskell Labs Study; Inhalation Toxicity Screen with Zonyl FSP
D.2928	7/11/91 Haskell Labs Study; Inhalation Toxicity Screen with Zonyl 9027
D.2929	5/18/99 Haskell Labs Study; Zonyl 8740 (15%): Inhalation Approximate Lethal Concentration (ALC) in Rats
D.2930	002-0002-0000644
D.2931	48 FR 53280, Rules and Regulations (11/25/1983)
D.2932	29 CFR 1910.1200, Hazard Communication
D.2933	29 CFR 1910.1200, Hazard Communication
D.2934	B. Schneider, D. Freeman; The Use of Brine as an Injection Fluid to Reduce Disposal Cost and Increase Gas Production; SPE 65615 (2000)
D.2935	EID509019-32; PJB002144-57
D.2936	Demonstrative slide; Dose Matters
D.2937	EID082821-24; CS000091-94
D.2938	Sigma-Aldrich Safety Data Sheet re Perfluorooctanoic Acid, 6/29/14
D.2939	NIOSH ICSC: 1613, Perfluorooctanoic Acid, 10/20/05
D.2940	009-0139-0001207 - 009-0139-0001207.0029
D.2941	EID503686-89; HDR005849-52
D.2942	EID196707-36
D.2943	Demonstrative slide; DuPont's Knowledge-Little Hocking
D.2944	EDD0032570-71
D.2945	EDD0032572-73
D.2946(R-TR2)	DuPont Employee Cancer Registry Report
D.2947(R-TR2)	DuPont Employee Medical Data 1981
D.2948(R-TR2)	DuPont Employee Medical Data 1971

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2949(R-TR2)	DuPont Employee Medical Data 66095
D.2950(R-TR2)	DuPont Employee Cancer Registry Report
D.2951(R-TR2)	DuPont Employee Profile
D.2952(R-TR2)	DuPont Employee Medical Data 1976
D.2953(R-TR2)	DuPont Employee Cancer Registry Report
D.2954(R-TR2)	DuPont Employee Medical Data 1978
D.2955(R-TR2)	DuPont Employee Medical Data
D.2956	DuPont Employee Cancer Registry Report
D.2957(R-TR2)	DuPont Employee Medical Data 1979
D.2958(R-TR2)	DuPont Employee Cancer Registry Report
D.2959(R-TR2)	DuPont Employee Medical Data 1984
D.2960(R-TR2)	DuPont Employee Medical Data
D.2961(R-TR2)	DuPont Employee Cancer Registry Report
D.2962(R-TR2)	DuPont Employee Medical Data
D.2963(R-TR2)	DuPont Employee Cancer Registry Report
D.2964(R-TR2)	DuPont Employee Profile
D.2965(R-TR2)	DuPont Employee Cancer Registry Report
D.2966(R-TR2)	DuPont Employee Profile
D.2967	003-0131-0003281-003 - 0131-0003281.0028
D.2968	CV of John M. Flaherty
D.2969	EID127793-811; AC002781-99
D.2969A	Demonstrative slides; Water Constituent Concentrations
D.2970	EID612471-586; MAK010038-153
D.2971	RESERVED
D.2972	Demonstrative slides; Blood C-8 in Workers
D.2973	A. Bar; Significance of Leydig Cell Neoplasia in Rats Fed Lactitol or Lactose; Journal of the American College of Toxicology, Vol. 11, No. 2, 1992
D.2974(R-TR2)	EID648464-98; WVDHHR000248-82
D.2975	GK(p)000987-88; 000021894-95
D.2976	2013 DuPont Form 10-K
D.2977	2014 DuPont Form 10-K
D.2978	2015 DuPont Form 10-K
D.2979	2/16/16 Affidavit of Christopher Butler
D.2980	MDL00007847
D.2981	2010/15 PFOA Stewardship Program Report, 6/30/15
D.2982	1/11/05 Results to Date from the PFOA Worker Health Study

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.2983	2010/15 PFOA Stewardship Program DuPont Update for US EPA, 10/5/11
D.2984	EPA's Baseline Year Summary Report; <a href="http://www.epa.gov/oppt/pfoa/pubs/sumrpt.htm">http://www.epa.gov/oppt/pfoa/pubs/sumrpt.htm</a>
D.2985	DuPont 2015 Annual Meeting and Proxy Statement
D.2986	DuPont 2016 Annual Meeting and Proxy Statement
D.2987	061-0082-0000564 - 569
D.2988	HLAB000004-20; 194-2009-0005871-6887
D.2989	HLAB000045-46; 194-2009-0002094-95
D.2990	HLAB000047-55; 194-2009-0002096-2104
D.2991	HLAB000056-59; 194-2009-0002105-2108
D.2992	HLAB000060-63; 194-2009-0002109-2112
D.2993	HLAB000064-66; 194-2009-0002113-2115
D.2994	HLAB000072-75; 194-2009-0002121-2124
D.2995	HLAB000107-10. 194-2009-0002147-2150
D.2996	HLAB000076-84; 194-2009-0002125-2133
D.2997	HLAB000104-06; 194-2009-0002144-2146
D.2998	HLAB000458-517; 194-2009-0002484-2543
D.2999	HLAB000092-94; 194-2009-0006954-6956
D.3000	HLAB000129-131; 194-2009-0002169-2171
D.3001	HLAB000399-457; 194-2009-0002425-2483
D.3002	HLAB001308-2586; 194-2009-0000007-1285
D.3003	HLAB000111-15; 194-2009-0002151-2155
D.3004	HLAB000116-22; 194-2009-0002156-2162
D.3005	HLAB000132-36; 194-2009-0002172-2176
D.3006	HLAB000192-95; 194-2009-0002224-2227
D.3007	HLAB000123-28; 194-2009-0002163-2168
D.3008	HLAB000196-200; 194-2009-0002228-2232
D.3009	HLAB000162-65; 194-2009-0002202-2205
D.3010	HLAB000166-69; 194-2009-0002206-2209
D.3011	HLAB000308-32; 194-2009-0002340-2364
D.3012	HLAB000352-98; 194-2009-0002376-2424
D.3013	J. Cook, G. Klinefelter, et al.; Rodent Leydig Cell Tumorigenesis: A Review of the Physiology, Pathology, Mechanisms and Relevance to Humans; Crit. Review in Tox, 29(2); 169-261 (1999)
D.3014	HLAB004010-80; 194-2009-0002709-2779
D.3015	HLAB004081-145; 194-2009-0002780-2844

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3016	001-0002-0000287-311
D.3017	EID773303-11
D.3018	001-0002-0001379-1386
D.3019	X. Han, P. Hinderliter, T. Snow, G. Jepson; Binding of Perfluorooctanoic Acid to Rat Liver-form and Kidney-form x2u-Globulins#; Drug and Chemical Toxicology, Vol. 27, No. 4, pp. 341-360, 2004
D.3020	R. Kemper, D. Nabb; InVitro Studies in Microsomes from Rat and Human Liver, Kidney, and Intestine Suggest That Perfluorooctanoic Acid Is Not A Substrate for Microsomal UDP-Glucuronosyltransferases; Drug and Chemical Toxicology, 28:281-287, 2005
D.3021	X. Han, R. Kemper, G. Jepson; Subcellular Distribution and protein Binding of Perfluorooctanoic Acid in Rat Liver and Kidney; 28:197-209, 2005
D.3022	003-0131-0004241-4641
D.3023	S. G. Hundley, A. M. Sarraf, G. L. Kennedy, Jr.; Absorption, Distribution, and Excretion of Ammonium Perfluorooctanoate (APFO) After Oral Administration to Various Species; Drug and Chemical Toxicology, 29:137-145, 2006
D.3024	S. Loveless, C. Finaly, N. Everds, et al.; Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO); Toxicology 220 (2006) 203-217
D.3025	Powley, George, van Leeuwen, et al.; Follow-up Studies on the First Interlaboratory Study on Perfluorinated Compounds in Human and Environmental Matrices; Organohalogen Compounds Vol. 68 (2006) 1688-1691
D.3026	C. Sakr, J. Symons, K. Kreckmann, R. Leonard; Ischemic Heart Disease Mortality Study among Workers with Occupational Exposure to Ammonium Perfluorooctanoate; OEM Online, 2009
D.3027	K. Kreckmann, C. Sakr, R. Leonard, B. Dawson; Estimation and Validation of Biomarker-Based Exposures for Historical Ammonium Perfluorooctanoate; J of Occup. and Env. Hygiene, 6: 511-516 (2009)
D.3028	A. Loccisano, J. Campbell Jr., J. Butenhoff, et al.; Comparison & Evaluation of Pharmacokinetics of PFOA and PFOS in the Adult Rat using a Physiologically Based Pharmacokinetic Model; Reproductive Toxicology (2011)
D.3029	A. Loccisano, J. Campbell Jr., J. Butenhoff, et al.; Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model; Reproductive Toxicology (2011)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3030	A. Loccisano, M. Longnecker, J. Campbell Jr., et al.; Development of PBPK Models for PFOA and PFOS for Human Pregnancy and Lactation Life Stages; J of Toxic and Env. Health, Part A, 76:25027, 2013
D.3031	P. Palkar, N. Torsell, P. Krishnan, et al.; A Species Difference in the Peroxisome Proliferator-Activated Receptor $\alpha$ (PPAR $\alpha$ )-Dependent Response to the Developmental Effects of Perfluorooctanoic Acid; Toxicological Sciences, 2012
D.3032	N. Everds, G. Kennedy; Serum perfluorooctanoic acid (PFOA) concentrations in normal and hyperlipidemic femal hamsters dosed orally with ammonium perfluorooctanoate (APFO) for up to 30 days; Toxicology Reports 2 (2015) 70-77
D.3033	Biegel, Liu, Hurtt, Cook; Effects of ammonium perfluorooctanoate in Leydig cell function: in vitro, in vivo, and ex vivo studies; Toxicol Appl Pharmacol. 1995 Sep; 134(1): 18-25
D.3034	W. Fasano, G. Kennedy, B. Szotek, et al.; Penetration of Ammonium Perfluorooctanoate Through Rat and Human Skin in Vitro; Drug and Chemical Toxicology, 1:79-90, 2005
D.3035	Summary of Studies 1
D.3036	RESERVED
D.3037	Table II - EPCRA Section 313 Chemical List
D.3038	Table of Regulated Drinking Water Contaminants
D.3039	TRI-Listed Chemicals
D.3040	Liu, Raymond, C., Effect of the Peroxisome Proliferator, Ammonium Perfluorooctanoate (C8), on Hepatic Aromatase Activity in Adult Male Crl:CD BR (CD) Rats
D.3041	Olsen, G.W. 2015. Chapter 4. PFAS Biomonitoring in Higher Exposed Populations, In: J.C. DeWitt (ed.). Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances. Molecular and Integrative Toxicology. Spring International Publishing. P77-125.
D.3042	U.S. Geological Survey (USGS). 2004. Geohydrology and Simulation of Ground-Water Flow in Ohio River Alluvial Aquifers new Point Pleasant, Lubeck, Parkersburg, Vienna, Moundsville, and Glendale, West Virginia. Scientific Investigations Report 2004-5088.
D.3043	Winqvist, A. et al. 2003. Design, Methods, and population for a study of PFOA Health Effects among Highly Exposed Mid-Ohio Valley Community Members and Workers. Environmental Health Perspectives. 121(8):893-899.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3044	Bureau of Labor Standards (BLS). (1970). Safety and health regulations for ship repairing, shipbuilding, and shipbreaking; hazardous materials. 35 FR 10. January 1.
D.3045	Department of Labor (DOL). (1960a). Safety and helath regulations for ship repairing. 25 FR 1543. February 20.
D.3046	Department of Labor (DOL). (1960b). Safety and helath regulations for logshoring. 25 FR 1565. February 20.
D.3047	NIOSH (1974). A Recommended Standard....An Identification System for Occupationally Hazardous Materials. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Center for Disease Control, National Institute for Occupational Safety and Health.
D.3048	Occupational Safety and Health Administration (OSHA). (1972). Material Safety Data Sheet. Form OSHA-20 Rev. May 72.
D.3049	Occupational Safety and Health Administration (OSHA). (1985). Material Safety Data Sheet. Form OSHA 174 Sept. 1985.
D.3050	42 Federal Register, 5372, January 28, 1972.
D.3051	46 Federal Register, 4411, January 16, 1982.
D.3052	46 Federal Register, 12214, February 13, 1981.
D.3053	48 Federal Register, 53280, November 25, 1983.
D.3054	47 Federal Register, 12092, March 19, 1982.
D.3055	Hanhijarvi, H., et al. "Elimination and toxicity of perfluorooctanoic acid during subchronic administration in the Wistar rat." <i>Pharmacol Toxicol</i> 61.1 (1978): 66-68.
D.3056	Hanhijarvi, H., R.H. Ophaug, and L. Singer. "The sex-related difference in perfluorooctanoate excretion in the rat." <i>Exp Biol Med</i> 171.1 (1982): 50-55.
D.3057	Olsen, G.W., et al. "Plasma Cholecystikinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers." <i>Drug Chem Toxicol</i> 23.4 (2000): 603-620.
D.3058	Sohlenius, A., K. Andersson, and J.W. DePierre, "The effects of perfluorooctanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice." <i>Biochem J</i> 285.3 (1992): 779-783.
D.3059	Thottassery, J. et al. "Regulation of perfluorooctanoic acid-induced peroxisomal enzyme activities and hepatocellular growth by adrenal hormones." <i>Hepatol</i> 15.2 (1992):316-322.
D.3060	Ylinen, M., et al. "Disposition of Perfluorooctanoic acid in the rat after single and subchronic administration." <i>B Environ Contam Tox</i> 44.1 (1990): 46-53.
D.3061	Ylinen, M., et al. "Stimulation by oestradiol of the urinary excretion of perfluorooctanoic acid in the male rat." <i>Pharmacol Toxicol</i> 65.4 (1989): 274-277.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3062	Leach et al. v. DuPont, Joint Motion for Preliminary Approval of Settlement and Related Matters, 9/25/2005.
D.3063	U.S. EPA - Lifetime Health Advisories and Health Effects Support Documents for Perfluorooctanoic Acid and Perfluorooctane Sulfonate, Federal Register 81(101): 33250-33251, 5/25/16
D.3064	U.S. EPA - Fact Sheet PFOA & PFOS Drinking Water Health Advisories, May 2016
D.3065	U.S. EPA - Health Effects Support Document for Perfluorooctane Sulfonate (PFOS), EPA 822-R-16-003, May 2016.
D.3066	U.S. EPA - Health Effects Support Document for Perfluorooctanoic Acid(PFOA), EPA 822-R-16-003, May 2016.
D.3067	U.S. EPA - Drinking Water Health Advisory for Perfluorooctane Sulfonate (PFOS), EPA 822-R-16-004, May 2016.
D.3068	U.S. EPA - Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA), EPA 822-R-16-005, May 2016.
D.3069	U.S. EPA - EPA Response to External Peer Review Comments on EPA Draft Documents: Health Effects Support Document for Perfluorooctanoic Acid (PFOA) and Health Effects Support Document for Perfluorooctane Sulfonate (PFOS), May 2016.
D.3070	Bockenforde, M. The operationalization of the precautionary approach in international environmental law treaties - Enhancement or façade ten years after Rio?" 2003, Max-Planck-Institut fur auslandisches offentliches Recht und Volkerrecht, ZaoRV 63(2003).
D.3071	Kriebel, D., et al. The Precautionary Principle in Environmental Science, Environmental Health Perspectives, 109(9), 9/01
D.3072	Graham, J.D., The perils of the precautionary principle: Lessons from the American and European Experience, Heritage Lectures, No. 818, Delivered 10/20/2003.
D.3073	Ames, B. and Gold, L.S. Holiday Dinner Menu. New York: American Council on Science and Health (ACSH); 2004.
D.3074	Borowska, S. and Brzoska, M.M. Metals in cosmetics: implications for human health. J Appl Toxicol. 2015; 35(6):551-72.
D.3075	Gribble. G.W. Food Chemistry and chemophobia. Food Security. 2013; 5(2):177-87
D.3076	Marchant, G.E. From General Policy to Legal Rule: Aspirations and Limitations of the Precautionary Principle. Environ Health Perspect. 2003; 111(14):1799-803.
D.3077	National Research Council. Risk Assessment in the Federal Governmente -- Managing the Process. Washington DC: National Academy Press. 1983.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3078	National Research Council. Science and Decisions. Advancing Risk Assessment. Washington DC: National Academies Press. 2009
D.3079	National Toxicology Program. 13th Annual Report on Carcinogens. Research Triangle Park: National Toxicology Program, US Dept of Health and Human Services, Public Health Service, 2014.
D.3080	US EPA. Terms of Environment: definition of precautionary principle. Office of the Administrator/Officer of External Affairs and Environmental Education. 2009.
D.3081	US EPA. Risk assessment for carcinogens 2016. [updated February 5, 2016]. Available from: <a href="https://www.epa.gov/fera/risk-assessment-carcinogens">https://www.epa.gov/fera/risk-assessment-carcinogens</a> .
D.3082	US EPA. Table 1. Prioritized chronic dose-response values (5/9/2014). <a href="https://www.epa.gov/fera/dose-response-assessment-assessing-health-risks-associated-exposure-hazardous-air-pollutants">https://www.epa.gov/fera/dose-response-assessment-assessing-health-risks-associated-exposure-hazardous-air-pollutants</a> , as link to Table 1, <a href="https://www.epa.gov/sites/production/files/2014-05/documents/table1.pdf">https://www.epa.gov/sites/production/files/2014-05/documents/table1.pdf</a>
D.3083	Abu-Zidan FM, Abbas AK, Hefney AF. 2012. Clinical "case series": a concept analysis. <i>Afr Helath Sci. Dec</i> ;12(4):557-62
D.3084	Alexander DD, et al. Dairy consumption and CVD: a systemic review and meta-analysis. <i>Br J Nutr.</i> 2016 Feb;115(4):737-50. doi: 10.1017/S0007114515005000. Epub 2016 Jan 20.
D.3085	Alexander DD, et al. Meta-anlaysia of Long-chain Omega-3 Polyunsaturated Fatty Acids and prostate cancer. <i>Nutr Cancer.</i> 2015;67(4):543-54. doi: 10.1080/01635581.2015.1015745. Epub 2015 Mar 31.
D.3086	American Cancer Society. 2016. Testis: at a glance <a href="https://cancerstatisticscenter.cancer.org/">https://cancerstatisticscenter.cancer.org/</a> : Cancer Statistics Center.
D.3087	Aderson RE, et al. 2016. Cancer risks in first- and second-degree relatives of men with poor semen quality. <i>Fertil Steril.</i> Jun 20. pii: S0015-0282(16)61288-8.
D.3088	Borenstein M, et al. 2009. Introduction to Meta-Analysis. Chichester, West Sussex, UK: Wiley.
D.3089	Butenhoff JL, et al. 2012. Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. <i>Toxicology</i> , 298, 1-13.
D.3090	Cole P. 1997. Causality in epidemiology, health policy, and law. <i>Environ Law Rep</i> 27:10279-10285
D.3091	Deeks JJ, et al. 2011. Analysing data and undertaking meta-anlaysia. In: Higgins JPT, Green S, editors. Chochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
D.3092	DerSimonian R, Laird N. 1986. Meta-Analysis in Clinical Trials. Controlled Clinical Trials. New York: Elsevier Science Publishing Co., Inc; p. 177-88.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3093	Egger M, Smith GD. 1997. Meta-Analysis. Potentials and Promise. BMJ 315:1371-1374.
D.3094	Finckh A, Tramer MR. 2008. Primer: strengths and weaknesses of meta-anlaysis. Nat Clin Pract Rheumatol 4:146-152.
D.3095	Giannadrea F, et al. 2012. Case-control study of anthropometric measures and testicular cancer risk. Front Endocrinol (Lausanne). Nov 26;3:144.
D.3096	Green MD, Freedman M, Gordis L, Federal Judicial Center. 2011. Reference guide on epidemiology. Reference manual on scientific evidence. Washington, D.C.: Federal Judicial Center. P 549-632.
D.3097	Greenland S, O'Rourke, K. 2008. Meta-analysis. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins. P 652-732.
D.3098	Gurney J, et al. 2015. Cannabis exposure and risk of testicular cancer: a systemic review and meta-analysis. BMC Cancer. Nov 11;15:897.
D.3099	Hanson HA, et al. 2016. Subfertility increases risk of testicular cancer: evidence from population-based semen samples. Fertil Steril. Feb;105(2):322-8.e1.
D.3100	Hennekens, C.H. and Burning, J.E. Epidemiology in medicine. Statistical association and cause-effect relationships. Mayrent, S.L. 30-53. 1987. Toronto, Little, Brown and Company.
D.3101	Higgins JP & Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21,1539-1558.
D.3102	Humphrey PA, Schuz J. 2014. Cancers of the male reproductive organs. In: Stewart BW, Wild CP editors. World Cancer Report 2014 Lyon: International Agency for Research on Cancer. P 453-464.
D.3103	Kozlowski P, et al. 2016. Epidemiology and risk factors of testicular tumours. Pol Merkur Lekarski. Apr;10(238):211-5
D.3104	McGlynn KA, Trabert B. 2012. Adolescent and adult risk factors for testicular cancer. Nat Rev Urol. Apr 17;9(6):339-49.
D.3105	National Cancer Institute. 2016. Testicular Cancer -- health profession version. <a href="http://www.cancer.gov/types/testicular/hp">Http://www.cancer.gov/types/testicular/hp</a> . National Cancer Institute at the National Institutes for Health.
D.3106	Noble JH, Jr. 2006. Meta-analysis: Methods, strengths, weaknesses, and political uses. J Lab Clin Med 147:7-20
D.3107	Pathak A, et al. 2015. Prospectively Identified Incident Testicular Cancer Risk in a Familial Testicular Cancer Cohort. Cancer Epidemiol Biomarkers Prev. Oct;24(10):1614-21.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3108	Sibinski LJ. 1987. Two year oral (diet) toxicity/carcinogenicity study of fluorochemical FC-143 in rats. Experiment No. 0281CR0012. Report prepared for 3M, St. Paul, Minnesota by Riker Laboratories, Inc., U.S. EPA Public Docket AR 226-0437, Washington, D.C.
D.3109	Stevenson SM, Lowrance WT. 2015. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am. Aug;42(3):269-75.
D.3110	Walker E, et al. 2008. Meta-analysis: Its strengths and limitations. Cleve Clin J Med 75:431-439.
D.3111	Zwahlen, et al. 2008. Meta-analysis in medical research: potentials and limitations. Urol Oncol 26:320-329.
D.3112	Expert Report of Dominik D. Alexander, Ph.D., M.S.P.H.
D.3113	Expert Report of Robert E. Glenn, M.P.H., CIH
D.3114	Expert Report of Bryan D. Hardin, Ph.D., A.T.S.
D.3115	Expert Report of Marianne L. Horinko
D.3116	Supplemental Expert Report of Robert W. Rickard, Ph.D., D.A.B.T.
D.3117	Expert Report of Stephen T. Washburn (Aug. 2016)
D.3118	MSDS Boos Block Board Cream
D.3119	MSDS North 201 Protective Hand Cream
D.3120	MSDS Sulf/OxyDex Shampoo
D.3121	MSDS DVM HyLyt Dog Shampoo
D.3122	MSDS P&G Tide
D.3123	EID136830-31
D.3124	Olsen, G.W., et al. 2007b. Preliminary Evidence of a Decline in Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations in American Red Cross Blood Donors. Chemosphere. 68(1):105-117.
D.3125	Olsen, G.W., et al. 2012. Temporal Trends of Perfluoroalkyl Concentrations in American Red Cross Adult Blood Donors, 2000-2010. Environmental Science and Technology. 146:6330-6338.
D.3126	Paustenbach, D.J., et al. 2007. A Methodology for Estimating Human Exposure to Perfluorooctanoic Acid (PFOA): A Retrospective Exposure Assessment of a Community (1951-2003). J. Toxicology Envtl. Health. 70(Part A):28-57.
D.3127	Sakr, C.J., et al. 2007. Longitudinal Study of Serum Lipids and Liver Enzymes in Workers with Occupational Exposure to Ammonium Perfluorooctanoate. JOEM. 49(8):872-879.
D.3128	016-0002-0007570 - 94
D.3129	20150623_173023_00016775-1 to 00016777-1

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3130	EID077278
D.3131	EID079710-27
D.3132	EID110963
D.3133	EID127329-68
D.3134	EID160301-04
D.3135	EID350212
D.3136	EID455907-08
D.3137	EID522167-85
D.3138	EID577579-80
D.3139	EID579287-96
D.3140	EID691489-506
D.3141	EID691507-28
D.3142	EID712682-84
D.3143	EID715345-52
D.3144	EID775918-42
D.3145	Anderson-Mahoney P, Kotlerman J, Takhar H, et al. Self-reported health effects among community residents exposed to perfluorooctanoate. <i>New Solut</i> 2008;18(2):129-143.
D.3146	MacNeil J, Steenland NK, Shankar A, et al. A cross-sectional analysis of type II diabetes in a community with exposure to perfluorooctanoic acid (PFOA). <i>Environ Res</i> 2009;109(8):997-1003.
D.3147	So MK, Yamashita N, Taniyasu S, et al. Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. <i>Environ Sci Technol</i> 2006;40(9):2924-2929.
D.3148	Apelberg BJ, Witter FR, Herbstman JB, et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. <i>Environ Health Perspect</i> 2007;115(11):1670-1676.
D.3149	Lin CY, Chen PC, Lin YC, et al. Association among serum perfluoroalkyl chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. <i>Diabetes Care</i> 2009;32(4):702-707.
D.3150	Hall, A.P. et al. Liver Hypertrophy: A Review of Adaptive (Adverse and Non-adverse) Changes—Conclusions from the 3rd International ESTP Expert Workshop. <i>Toxicol Path</i> , 40:971-994, 2012.
D.3151	James, J.T and Gardner, D.E. Exposure limits for airborne contaminants in spacecraft atmospheres. <i>App Occup Environ Hyg</i> , 11(12):1424-1432, 1996.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3152	Gortner, EG. 1982. Oral Teratology study of T-3141CoC in rabbits. Safety Evaluation Laboratory and Riker Laboratories, Inc. Experiment No. 0681TB0398. USEPA Public Docket AR-226-0465; Gortner, EG. 1982.
D.3153	Weisberger, J.H. and Williams, G.M, Chemical Carcinogens, Chapter 6 in Casarett and Doull's Toxicology: The Basis Science of Poisons (2nd Edition), Macmillan Publishing Co., 1980, pp 84-138.
D.3154	U.S. EPA, Integrated Risk Information System (IRIS) Assessment for chloroform, available at <a href="https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=25">https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=25</a> .
D.3155	U.S. EPA, Integrated Risk Information System (IRIS) Assessment for perchlorate (ClO <sub>4</sub> ) and perchlorate salts, available at <a href="https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=1007">https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=1007</a> .
D.3156	U.S. EPA, Integrated Risk Information System (IRIS) Assessment for ethylene glycol monobutyl ether (EGBE) (2-butoxyethanol), available at <a href="https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=500">https://cfpub.epa.gov/ncea/iris2/chemicalLanding.cfm?substance_nmbr=500</a> .
D.3157	Ikeda, T., et al., The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. J. Biochem. 98:475-482, 1985.
D.3158	Elcombe, C.R., and Mitchell, A.M., Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): Species differences and possible mechanisms, Environmental Health Perspectives 70:211-219, 1986;
D.3159	Clegg E.D. et al., Leydig cell hyperplasia and adenoma formation: Mechanisms and relevance to humans. Reprod Toxicol 11(1):107-21, 1997.
D.3160	U.S. EPA. Guidelines for Carcinogen Risk Assessment. U.S. Environmental Protection Agency. EPA/630/R-00/004. September 1986.
D.3161	Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009 Nov 15;170(10):1268-78. Epub 2009 Oct 21.
D.3162	U.S. EPA. Guidelines for Carcinogen Risk Assessment, Review Draft. U.S. Environmental Protection Agency. NCEA-F-0644, July 1999.
D.3163	U.S. EPA. An SAB Report: Guidelines for Cancer Risk Assessment. Science Advisory Board. EPA-SAB-EHC-97-410, September 1997.
D.3164	Anna. D.H. The Occupational Environment: It's Evaluation. Control and Management. Vol. I, 3rd. AIHA, Fairfax, VA. 2011, p.60.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3165	Klaassen, C.D. Assert and Doull's Toxicology: The Basic Science of Poisons. New York. McGraw-Hill. 2013. p.1394.
D.3166	International Agency for Research on Cancer (IARC). 2004. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 83: Tobacco Smoke and Involuntary Smoking. Lyon, France: IARC.
D.3167	Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med 2010;164(9):860-869.
D.3168	RESERVED
D.3169	Lin CY, Wen LL, Lin LY, et al. Associations between levels of serum perfluorinated chemicals and adiponectin in a young hypertension cohort in Taiwan. Environ Sci Technol 2011;45(24):10691-10698.
D.3170	RESERVED
D.3171	RESERVED
D.3172	Bloom MS, Kannan K, Spliethoff HM, et al. Exploratory assessment of perfluorinated compounds and human thyroid function. Physiol Behav 2010;99(2):240-245.
D.3173	Chan E, Burstyn I, Cherry N, et al. Perfluorinated acids and hypothyroxinemia in pregnant women. Environ Res 2011;111(4):559-564.
D.3174	Inoue K, Okada F, Ito R, et al. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect 2004;112(11):1204-1207.
D.3175	Kim S, Choi K, Ji K, et al. Trans-placental transfer of thirteen perfluorinated compounds and relations with fetal thyroid hormones. Environ Sci Technol 2011;45(17):7465-7472.
D.3176	Knox SS, Jackson T, Frisbee SJ, et al. Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. J Toxicol Sci 2011;36(4):403-410.
D.3177	Melzer D, Rice N, Depledge MH, et al. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect 2010;118(5):686-692.
D.3178	Pirali B, Negri S, Chytiris S, et al. Perfluorooctane sulfonate and perfluorooctanoic acid in surgical thyroid specimens of patients with thyroid diseases. Thyroid 2009;19(12):1407-1412.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3179	Raymer JH, Michael LC, Studabaker WB, et al. Concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements. <i>Reprod Toxicol</i> 2012;33(4):419-427. Epub date 2011/07/09.
D.3180	EPA. 2002. A review of the reference dose and reference concentration processes. EPA/630/P-02/002F. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC.
D.3181	RESERVED
D.3182	Harada K, Inoue K, Morikawa A, Yoshinaga T, Saito N, Koizumi A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. <i>Environ Res</i> 2005;99(2):253-261.
D.3183	Cain L, Shankar A, Ducatman AM, Steenland K. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. <i>Nephrol Dial Transplant</i> 2010;25(11):3593-3599.
D.3184	RESERVED
D.3185	Lopez-Espinosa MJ, Fletcher T, Armstrong B, Genser B, Dhatariya K, Mondal D, Ducatman A, Leonardi G. Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with age of puberty among children living near a chemical plant. <i>Environ Sci Technol</i> 2011;45(19):8160-8166.
D.3186	Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in women exposed to perfluorocarbons. <i>J Clin Endocrinol Metab</i> 2011;96(6):1747-1753.
D.3187	Klaassen, CD et al. 2009. Metallothionein Protection of Cadmium Toxicity. <i>Toxicol Appl Pharmacol</i> , 238, 215-220.
D.3188	Tabershaw I. R. Conference on Ethical Issues in Occupational Medicine. Summary. <i>Bull N Y Acad Med</i> . 1978 Sep; 54(8): 810–817.
D.3189	Lieberman M. Summary of the discussion: the duty to report hazards. <i>Bull N Y Acad Med</i> . 1978 Sep; 54(8): 795– 796.
D.3190	United Nations Conference of Environmental and Development (UNCED), Declaration of Rio. Rio de Janeiro, Brazil: UN 1992. (Principle 15).
D.3191	Scientific and Policy Analysis of Persistent, Bioaccumulative, and Toxic Chemicals: A Comparison of Practices in Asia, Europe, and North America. Consensus Panel Report, November 2013.
D.3192	Casarett & Doull's Toxicology: The Basic Science of Poisons, 8th ed. Chapter 7: Toxicokinetics



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3193	Fourth National Report on Human Exposure to Environmental Chemicals. Centers for Disease Control and Prevention, 2009.
D.3194	Casarett & Doull's Toxicology: The Basic Science of Poisons, 8th ed. Chapter 14: Toxic Responses of the Kidney
D.3195	U.S. EPA. Proposed Guidelines for Carcinogen Risk Assessment. U.S. Environmental Protection Agency. EPA/600/P-92/003C, April 1996.
D.3196	RESERVED
D.3197	RESERVED
D.3198	Adami HO, Hunter D, Trichopoulos D. 2008. Textbook of cancer epidemiology Oxford: Oxford University Press. i-748 p.
D.3199	Alexander DD, Weed DL, Miller PE, Mohamed MA. 2015. Red Meat and Colorectal Cancer: A Quantitative Update on the State of the Epidemiologic Science, J Am Coll Nutr. 2015 Nov-Dec;34(6):521-43.
D.3200	Alexander DD, Mink PJ, Cushing CA, Scurman B. 2010. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. NutrJ 9:50.
D.3201	Alexander, D.D., Mink, P.J., Adami, H-O., et al. Multiple myeloma: a review of the epidemiologic literature. Int. J. Cancer 120, 40-61.
D.3202	Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D. 2007. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120 Suppl 12:1-39.
D.3203	American Cancer Society. 2016. Key Statistics / Risk Factors. Atlanta, GA.
D.3204	American Diabetes Association. (last edited, April 1, 2016). Statistics about Diabetes; National Diabetes Statistics Report 2014. <a href="http://www.diabetes.org/diabetes-basics/statistics/?loc=dbslabnav">http://www.diabetes.org/diabetes-basics/statistics/?loc=dbslabnav</a>
D.3205	Amirian ES, Armstrong GN, Zhou R., et al. 2016. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am J Epidemiol, 183(2), 85-91.
D.3206	Archer, NP, Napier TS, Villanacci, JF. 2016. Fluoride exposure in public drinking water and childhood and adolescent osteosarcoma in Texas. Cancer Causes Control, 27(7), 863-868.
D.3207	Baker D, Nieuwenhuijsen MJ. 2008. Environmental epidemiology: study methods and application. Oxford University Press. 398 p.
D.3208	Boffetta P, Trichopoulos D. 2008. Cancer of the Lung, Larynx, and Pleura. In: Adami HO, Hunter D, Trichopoulos D editors. Textbook of cancer epidemiology, Second edition New York: Oxford University Press. p 349-377.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3209	RESERVED
D.3210	Burger, M et al. 2013. Epidemiology and Risk Factors of Urothelial Bladder Cancer. <i>European Urology</i> 63(2): 234-241.
D.3211	Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. <i>Nutr J.</i> 2015 Dec 21;14(1):125.
D.3212	Capstick, Kuster, Kühn, et al. (2016). Report of Partial Findings from the National Toxicology Program Carcinogenesis Studies of Cell Phone Radiofrequency Radiation in Hsd: Sprague Dawley® SD rats (Whole Body Exposures).
D.3213	Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014.
D.3214	Chang ET, Adami HO, Boffetta P, Wedner HJ, Mandel JS. 2016. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. <i>Crit Rev Toxicol.</i> 44, NO. 4, 279-331.
D.3215	Chen, Xin-Zu et al.2015. Epstein–Barr Virus Infection and Gastric Cancer: A Systematic Review. Ed. Mohammad Derakhshan. <i>Medicine</i> 94.20 (2015): e792.
D.3216	Cho E, Lindblad P, Adami HO. 2008. Kidney Cancer. In: Adami HO, Hunter D, Trichopoulos D editors. <i>Textbook of Cancer Epidemiology</i> New York: Oxford University Press. p 597-616.
D.3217	Coca-Pelaz A, Rodrigo JP, Takes RP, et al. (2013). Relationship between reflux and laryngeal cancer. <i>Head Neck</i> , 35(12), 1814-1818.
D.3218	Coureau, G., Bouvier, G., Lebailly, P., et al. 2014. Mobile phone use and brain tumours in the CERENAT case-control study. <i>Occup Environ Med</i> , 71(7), 514-522.
D.3219	Da Li, Qing et al. 2012. Nutrition Deficiency Increases the Risk of Stomach Cancer Mortality. <i>BMC Cancer</i> 12: 315.
D.3220	Deeks JJ, Higgins JPT, Altman DG. 2011. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0. The Cochrane Collaboration.
D.3221	Eastmond, D.A., Keshava, N., Sonawane, B., 2014. Lymphohematopoietic cancers induced by chemicals and other agents and their implications for risk evaluation: an overview. <i>Mutation Research/Reviews in Mutation Research</i> 761, 40-64.
D.3222	Egger M, Smith GD, Altman DG. 2001. <i>Systematic reviews in health care: Meta-analysis in context</i> . London: BMJ Publishing Group. 487 p.
D.3223	Elwood JM. 1998. <i>Critical appraisal of epidemiological studies and clinical trials</i> . Oxford: Oxford University Press. 448 p.



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3224	Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors. <i>Ann Intern Med</i> . 2000;133:635-646.
D.3225	Fortes C, Mastroeni S, Segatto MM, et al. 2016. Occupational Exposure to Pesticides With Occupational Sun Exposure Increases the Risk for Cutaneous Melanoma. <i>J Occup Environ Med</i> , 58(4), 370-375.
D.3226	RESERVED
D.3227	Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. <i>Circulation</i> 2014 Jan 21;129(3):399-410.
D.3228	Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. <i>Circulation</i> 2014 Jan 21;129(3):e28-e292.
D.3229	Gordis L. 2009. <i>Epidemiology</i> . Philadelphia, PA: Saunders- Elsevier.
D.3230	Gousias, K., Markou, M., Voulgaris, S., et al. (2009). Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005-2007. <i>Neuroepidemiology</i> , 33(2), 89-95.
D.3231	Hankinson S, Tamimi R, Hunter D. 2008. Breast Cancer. In: Adami HO, Hunter D, Trichopoulos D editors. <i>Textbook of Cancer Epidemiology</i> New York: Oxford University Press. p 403-445.
D.3232	Hardell, L., Carlberg, M., Soderqvist, F., & Mild, K. H. (2013). Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use. <i>Int J Oncol</i> , 43(6), 1833-1845.
D.3233	RESERVED
D.3234	IARC. International Agency For Research On Cancer: Cancer Today. World Health Organization, 2016. <a href="http://gco.iarc.fr/today/home">http://gco.iarc.fr/today/home</a> ; <a href="http://gco.iarc.fr/today/fact-sheets-cancers">http://gco.iarc.fr/today/fact-sheets-cancers</a> .
D.3235	IARC. 2014. World Cancer Report 2014 Lyon, France: International Agency for Research on Cancer, World Health Organization.
D.3236	Innes KE, Ducatman AM, Luster MI, Shankar A. Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large Appalachian population. <i>Am J Epidemiol</i> 2011;174:440-450.
D.3237	Kawicka A et al. 2015. Metabolic disorders and nutritional status in autoimmune thyroid diseases. <i>Postepy Hig Med Dosw (Online)</i> . 2015 Jan 2;69:80-90.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3238	Kim, S. J., Ioannides, S. J., & Elwood, J. M. (2015). Trends in incidence of primary brain cancer in New Zealand, 1995 to 2010. <i>Aust N Z J Public Health</i> , 39(2), 148-152.
D.3239	Klein, Alison P. 2013. Identifying People at a High Risk of Developing Pancreatic Cancer. <i>Nature reviews. Cancer</i> 13.1: 66–74.
D.3240	Kochanek KD, Xu JQ, Murphy SL, Minino AM, Kung HC. Deaths: final data for 2009. <i>National vital statistics reports</i> . U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention; 2011 Dec 29.
D.3241	Kuo CL, Chen YT, Shiao AS, et al. 2015. Acid reflux and head and neck cancer risk: A nationwide registry over 13 years. <i>Auris Nasus Larynx</i> , 42(5), 401-405.
D.3242	Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. <i>Stroke</i> 2014 Jan;45(1):315-53.
D.3243	Last JM. 1995. A dictionary of epidemiology (Handbooks sponsored by the IEA and WHO). Oxford University Press; 3 edition (May 25, 1995).
D.3244	Le Clair MZ, Cockburn MG 2016. Tanning bed use and melanoma: Establishing risk and improving prevention interventions. <i>Prev Med Rep</i> , 3, 139-144.
D.3245	Lichtman, M.A., 2010. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. <i>Oncologist</i> . 15, 1083-1101.
D.3246	Lilienfeld DE, Stolley PD. 1994. <i>Foundations of Epidemiology</i> . New York: Oxford University Press.
D.3247	RESERVED
D.3248	RESERVED
D.3249	Linnet, M., Devesa, S., Morgan, G., 2006. The Leukemias, in: Schottenfeld, D., Fraumeni, J.F., Jr. (Eds.), <i>Cancer Epidemiology and Prevention</i> . Oxford University Press, U.S.A., pp. 841-871.
D.3250	Liu, YX., Li, GQ, Fu, XP, et al. 2015. Exposure to 3G mobile phone signals does not affect the biological features of brain tumor cells. <i>BMC Public Health</i> , 15, 764.
D.3251	Maasland DH, van den Brandt PA, Kremer B, Schouten LJ. 2015. Body mass index and risk of subtypes of head-neck cancer: the Netherlands Cohort Study. <i>Sci Rep</i> , 5, 17744.
D.3252	Mackie RM, Hauschild A, Eggermont AM. 2009. Epidemiology of invasive cutaneous melanoma. <i>Ann Oncol</i> , 20 Suppl 6, vi1-7.
D.3253	March of Dimes. Preeclampsia Available: <a href="http://www.marchofdimes.org/complications/preeclampsia.aspx">http://www.marchofdimes.org/complications/preeclampsia.aspx</a> . Accessed 9/12/2016, 2016.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3254	Mausner JS, Kramer S. 1985. Epidemiology: An Introductory Text. Philadelphia: WB Saunders Company.
D.3255	Melbye, M., Ekstrom Smedby, K., Trichopoulos, D., 2008a. Non-Hodgkin Lymphoma, in: Adami, H.O., Hunter, D., Trichopoulos, D. (Eds.), Textbook of Cancer Epidemiology. Oxford University Press, New York, pp. 669-693.
D.3256	RESERVED
D.3257	Menvielle G, Fayosse A, Radoi L, et al. 2016. The joint effect of asbestos exposure, tobacco smoking and alcohol drinking on laryngeal cancer risk: evidence from the French population based case-control study, ICARE. Occup Environ Med, 73(1), 28-33.
D.3258	RESERVED
D.3259	RESERVED
D.3260	RESERVED
D.3261	Murphy SL, Xu JQ, Kochanek KD. Deaths: Final data for 2010. National Vital Statistics Report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2013.
D.3262	National Cancer Institute. (2016). General Information about Melanoma. Melanoma Treatment – Health Professional Version.
D.3263	National Cancer Institute. 2016. General Information About Adult Primary Central Nervous System (CNS) Tumors. Adult Central Nervous System Tumors Treatment-Health Professional Version. Retrieved from <a href="https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq">https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq</a> .
D.3264	National Cancer Institute. (2016). Laryngeal Cancer Treatment –Health Professional Version. Head and Neck Cancer. Retrieved from <a href="https://www.cancer.gov/types/head-and-neck/hp/laryngeal-treatment-pdq">https://www.cancer.gov/types/head-and-neck/hp/laryngeal-treatment-pdq</a>
D.3265	National Institute of Diabetes and Digestive and Kidney Diseases. (2014). Causes of Diabetes. <a href="https://www.niddk.nih.gov/health-information/diabetes/causes">https://www.niddk.nih.gov/health-information/diabetes/causes</a>
D.3266	National Institutes of Health. 2016. A Snapshot of Liver Cancers. Bethesda, MD: National Cancer Institute, 2016. Print.
D.3267	National Institutes of Health. 2016. SEER Stat Fact Sheets: National Cancer Institute. Bethesda, MD.
D.3268	Nelson JW, EE Hatch, and TF Webster. 2010. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 118:197-202.
D.3269	Ngoan, L T et al. 2002. Dietary Factors and Stomach Cancer Mortality. British Journal of Cancer 87.1 (2002): 37–42.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3270	RESERVED
D.3271	Offermans NS, Vermeulen R, Burdorf A, et al. 2014. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in the prospective Netherlands cohort study. <i>J Occup Environ Med</i> , 56(1), 6-19.
D.3272	Ostrom, QT, Gittleman, H, Stetson, L, et al. 2015. Epidemiology of gliomas. <i>Cancer Treat Res</i> , 163, 1-14.
D.3273	Park SM, Li T, Wu S, et al. 2016. Vitamin D Intake and Risk of Skin Cancer in US Women and Men. <i>PLoS One</i> , 11(8), e0160308.
D.3274	Petitti DB. 2000. Meta-analysis, decision analysis, and cost-effectiveness analysis. <i>Methods for quantitative synthesis in medicine</i> . New York: Oxford University Press. 303 p.
D.3275	Petridou, E., Pourtsidis, A., Trichopoulos, D., 2008. Leukemias, in: Adami, H.O., Hunter, D., Trichopoulos, D. (Eds.), <i>Textbook of cancer epidemiology</i> . Oxford University Press, Oxford, pp. 694-715.
D.3276	Ribero S, Glass D, Bataille V. 2016. Genetic epidemiology of melanoma. <i>Eur J Dermatol</i> , 26(4), 335-339.
D.3277	Rothman KJ, Greenland S, Lash TL. 2008. <i>Modern epidemiology</i> . Lippincott Williams & Wilkins. 758 p.
D.3278	Rubenstein, Joel H., and Nicholas J. Shaheen. 2015. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma <i>Gastroenterology</i> 149.2 : 302–317.
D.3279	Ryerson, A. Blythe et al. Annual Report To The Nation On The Status Of Cancer, 1975-2012, Featuring The Increasing Incidence Of Liver Cancer. <i>Cancer</i> 122.9 (2016): 1312-1337.
D.3280	Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease. <i>Circulation</i> 2007 Jan; 115:450-458.
D.3281	Sato Y, Kiyohara K, Kojimahara N, Yamaguchi N. 2016. Time trend in incidence of malignant neoplasms of the central nervous system in relation to mobile phone use among young people in Japan. <i>Bioelectromagnetics</i> , 37(5), 282-289.
D.3282	Schlesselman JJ. 1982. <i>Case-Control Studies: Design, Conduct, Analysis</i> . New York: Oxford University Press.
D.3283	RESERVED
D.3284	Shankar, A., J. Xiao, and A. Ducatman. 2011. Perfluoroalkyl chemicals and chronic kidney disease in US adults. <i>Am J Epidemiol</i> 174:893-900.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3285	Shivappa N, Hebert JR, Rosato V, et al. 2016. Inflammatory potential of diet and risk of laryngeal cancer in a case-control study from Italy. <i>Cancer Causes Control</i> , 27(8), 1027-1034.
D.3286	Shrestha M, Raitanen J, Salminen T, et al. 2015. Pituitary tumor risk in relation to mobile phone use: A case-control study. <i>Acta Oncol</i> , 54(8), 1159-1165.
D.3287	Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, N.L., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W., 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon.
D.3288	Szklo M, Nieto FJ. 2007. <i>Epidemiology: beyond the basics</i> . Sudbury, Massachusetts: Jones and Bartlett Publishers. 488 p.
D.3289	Walsh KM, Ohgaki H, Wrensch, MR. 2016. <i>Epidemiology</i> . <i>Handb Clin Neurol</i> , 134, 3-18.
D.3290	Wang, J., Liu, H., Liu, X., & Qi, X. (2015). Effect of variation of FGF2 genotypes on the risk of osteosarcoma susceptibility: a case control study. <i>Int J Clin Exp Med</i> , 8(4), 6114-6118
D.3291	World Health Organization (WHO). Global status report on noncommunicable diseases 2010. World Health Organization; 2011.
D.3292	World Health Organization. (2016). Skin cancers. Ultraviolet radiation and the INTERSUN Programme.
D.3293	World Health Organization. (2016). Chronic rheumatic conditions; Department of Chronic Diseases and Health Promotion, Chronic Respiratory Diseases and Arthritis (CRA). Source: <a href="http://www.who.int/chp/topics/rheumatic/en/">http://www.who.int/chp/topics/rheumatic/en/</a> .
D.3294	Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. <i>JAMA</i> 2012 Mar 28;307(12):1273-83.
D.3295	Yang, Yang et al. Prospective Cohort Studies of Association between Family History of Liver Cancer and Risk of Liver Cancer. <i>International Journal of Cancer</i> . <i>Journal international du cancer</i> 135.7 (2014): 1605–1614. PMC. Web. 14 Sept. 2016.
D.3296	Yoo WS, Chung HK. Recent Advances in Autoimmune Thyroid Diseases. <i>Endocrinol Metab</i> (Seoul). 2016. <a href="http://www.ncbi.nlm.nih.gov/pubmed/27586448">http://www.ncbi.nlm.nih.gov/pubmed/27586448</a>
D.3297	Chapman, S., Azizi, L., Luo, Q., & Sitas, F. (2016). Has the incidence of brain cancer risen in Australia since the introduction of mobile phones 29 years ago? <i>Cancer Epidemiol</i> , 42, 199-205.
D.3298	Centers for Disease Control (CDC). 2014. Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, February 2015.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3299	The Chemours Company (Chemours). 2015. Quarterly Progress Report No. 36. Order on Consent, Chemours Washington Works. SDWA-03-2009-0127 DS, SDWA-05-2009-0001, Order on Consent. October 1.
D.3300	Animal Study - J. Klaunig, M. Babich, K. Baetcke, et al.; PPAR $\alpha$ Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance; Critical Review in Toxicology, 33(6): 655-780, 2003
D.3301	Animal Study - J. Rae, S. Frame, G. Kennedy, J. Butenhoff, S. Chang; Pathology review of proliferative lesions of the exocrine pancreas in two chronic feeding studies in rats with ammonium perfluorooctanoate; Toxicology Reports 1 (2014) 85-91
D.3302(R)	Costa, G.C., et al. 2009. Thirty Years of Medical Surveillance in Perfluorooctanoic Acid Production Workers. Journal of Occupational and Environmental Medicine. 51(3): 1-9. (Miteni Study) - with cover page, Bilott 3/6/09 cover letter to TSCA and Joensen article, DO Perfluoroalkyl Compounds Impair Human Semen Quality?
D.3303	RJZ005098-100
D.3304	EID134428-69 DE000203-44
D.3305	Praxair Safety Data Sheet (SDS) P-4562 for Ammonia, anhydrous
D.3306	Chemours Safety Data Sheet (SDS) re Hydrogen Fluoride Anhydrous, Ref. 130000052757
D.3307	Synquest Labs Safety Data Sheet (SDS) 1100375 re 1H-Perfluoroheptane
D.3308	P. Brownson; Dow emails with M. Dreger; ACDEM re Council Review of Positoin Statement on Indoor Mold
D.3309	J. Jaffe, M. Masanari; Nondisclosure of conflicts of interest is perilous to the advancement of science; Journal of Allergy and Clinical Immunology, February, 2007
D.3310	J. Craner; A Critique of the ACOEM Statement on Mold: Undisclosed Conflicts of Interest in the Creation of an "Evidence-based" Statement; Int. J. Occup Environ Health 2008, 14:283-298
D.3311	Slide - Percentage of C8 Released to the Ohio River or Air versus Recovered, Treated and Destroyed, or Disposed Offsite (1980-2003)
D.3312	DuPont Form 8-K
D.3313	DuPont Form 10-Q - Quarterly Report for period ending 9/30/16
D.3314	H. Deitzler email to L. Stennes, L. Janssen "commending the 'extraordinary' effort of DuPont leadership"
D.3315	DuPont Washington Works Final CATT Report with Attachments August 2002 (262.972)



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3316	Federal Register, Vol. 64, No. 209 - EPA 40 CFR Part 372: Persistent Bioaccumulative Toxic (PBT) Chemicals; Lowering of Reporting Thresholds for Certain PBT Chemicals; Addition of Certain PBT Chemicals; Community Right-to-Know Toxic Chemical Reporting
D.3317	Textbook of Clinical Occupational and Environmental Medicine", 2nd Edition; Edited by Linda Rosenstock, Mark R. Cullen, Carl Andrew Brodtkin, Carrie A. Redlich. 1st Edition 1994; 2nd Edition 2005
D.3318	CV of Dominik D. Alexander, PhD, MSPH (June 2016)
D.3319	CV of Charles David Cooper, PhD, PE, QEP (Updated: Aug. 2014)
D.3320	CV of Marion J. Fedoruk, MD, CH, DABT, FACMT, FACOEM (12/2015)
D.3321	CV of Robert E. Glenn, CIH, M.P.H.; Glenn Consulting Group, LLC
D.3322	CV of Tony Luongo, MD, FRCSC, FACS (10/15)
D.3323	CV of Michael Andrew Maier, M.S., Ph.D., CIH, DABT; University of Cincinnati
D.3324	Information regarding TERA (Toxicology Excellence for Risk Assessment); University of Cincinnati's College of Medicine, Department of Environmental Health
D.3325	Select pages from book by Elissa A. Resnick and Michael Siegel; Marketing Public Health-Strategies to Promote Social Change
D.3326	Carrie Redlich handwritten notes re Flu vaccine and Standard of Care
D.3327	"The Finalists in Dr. Siegel's 2010 'Lie of the Year Award'"; Missouri Group Against Smoking Pollution
D.3328	"Finalists Announced for 2016 Lie of the Year Award"; The Rest of the Story: Tobacco News Analysis and Commentary
D.3329	"Surgeon General's Communications Misrepresent Findings of Report; Tobacco Control Practitioners Appear Unable to Accurately Portray the Science"; The Rest of the Story: Tobacco News Analysis and Commentary, by Michael Siegel
D.3330	"Where there's smoke...there's Dr. Siegel"; Boston Globe
D.3331	Review of "The Merchants of Doubt: A Review ... And The Curious Case of Michael Siegel"; by Naomi Oreskes and Erik M. Conway (posted on Pepe's Non-Smoking Party Time Lounge
D.3332	"Mike Siegel inappropriately blames the failure of his ill-advised research plans on others"; EP-ology research and analysis by Carl V. Phillips
D.3333	"A study of potential human health impacts from petroleum coke transfer facilities"; Michael Dourson, Lyle Chinkin; David MacIntosh, Jennifer Finn, Kathleen Brown, Stephen Reid, and Jeanelle Martinez; Journal of the Air & Waste Management Association, 2016 Vol. 66, No. 11, 1061-1076

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.3334	U.S. Patent No. 5,789,508, Baker et al.; Polymerization Process. Inventors: Bruce Baker, Roger Zipfel; Assignee: E. I. du Pont de Nemours and Company
D.3335	U.S. EPA Air Pollution Control Technology Fact Sheet - Incinerator-Recuperative Type (EPA-425/F-03-020)
D.3336	U.S. EPA Air Pollution Control Technology Fact Sheet - Thermal Incinerator (EPA-425/F-03-022)
D.3337	Book cover; "Forensic Engineering - Damage Assessments for Residential and Commercial Structures", and Chapter 23 Contents page re: Serving as an Expert Witness - by Thomas Schwartz and Stephen Petty
D.3338	"Reducing patients' exposures to asthma and allergy triggers in their homes: an evaluation of effectiveness of grades of forced air ventilation filters"; Journal of Asthma, 2014; 51(6): 585-594. Authors include David L. MacIntosh
D.3339	Voluntary Children's Chemical Evaluation Program (VCCEP) Peer Consultations on Benzene - List of Attendees and Meeting Materials
D.3340	"Predicted indoor radon concentrations from a Monte Carlo simulation of 1 000 000 granite countertop purchases"; Journal of Radiological Protection, 33 (2013) 151-162; J G Allen, L M Zwack, D L MacIntosh, T Minegishi, J H Steward, J F McCarthy
D.3341	"Ohio River Toxic Release Inventory Analysis (TRI) Reporting Year 2013 (Updated May 2015)"; Ohio River Valley Water Sanitation Commission (ORSANCO)
D.3342	"Coffee no longer listed as carcinogen"; Dallas News re Cancer Research
D.3343 - 3399	RESERVED
D.4000	EID360210 - EID360118
D.4001	DRS002041-2082 EID463226 - EID463267
D.4002(R)	AJP000788 EID073170
D.4003(R)	AJP000795-799 EID073177 - EID073181
D.4004	JLO000432
D.4005(R)	YLP000008-24 EID093349 - EID093365
D.4006	RJZ002409
D.4007	G. Nakayama memo to Environmental Appeals Board re Consent Agreement and Proposed Final Order to Resolve DuPont's Alleged Failure to Submit Substantial Risk Information under the Toxic Substances Control Act (TSCA) and Failure to Submit Data Requested under the Resource Conservation and Recovery Act (RCRA)



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4008	C-8 Quick Facts Questions and Answers - from Bureau of Environmental Health-Health Assessment Section
D.4009	DuPont Global PFOA Overview (photocopies of powerpoint slides)
D.4010	Expert report of Dominik Alexander
D.4011	Expert Report of Samuel Cohen
D.4012	CV of Charles David Cooper, PhD, PE, QEP (Updated: Aug. 2014)
D.4013	Expert Report of C. David Cooper
D.4014	CV of Douglas Middleton Dahl, MD FACS
D.4015	CV of Marion J. Fedoruk, MD, CH, DABT, FACMT, FACOEM (12/2015)
D.4016	Expert Report of Marion J. Fedoruk
D.4017	Expert Report of John M. Flaherty
D.4018	CV of John M. Graham, Jr., M.D., Sc.D
D.4019	Expert Report of Robert W. Rickard, PhD., DAPT
D.4020	CV of Greg P. Sykes, V.M.D.
D.4021	Expert Report of Greg Sykes
D.4022	CV of Marie Tobin, M.D.
D.4023	CV of Stephen T. Washburn
D.4024	CV of Steven Kelly Clinton, M.D., Ph.D.
D.4025	CV, Testimony List and Materials Considered List of David MacIntosh (21 pgs)
D.4026	Pamphlet - What is High Blood Pressure?
D.4027	S. Clinton, P. Imrey, H. Mangian, et al; The Combined Effects of Dietary Fat, Protein, and Energy Intake on Azoxymethane-induced Intestinal and Renal Carcinogenesis. <i>Cancer Research</i> 52, 857-865, February 15, 1992
D.4028	S. Mayne, E. Giovannucci, S. Clinton, et al; Food, Nutrition, Physical Activity, and Cancer: Contributions of Different Types of Research to the Totality of the Evidence. <i>Nutrition Today</i> , Vol. 48, Number 1, January/February 2013
D.4029	B. Focht, S. Clinton, S. Devor, et al; Resistance exercise interventions during and following cancer treatment: a systematic review. <i>The Journal of Supportive Oncology</i> , Vol. 11, Number 2, June 2013
D.4030	Professional web page from OSUCCC James re experience of re Steven Clinton
D.4031	CV of Steven Kelly Clinton, M.D., Ph.D.
D.4032	World Cancer Research Fund - publication re Diet, Nutrition, Physical Activity and Kidney Cancer; Revised 2018
D.4033	B. Lauby-Secretan, C. Scoccianti, D. Loomis, et al; Body Fatness and Cancer - Viewpoint of the IARC Working Group. <i>New England Journal of Medicine</i> , 375:8, 794-798

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4034	M. Wong, W. Goggins, B. Yip, et al; Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Scientific Reports 7:15698
D.4035	P. Monk, E. Lam, A. Mortazavi, et al; A Phase I Study of High-Dose Interleukin-2 with Sorafenib in Patients with Metastatic Renal Cell Carcinoma and Melanoma. J. Ummunother, Vol. 37, Number 3, April 2014
D.4036	National Cancer Institute - Common Cancer Types
D.4037	American Cancer Society - Key Statistics about Kidney Cancer
D.4038	American Cancer Society - Survival Rates for Kidney Cancer by Stage
D.4039	American Cancer Society - Risk Factors for Kidney Cancer
D.4040	World Cancer Research Fund - publication re Diet, Nutrition, Physical Activity and Kidney Cancer; Revised 2018
D.4041	World Cancer Research Fund - publication re Body fatness and weight gain and the risk of cancer
D.4042	World Cancer Research Fund - publication re Height and birthweight and the risk of cancer
D.4043	World Cancer Research Fund - publication re Physical activity and the risk of cancer
D.4044	World Cancer Research Fund - publication re The cancer process
D.4045	World Cancer Research Fund - publication re Judging the evidence
D.4046	World Cancer Research Fund - publication re Diet, Nutrition, Physical Activity and Kidney Cancer: a Global Perspective. The Third Expert Report
D.4047	J. Colt, K. Schwartz, B. Graubard, et al; Hypertension and Risk of Renal Cell Carcinoma among White and Black Americans. Epidemiology. 2001 November; 22(6): 797-804 [NIH Public Access]
D.4048	K. Flaherty, C. Fuchs, G. Colditz, et al; A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes and Controls (2005) 16:1099-1106
D.4049	M. McCredie, J. H. Stewart; Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes and Control, 3, 323-331
D.4050	Cleveland Clinic Cancer Center - information re Psycho-Oncology Program
D.4051	L. Lipworth, R. Tarone, J. McLaughlin; The Epidemiology of Renal Cell Carcinoma. Journal of Urology, Vol. 176, 2353-2358, December 2006
D.4052	J. Sims, CV. Yedjou, D. Abugri; Racial Disparities and Preventive Measures to Renal Cell Carcinoma. Int. J. Environ. Res. Public Health 2018, 15, 1089

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4053	B. Kendall, L. Wilson, C. Olsen, et al; Cancers in Australia in 2010 attributable to overweight and obesity. Australian and New Zealand Journal of Public Health, 2015, Vol. 39, No. 5, 452-457
D.4054	A. Bergstron, C-C Hsieh, P. Lindblad, et al; Obesity and renal cell cancer - a quantitative review. British Journal of Cancer (2001) 85(7), 984-990
D.4055	C. Tomasetti, L. Li, B. Vogelstein; Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017 March 24; 355(6331): 1330-1334
D.4056	C. Tomasetti, L. Li, B. Vogelstein; Supplementary Materials for Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017 March 24; 355(6331): 1330-1334
D.4057	J. Bencichou, W. Chow, J. McLaughlin, et al; Population Attributable Risk of Renal Cell Cancer in Minnesota. Am J Epidemiol, Vol 148, No. 5, 1998
D.4058	P. Pierorazio, M. Johnson, H. Patel, et al; Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol 2016 October; 196(4): 989-999
D.4059	C. Haggstrom, K. Rapp, T. Stocks, et al; Metabolic Factors Associated with Risk of Renal Cell Carcinoma. PLOS ONE, February 2013, Vol. 8, Issue 2, e57475
D.4060	W. Chow, L. Dong, S. Devesa; Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010 May; 7(5): 245-257
D.4061	Y. Lotan, J. Karam, S. Shariat, et al; Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urologic Oncology: Seminars and Original Investigations 34(4) (2016) 167.e9-167.e16
D.4062	Ohio Department of Health - C-8 Quick Facts Questions and Answers
D.4063	C8 Science Panel - website home page
D.4064	C8 Science Panel - website page re Panel Members (includes Fletcher, Savitz, Steenland)
D.4065	Supplemental information regarding cancer analyses - Winqvist, Steenland: PFOA exposures and incident cancers among adults living near a chemical plant. Environ Health Perspect. 2013 Nov-Dec; 121(11-12): 1313-8
D.4066	American Cancer Society - Teflon and Perfluorooctanoic Acid (PFOA - What are Teflon and PFOA? Where are they found?
D.4067	Australian Expert Panels; Expert Health Panel for PFAS: Summary (2018)
D.4068	M. Convertino, T. Church, G. Olsen, et al; Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), 2018, 293-306

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4069	CDC Perfluorooctanoic Acid (PFOA) Factsheet
D.4070	ATSDR Public Health Statement re Perfluoroalkyls
D.4071	CDC National Biomonitoring Program Factsheet re Perfluorooctanoic Acid (PFOA)
D.4072	American Cancer Society information re Teflon and Perfluorooctanoic Acid (PFOA)-What are these substances? Where are they found?
D.4073	CDC/ATSDR Interim Guidance - An Overview of Perfluoroalkyl and Polyfluoroalkyl Substances and Interim Guidance for Clinicians Responding to Patient Exposure Concerns
D.4074	US EPA Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA) - EPA 822-R-16-005
D.4075	IARC Monographs-110 - Perfluorooctanoic Acid
D.4076	ATSDR Toxicological Profile for Perfluoroalkyls - Draft for Public Comment (CS274127-A)
D.4077	CDC/ATSDR Interim Guidance - An Overview of Perfluoroalkyl and Polyfluoroalkyl Substances and Interim Guidance for Clinicians Responding to Patient Exposure Concerns
D.4078	L. Darrow, A. Groth, A. Winquist, et al; Modeled Perfluorooctanoic Acid (PFOA) Exposure and Liver Function in a Mid-Ohio Valley Community. Environmental Health Perspectives, Vol. 124, Number 8, August 2016
D.4079	R. Dhingra, A. Winquist, L. Darrow, et al; A Study of Reverse Causation: Examining the Associations of Perfluorooctanoic Acid Serum Levels with Two Outcomes. Environmental Health Perspectives, Vol. 125, Number 3, March 2017
D.4080	K. Steenland, V. Barry, D. Savitz; Serum Perfluorooctanoic Acid and Birthweight An Updated Meta-analysis with Bias Analysis. Epidemiology, Vol. 29, Number 6, November 2018
D.4081	V. Barry, A. Winquist, K. Steenland; Perfluorooctanoic Acid (PFOA) Exposures and Incident Cancers among Adults Living Near a Chemical Plant. Environmental Health Perspectives, Vol. 121, Number 11-12, November-December 2013 (1313-1318)
D.4082	US EPA Technical Fact Sheet - Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoic Acid (PFOA) November 2017 (EPA 505-F-17-001)
D.4083	East Metro PFC Biomonitoring Follow-up Project Meeting
D.4084	Freeman Trial Opening Slide re Samples of Disclosures to Government Agencies
D.4085	Freeman Trial Opening Slide re Samples of Published C8 Studies and Additional Samples of Published C8 Studies
D.4086	DuPont-prepared Washington Works - Map
D.4087	008-0018-002031

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4088	EID082000 - EID082003 AJP001385 - AJP001388
D.4088(R)	EID082000 - EID082003 AJP001385 - AJP001388
D.4089	Freeman Opening Powerpoint Slide - Graph re DuPont dramatically reduced emissions more than a decade before the science panel finding
D.4090	054-0001-0000229 - 230
D.4091	US EPA PFOA Stewardship Program re PFOA and Fluorinated Telomers
D.4092	A. Bergstrom, C-C Hsieh, P. Lindblad, et al; Obesity and renal cell cancer - a quantitative review. <i>British Journal of Cancer</i> (2001) 85(7), 984-990
D.4093	T. Bjorge, S. Tretli, A. Engeland; Relation of Height and Body Mass Index to Renal Cell Carcinoma in Two Million Norwegian Men and Women; <i>Am J Epidemiol</i> 204; 160:1168-1176
D.4094	L. Lipworth, R. Tarone, J. McLaughlin; The Epidemiology of Renal Cell Carcinoma. <i>Journal of Urology</i> , Vol. 176, 2353-2358, December 2006
D.4095	J. Sims, CV. Yedjou, D. Abugri; Racial Disparities and Preventive Measures to Renal Cell Carcinoma. <i>Int. J. Environ. Res. Public Health</i> 2018, 15, 1089
D.4096	World Cancer Research Fund - publication re Body fatness and weight gain and the risk of cancer
D.4097	American Cancer Society - Key Statistics about Kidney Cancer
D.4098	P. Pierorazio, M. Johnson, H. Patel, et al; Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. <i>J Urol</i> 2016 October; 196(4): 989-999
D.4099	C. Haggstrom, K. Rapp, T. Stocks, et al; Metabolic Factors Associated with Risk of Renal Cell Carcinoma. <i>PLOS ONE</i> , February 2013, Vol. 8, Issue 2, e57475
D.4100	W. Chow, L. Dong, S. Devesa; Epidemiology and risk factors for kidney cancer. <i>Nat Rev Urol.</i> 2010 May; 7(5): 245-257
D.4101	Cancer Incidence Investigation 1995-2004, Hoosick Falls, Rensselaer County, NY
D.4102	Contamination in Ohio by Per- and Polyfluoroalkyl Substances, Jeff Patzke, Ohio EPA
D.4103(R)	LE2454 - LE2522
D.4104	Supplemental Material Perfluorooctanoic Acid (PFOA) Exposures and Incident Cancers among Adults Living Near a Chemical Plant; V. Barry, A. Winqvist, K. Steenland
D.4105	An Overview of Perfluoroalkyl and Polyfluoroalkyl Substances and Interim Guidance for Clinicians Responding to Patient Exposure Concerns; CDC / ATSDR

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4106	Scientific Evidence and Recommendations for Managing PFAS Contamination in Michigan; Michigan PFAS Science Advisory Panel - Bartell, Field, Jones, Lau, Masten, Savitz
D.4107	A Rough Guide to IARC Carcinogen Classifications (Compound Interest 2015)
D.4108	Perfluorooctanoic acid and its salts - Evaluation of carcinogenicity and genotoxicity; Health Council of the Netherlands
D.4109(R)	EID255850 - EID255888 JLO001595 - JLO001633
D.4110(R)	EID255797 - EID255800 JLO001326 - JL001329
D.4111	Australian Government Department of Health - Health Based Guidance Values for PFAS for Use in Site Investigations in Australia
D.4112	British Columbia - Environmental Management Act, Contaminated Sites Regulation B.C. Reg. 275/96 (Current to 3/19/19)
D.4113	Water Talk - Drinking Water Screening Values: Perfluoroalkylated Substances - Health Canada
D.4114	Guidelines for Canadian Drinking Water Quality - Guideline Technical Document, Perfluorooctanoic Acid (PFOA) - Health Canada
D.4115	Perfluoroalkylated substances: PFOA, PFOS and PFOSA - Evaluation of health hazards and proposal of a health based quality criterion for drinking water, soil and ground water. Environmental project No. 1665, 2015 - Danish Ministry of the Environment, Environmental Protection Agency
D.4116	Proposal for a Directive of the European Parliament and of the Council on the quality of water intended for human consumption (recast) - European Commission, Brussels 1/2/18 COM(2017) 753 final
D.4117	Provisional evaluation of PFT in drinking water with the guide substances perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) as examples - Statement by the Drinking Water Commission (Trinkwasserkommission) of the German Ministry of Health at the Federal Environment Agency June 21, 2006/revised July 13, 2006
D.4118	K. Theo von der Trenck, R. Konietzka, A. Biegel-Engler, et al.; Significance thresholds for the assessment of contaminated groundwater: perfluorinated and polyfluorinated chemicals; Environ Sci Eur (2018) 30:19
D.4119	S. Valsecchi, D. Conti, R. Crebelli, et al.; Deriving environmental quality standards for perfluorooctanoic acid (PFOA) and related short chain perfluorinated alkyl acids; Journal of Hazardous Materials, Volume 323, Part A, 5 February 2017, Pgs. 84-98



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4120	Kvalitetssikring av miljokvalitetsstandarter, 2014 - contains English translation of methods and results
D.4121	J. Smith, B. Beuthe, M. Dunk, et al.; Environmental fate and effects of poly- and perfluoroalkyl substances (PFAS) - prepared for the Concawe Soil and Groundwater Taskforce (STF/33); Concawe Report No. 8/16
D.4122	Guidance on the Water Supply (Water Quality) Regulations 2000 specific to PFOS (perfluorooctane sulphonate) and PFOA (perfluorooctanoic acid) concentrations in drinking water; Drinking Water Inspectorate, October, 2009
D.4123	Maximum acceptable concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) in drinking water; Health Protection Agency, August, 2007
D.4124	Cancer Incidence Report - prepared by New Hampshire Dept. of Health and Human Services, Division of Public Health Services
D.4125	R. Crebelli, S. Caiola, L. Conti, et al.; Can sustained exposure to PFAS trigger a genotoxic response? A comprehensive genotoxicity assessment in mice after subacute oral administration of PFOA and PFBA; Regulatory Toxicology and Pharmacology 106 (2019) 169-177
D.4126	Y. Li, T. Fletcher, D. Mucs, et al.; Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water; Occup Environ Med 2018; 75:46-51
D.4127	J. Guelfo, T. Marlow, D. Klein, et al.; Evaluation and Management Strategies for Per- and Polyfluoroalkyl Substances (PFASs) in Drinking Water Aquifers: Perspectives from Impacted U.S. Northeast Communities; Environmental Health Perspectives 126(6) June 2018
D.4128	E. Negri, F. Metruccio, V. Guercio, et al.; Exposure to PFOA and PFOS and fetal growth: a critical merging of toxicological and epidemiological data; Critical Reviews in Toxicology, 2017 Vol. 47, No. 6, 489-515
D.4129	U. Vedagiri, R. Anderson, H. Loso, C. Schwach; Ambient levels of PFOS and PFOA in multiple environmental media; Remediation, 2018;28:9-51
D.4130	Occurrence of perfluorinated substances in an adult German population in southern Bavaria; International Archives of Occupational and Environmental Health, February 2007, Volume 80, Issue 4, Pgs. 313-329
D.4131	M. Hamm, N. Cherry, E. Chan, et al.; Maternal exposure to perfluorinated acids and fetal growth; Journal of Exposure Science and Environmental Epidemiology (2010) 20, 589-597

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4132	R. Monroy, K. Morrison, K. Teo, et al.; Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples; Environmental Research Vol. 108, Issue 1, September 2008, pgs. 56-62
D.4133	S. Tittlemier, J van Oostdam; Presence of anionic perfluorinated organic compounds in serum collected from Northern Canadian populations - Conference, report ETDE-DE-1546
D.4134	C. Kubwabo, N. Vais, FM Benoit; A pilot study on the determination of perfluorooctanesulfonate and other perfluorinated compounds in blood of Canadians; J Environ Monit. 2004 Jun;6(6):650-5
D.4135	S. Beesoon, G. Webster, M. Shoeib, et al.; Isomer Profiles of Perfluorochemicals in Matched Maternal, Cord, and House Dust Samples: Manufacturing Sources and Transplacental Transfer; Environ Health Perspect 2011 Nov; 119(11): 1659-1664
D.4136	T. Halldorsson, D. Rytter, L. Haug, et al.; Prenatal Exposure to Perfluorooctanoate and Risk of Overweight at 20 Years of Age: A Prospective Cohort Study; Environ Health Perspect 2012 May; 120(5): 668-673
D.4137	C. Fei, J. McLaughlin, R. Tarone, J. Olsen; Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth Cohort; Environ Health Perspect 2007 Nov; 115(11): 1677-1682
D.4138	Perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts - Scientific Opinion of the Panel on Contaminants in the Food Chain - EFSA Journal (2008) 653, 1-131. W
D.4139	Human biomonitoring: facts and figures. World Health Organization, 2015
D.4140	Perfluorooctanoic Acid - Exposure Data. IARC Monographs-110
D.4141	K. Whitworth, L. Haug, D. Baird, et al.; Perfluorinated compounds and subfecundity in pregnant women. Epidemiology, 2012 Mar; 23(2): 257-263
D.4142	K. Christensen, M. Maisonet, C. Rubin, et al.; Exposure to polyfluoroalkyl chemicals during pregnancy is not associated with offspring age at menarche in contemporary British cohort. Environ Int. 2011 Jan; 37(1): 129-135
D.4143	M. Maisonet, M. Terrell, M. McGeehin, et al.; Maternal Concentrations of Polyfluoroalkyl Compounds during Pregnancy and Fetal and Postnatal Growth in British Girls. Environ Health Perspect. 2012 Oct; 120(10): 1432-1437
D.4144	Powerpoint slide re: Benefits of C-8
D.4145	Air Toxics from Motor Vehicles (US EPA)
D.4146	ATSDR Public Health Statement re Benzene, CAS#: 71-43-1



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4147	B. Blount, R. Kobelski, D. McElprang, et al.; Quantification of 31 volatile organic compounds in whole blood using solid-phase microextraction and gas chromatography-mass spectrometry. <i>Journal of Chromatography B</i> , 832 (2006) 292-301
D.4148	C. Villanueva, M. Kogevinas, S. Cordier, et al.; Assessing Exposure and Health Consequences of Chemicals in Drinking Water: Current State of Knowledge and Research Needs. <i>Environmental Health Perspectives</i> , Vol. 122, No. 3, March 2014, pg. 213-221
D.4149	S. Glassmeyer, E. Furlong, D. Kolpin, et al.; Nationwide reconnaissance of contaminants of emerging concern in source and treated drinking waters of the United States. <i>Science of the Total Environment</i> 581-582 (2017) 909-922
D.4150	R. Westerhol,, K. Egeback; Exhaust Emissions from Light- and Heavy-duty Vehicles: Chemical Composition, Impact of Exhaust after Treatment, and Fuel Parameters. <i>Environmental Health Perspectives</i> , Vol. 102, Supplement 4, October 1994; pgs. 13-23
D.4151	Automobile Emissions: An Overview (US EPA)
D.4152	Pharmaceuticals in Drinking-water. World Health Organization, 2011
D.4153	The Master List of Compounds Emitted by Mobile Sources. EPA, 2006
D.4154	Expanding and Updating the Master List of Compounds Emitted by Mobile Sources - Phase III. Final Report. EPA, February 2006. EPA420-R-06-005
D.4155	D. Ashley, M. Bonin, F. Cardinali, et al.; Measurement of Volatile Organic Compounds in Human Blood. <i>Environmental Health Perspectives</i> , Vol. 10x, Supplement x, pgs. 871-877
D.4156	Occurrence of Antibiotic Compounds in Source Water and Finished Drinking Water from the Upper Scioto River Basin, Ohio, 2005-6. USGS, Scientific Investigations Report 2010-5083
D.4157	EID108167 - EID108169
D.4158	EID077897 - EID077906 AC003144 - AC003153
D.4159	DDJ001690
D.4160	EID150694 - EID150696
D.4161	030-0002-0000343; 030-0002-000344
D.4162	Article - Engineer questions DuPont C8 claims (Reed). <i>The Daily Sentinel</i>
D.4163	Article - TP-C shows dwindling C8 levels (Reed). <i>The Daily Sentinel</i>
D.4164	Article - DuPont settlement includes new water treatment systems (Maloney). <i>The Daily Sentinel</i>

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4165	Article - Judge Ok's terms of C8 settlement (Schelzig). The Daily Sentinel
D.4166	Article - Customers learn C8 settlement details (Reed). Sunday Times-Sentinel
D.4167	Article - DuPont to cut amount of chemical used to make teflon (AP). The Daily Sentinel
D.4168	Article - More C8 health studies planned in W.Va., Ohio (AP). The Daily Sentinel
D.4169	Article - C8 Panel links C8 to testicular, kidney cancer (Lyons). The Daily Sentinel
D.4170	Article - EPA orders nationwide monitoring of C8 in water supply (Lyons). Sunday Times-Sentinel
D.4171	Article - DuPont to phase out C8 by 2014 (Lyons). The Daily Sentinel
D.4172	Article - C8 medical monitoring begins in Mid-Ohio Valley. Wvgazette.com
D.4173	Article - DuPont found liable in first trial over Teflon-making chemical C8 (Dye, Gray). Reuters
D.4174	Article - DuPont loses C8 jury trial. The Marietta Times
D.4175	Legal Notices to People who have consumed certain water for at least one year in certain locations in West Virginia and Ohio
D.4176	Hill Peterson Legal Notice The Daily Sentinel
D.4177	CV of Dr. Samuel Cohen
D.4178	CV of Dr. Douglas Dahl
D.4179	CV of Dr. Mark Roberts
D.4180	Deposition of David Cooper
D.4181	Third Amended Notice of Deposition, C. David Cooper - Moody v. DuPont
D.4182	A. Fox letter of engagement with C. David Cooper
D.4183	Cooper invoice for services 7/1 - 7/31/16
D.4184	Cooper invoice for services 8/1 - 8/31/16
D.4185	Cooper invoice for services 9/1 - 9/30/16
D.4186	Expert report of C. David Cooper
D.4187	Deposition of Marion J. Fedoruk
D.4188	Expert Report of Marion J. Fedoruk
D.4189	Exponent 2015 Annual Report
D.4190	Second Amended Notice of Deposition, Marion J. Fedoruk - Moody v. DuPont
D.4191	Engagement letter between Meyer (Exponent) and Fox
D.4192	Exponent invoice for service 6/24 - 6/29/16
D.4193	Exponent invoice for service 7/14 - 7/29/16
D.4194	Exponent invoice for service 7/30 - 8/26/16
D.4195	W. Shields email to C. Burnton re DuPont Projects

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4196	Paustenbach, D.J., et al. 2007. A Methodology for Estimating Human Exposure to Perfluorooctanoic Acid (PFOA): A Retrospective Exposure Assessment of a Community (1951-2003). J. Toxicology Env'tl. Health. 70(Part A):28-57.
D.4197	Guidelines for Carcinogen Risk Assessment - NCEA-F-0644 Review Draft, July 1999
D.4198	Deposition of John Flaherty
D.4199	EID546037 - EID546063
D.4200	EID546803
D.4201	EID525680
D.4202	EID568382 - EID568407
D.4203	EID732732 - EID732733 MAK010896 - MAK010897
D.4204	EID739257 SMK000298
D.4205	EID739248 SMK000289
D.4206	EID772769-8 - EID772806
D.4207	V013 - V018
D.4208	The Parkersburg News notice re "C8"
D.4209	CV of John M. Flaherty
D.4210	EID598332 STB005561
D.4211	Deposition of Stephen T. Washburn
D.4212	Expert Report of Stephen T. Washburn - issued for Moody
D.4213	Washburn invoice for Moody
D.4214	Washburn invoice for Moody
D.4215	Washburn invoice for Moody
D.4216	Deposition of Stephen T. Washburn
D.4217	Notice of Deposition of Stephen T. Washburn
D.4218	Expert report of Stephen T. Washburn - issued in Fauver
D.4219	Expert report of Stephen T. Washburn - issued in Charles
D.4220	Expert report of Stephen T. Washburn - issued in Nutter
D.4221	Expert report of Stephen T. Washburn - issued in Weekley
D.4222	Expert report of Stephen T. Washburn - issued in R. White
D.4223	Expert report of Stephen T. Washburn - issued in S. White
D.4224	Expert report of Stephen T. Washburn - issued in Callihan
D.4225	Expert report of Stephen T. Washburn - issued in Mayle

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4226	Expert report of Stephen T. Washburn - issued in Balsley
D.4227	Expert report of Stephen T. Washburn - issued in Cross
D.4228	Engagement letter between Washburn and Fazio
D.4229	Washburn invoices for services
D.4230	Deposition of Stephen T. Washburn (Bartlett / Wolf)
D.4231	Expert report of Stephen T. Washburn - issued in Bartlett / Wolf
D.4232	Shin, Vieira, Ryan, et al., Environmental Fate and Transport Modeling for Perfluorooctanoic Acid Emitted from the Washington Works Facility in West Virginia. Environ. Sci. Technol, 2011, 45, 1435-1442
D.4233	A. Winquist, C. Lally, H. Shin, K. Steenland; Design, Methods, and population for a Study of PFOA Health Effects among Highly Exposed Mid-Ohio Valley Community Residents and Workers; Environmental Health Perspectives, Vol. 121, No. 8, August 2013
D.4234	Deposition of David MacIntosh in Bartlett / Wolf
D.4235	Washburn, Bingman, Braithwaite, et al.; Exposure Assessment and Risk Characterization for Perfluorooctanoate in Selected Consumer Articles; Environ. Sci. Technol. 2005, 39, 3904-3910
D.4236	Washburn, Bingman, Braithwaite, et al.; Exposure Assessment and Risk Characterization for Perfluorooctanoate in Selected Consumer Articles - Supporting Information
D.4237	Paustenbach, D.J., et al. 2007. A Methodology for Estimating Human Exposure to Perfluorooctanoic Acid (PFOA): A Retrospective Exposure Assessment of a Community (1951-2003). J. Toxicology Env'tl. Health. 70 (Part A):28-57.
D.4238	Engagement letter between Washburn and Fazio
D.4239	ATSDR, Draft Toxicological Profile For Perfluoroalkyls, June 2018
D.4240	Australia Expert Panes 2018 - for Per- and Poly-Fluoroalkyl Substances (PFAS)
D.4241	B. Karrh, S. Pell; Brain Cancer in the DuPont Company; 0077-8923/82/0381-0091 pp. 91-96 (1982)
D.4242	S. Banzhaf, M. Filipovic, J. Lewis, et al.; A Review of Contamination of Surface-, Groun-, and Drinking Water in Sweden by Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs); Ambio, vol. 46, no. 3, 2017, pp. 335-346
D.4243	L. Begnudelli, A. Valiani, B. Sanders; A balanced treatment of secondary currents, turbulence and dispersion in a depth-integrated hydrodynamic and bed deformation model for channel bends; Advances in Water Resources 33 (2010) 17-33
D.4244	B. Birnbaum, M. Bosniak, A. Megibow, et al.; Observations on the growth of renal neoplasms; Radiology, 176: 695-701 (1990)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4245	M. Bosniak, B. Birnbaum, G. Krinsky, J. Waisman; Small renal parenchymal neoplasms: further observations on growth. <i>Radiology</i> , Vol. 197, No. 3
D.4246	Cambell, et al. (2016). Malignant Renal Tumors. <i>Campbell-Walsh Urology</i> , 11th Ed. 1320-1321
D.4247	J. Chen, W. Fayerweather, S. Pell; Cancer Incidence of Workers Exposed to Dimethylformamide and/or Acrylonitrile; <i>JOM</i> Vol. 30, No. 10; pp. 813-818 (October 1988)
D.4248	Chen, Fayerweather, Pell; Mortality Study of Workers Exposed to Dimethylformamide and/or Acrylonitrile; <i>JOM</i> Vol. 30, No. 10; pp. 819-821 (October 1988)
D.4249	D. Brusick; Implications of treatment-condition-induced genotoxicity for chemical screening and data interpretation; <i>Mutation Research</i> , 189 (1987) 1-6
D.4250	D. Kirkland, M. Aarmeda, L. Henderson, L. Muller; Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. <i>Mutation Research</i> 584 (2005) 1-256
D.4251	D. Kirkland, P. Kasper, H. Martus, et al.; Updated recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests. <i>Mutation Research</i> 795 (2016) 7-30
D.4252	D. Kirkland, S. Pfuhler, D. Tweats, et al.; How to reduce false positive results when undertaking <i>in vitro</i> genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. <i>Mutation Research</i> 628 (2007) 31-55
D.4253	AF Fergany, KS Hafez, AC Novick; Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. <i>J Urol</i> . 2000 Feb; 163(2): 442-5
D.4254	H. Honda, Y. Fujita, T. Kasamatsu, et al.; Necessity for retrospective evaluation of past-positive chemicals in vitro chromosoma. Aberration tests using recommended cytotoxicity indices. <i>Genes and Environment</i> (2018) 40:2
D.4255	A. Hakimi, H. Furbert, E. Zabor, et al.; An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>JNCI</i> , Vol. 105, Issue 24, pp. 1862-1870
D.4256	Health Canada - Perfluorooctane sulfonate (PFOS), its salts and precursors - information sheet
D.4257	C. Higgins, R. Luthy; Sorption of Perfluorinated Surfactants on Sediments. <i>Environ. Sci. Technol.</i> 2006, 40, 7251-7256
D.4258	M. Hughes, B. Beck, Y. Chen, et al.; Arsenic Exposure and Toxicology: A Historical Perspective. <i>Toxicological Sciences</i> 123(2): 305-33 (2011)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4259	IARC Monograph 100e - Tobacco Smoking. International Agency for Research on Cancer (2012)
D.4260	IARC Monographs on the Identification of Carcinogenic Hazards to Humans - Preamble. International Agency for Research on Cancer (2019)
D.4261	IARC Agents Classified by the IARC Monographs, Vols. 1-123. International Agency for Research on Cancer (2019)
D.4262	J. Whitewell, R. Smith, K. Jenner, et al.; Relationships between p53 status, apoptosis and induction of micronuclei in different human and mouse cell lines <i>in vitro</i> : Implications for improving existing assays. <i>Mutation Research</i> 789-790 (2015) 7-27
D.4263	R. Jain, A. Ducatman; Selective Associations of Recent Low Concentrations of Perfluoroalkyl Substances with Liver Function Biomarkers - Nhanes 2011 to 2014 Data on US Adults Aged $\geq 20$ Years. <i>JOEM</i> 61(4): 293-302
D.4264	M. Jewett, K. Mattar, J. Basiuk, et al; Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. <i>European Urology</i> 60 (2011) 39-44
D.4265	P. Linblad; Epidemiology of Renal Cell Carcinoma. Review, <i>Scandinavian Journal of Surgery</i> 93: 88-96, 2004
D.4266	M. Lorber, P. Egeghy; Simple Intake and Pharmacokinetic Modeling to Characterize Exposure of Americans to Perfluorooctanoic Acid, PFOA. <i>Environ. Sci. Technol.</i> 2001, 45, 8006-8014
D.4267	L. Cheng, G. MacLennan, S. Zhang, et al.; Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. <i>Urologic Surgical Pathology</i> , 2nd Ed., Mosby/Elsevier, p. 77-172 (2008)
D.4268	L. Macleod, J. Hotaling, J. Wright, et al.; Risk Factors for Renal Cell Carcinoma in the Vitamin and Lifestyle (VITAL) Study. <i>J Urol.</i> 190(5); 1657-1661 (November 2013)
D.4269	R. Maronpot, A. Nyska, J. Foreman, Y. Ramot; The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms). <i>Crit. Rev. Toxicol.</i> , 46: 641-675 (2016)
D.4270	N. Miyao, S. Naito, S. Ozono, et al.; Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of the Japanese Society of Renal Cancer. <i>Urology</i> , 77: 379-384 (2011)
D.4271	Kidney Cancer Nomograms: Risk of Recurrence Following Surgery. <a href="http://MSKCC.org">MSKCC.org</a>
D.4272	W. Murphy, et al.; Tumors of the Kidney, Bladder, and Related Urinary Structures. AFIP Atlas of Tumor Pathology, 4th Series, Fascicle 1. American Registry of Pathology, Washington, DC (2004), p. 1-240



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4273	V. Nair, V. Sundaram, M. Gould, M. Desai; Use of [18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomographic Imaging in the National Lung Screening Trial. <i>Chest</i> , 150(3), 621-30
D.4274	K. Rijs, R. Bogers; PFOA exposure and health - A review of scientific literature. RIVM Report 2017-0086
D.4275	P. Nguyen, A. Thorstensen, S. Sorooshian, et al.; A high resolution coupled hydrologic-hydraulic model (HiResFlood-UCI) for flash flood modeling; <i>Journal of Hydrology</i> 541 (2016) 401-420
D.4276	T. Oda, N. Miyao, A. Takahashi, et al.; Growth rates of primary and metastatic lesions of renal cell carcinoma. <i>Int. J. Urol.</i> , 8: 473-277 (2001)
D.4277	K. Ong, E. Goldstein (NRDC); Letter re Setting a Maximum Contaminant Level for PFOA and PFOS
D.4278	P. Fowler, K. Smith, J. Young, et al.; Reduction of misleading ("false") positive results in mammalian cell genotoxicity assays. I. Choice of cell type. <i>Mutation Research</i> 742 (2012) 11-25
D.4279	S. Pell, C. D'Alonzo; Diabetes in Industry. Prevalence, Epidemiology, and Prognosis in a Large Employed Population. <i>Arch Environ Health</i> , Vol. 17; pp. 425-435 (September 1968)
D.4280	S. Pell, W. Fayerweather; Trends in the Incidence of Myocardial Infarction and in Associated Mortality and Morbidity in a Large Employed Population, 1957-1983. <i>NEJM</i> Vol. 312, No. 16; pp. 1005-1011 (1985)
D.4281	S. Pell, M. O'Berg, B. Karrh; Cancer Epidemiologic Surveillance in the DuPont Company. <i>JOM</i> November 1978 Vol. 20 No. 11; pp. 725-740
D.4282	S. Pell; Commentary - Health Insurance Claims as a Source of Morbidity Data - DuPont Company's Experience. <i>JOM</i> Vol. 31, No. 8; pp.679-681 (August 1989)
D.4283	S. Pell; Epidemiologists in Industry - Past Achievements, Unexplored Opportunities and Future Needs. <i>JOM</i> Vol. 35, No. 5; pp. 485-492 (May 1983)
D.4284	G. Post, J. Gleason, K. Cooper; Key scientific issues in developing drinking water guidelines for perfluoroalkyl acids: Contaminants of emerging concern. <i>PLOS Biology</i> , Vol. 15, No. 12 (2017) pp. 1-12
D.4285	G. Post, J. Gleason; Technical Support Document: Interim Specific Ground Water Criterion for Perfluorooctanoic Acid (PFOA, C8). (2019), pp. 1-275
D.4286	J. Reddy, N. Lalvvai, E. Farber; Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans. <i>Crit. Rev. Toxicol.</i> , 12: 1-58 (1983)



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4287	J. Shapiro; M. Williams, N. Weiss, et al.; Hypertension, Antihypertensive Medication Use, and Risk of Renal Cell Carcinoma. <i>Am. J. Epidemiol.</i> , 149: 521-530 (1999)
D.4288	R. Siegel, K. Miller, A. Jemal; Cancer Statistics, 2019. <i>CA Cancer J. Clin</i> 2019; 69: 7-34
D.4289	U.S. Surgeon General (2004) The health consequences of smoking: A report of the Surgeon General. Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
D.4290	V. Vieira, K. Hoffman, H-Moo Shin, J. Weinberg, T. Webster, T. Fletcher; Supplemental Material, Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community: A Geographic Analysis; Environmental Health Perspectives <a href="http://dx.doi.org/10.1289/ehp.1205829">http://dx.doi.org/10.1289/ehp.1205829</a>
D.4291	F. Want, Y. Xu; Body mass index and risk of renal cell cancer: A dose-response meta-analysis of published cohort studies; <i>Intl. J. Cancer</i> , 135(7), 1673-1686
D.4292	A. Wein, W. McDougal; Campbell-Walsh Urology, 10th Ed., Vol. 2, p. 1421-1432 (2011)-
D.4293	N. Yamashita, S. Taniyasu; G. Petrick; Perfluorinated acids as novel chemical tracers of global circulation of ocean waters. <i>Chemosphere</i> 70 (2008) 1247-1255
D.4294	L. Yang, B. Drake, G. Colditz; Obesity and Other Cancers. <i>J. Clin Oncol.</i> , 34(35), 4231-4237
D.4295	J-M Yuan, JE Castela, et al.; Hypertension, obesity and their medications in relation to renal cell carcinoma. <i>British J. of Cancer</i> 77, 1508-1513 (1998)
D.4295(S)	J-M Yuan, JE Castela, et al.; Hypertension, obesity and their medications in relation to renal cell carcinoma. <i>British J. of Cancer</i> 77, 1508-1513 (1998)
D.4296	J. Zhang, S. Kang, et al.; Distribution of Renal Tumor Growth Rates Determined by Using Serial Volumetric CT Measurements. <i>Radiology</i> , 250: 137-144 (2009)
D.4297	Chemours Quarterly Progress Report No. 9 - 2009 Consent Order as Amended Chemours Washington Works
D.4298	EID073100 - EID073102 AJP000706 - AJP000708
D.4299	060-0002-0008864 - 8868
D.4300	060-0002-0008869 - 8870
D.4301	060-0002-0008871 - 8873
D.4302	060-0002-0008874 - 8875
D.4303	006-0002-0008876 - 8887
D.4304	006-0002-0008888 - 8892
D.4305	006-0002-0008893 - 8902

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4306	006-0002-0008893 - 8902
D.4307	006-0002-0008893 - 8902
D.4308	006-0002-0008914 - 8918
D.4309	006-0002-0008919 - 8921
D.4310	006-0002-0008922 - 8926
D.4311	006-0002-0008927 - 8931
D.4312	006-0002-0008932 - 8933
D.4313	006-0002-0008934 - 8937
D.4314	006-0002-0008940 - 8942
D.4315	006-0002-0008943 - 8944
D.4316	006-0002-0008946 - 8947
D.4317	006-0002-0008948 - 8950
D.4318	006-0002-0008951 - 8953
D.4319	006-0002-0008954 - 8958
D.4320	006-0002-0008959 - 8961
D.4321	006-0002-0008962 - 8964
D.4322	006-0002-0008965 - 8966
D.4323	006-0002-0008968 - 8970
D.4324	006-0002-0008971 - 8974
D.4325	006-0002-0008975 - 8978
D.4326	006-0002-0008979 - 8981
D.4327	006-0002-0008982 - 8984
D.4328	EID522017 - EID522022 BLD003326 - BLD003331
D.4329	EID099733 - EID099738 GK000380 - GK000385
D.4330(R)	EID136016 - EID136018
D.4331(R)	EID136012 - EID136013
D.4332(R)	EID516905 - EID516907
D.4333	EID129308 - EID129350
D.4334	006-0002-0008985 - 8988
D.4335	006-0002-0008989 - 8991
D.4336	EID603679 - EID603746 AJP010164 - AJP010231
D.4337	EID113250 - EID114123 AJP004115 - AJP004988

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4338	EDD0054518 - EDD0054607
D.4339	EDD0054608 - EDD0055220
D.4340(R)	EID139577 - EID139675 AJP006335 - AJP006433
D.4341	EID140383 - EID140398 AJP007141 - AJP007156
D.4342	EID950287 - EID950333 AJP001022 - AJP001068
D.4343(R)	EID255714 - EID255749 JLO001195 - JLO001230
D.4344(R)	031031-0002-0000390
D.4345(R)	EID106846 RL000966
D.4346(R)	EID098747 JW000076
D.4347(R)	031-0240-0000006
D.4348(R)	EID093340 YLP000074
D.4349(R)	EID713867 - EID713868 EXP000053 - EXP000054
D.4350(R)	EID080198 AJP001383
D.4351(R)	EID641398 FML000002
D.4352(R)	EID081542 JLO000274
D.4353(R)	EID093313 YLP000047
D.4354	EID079300 - EID079308 AJP002438 - AJP002446
D.4355	EID079277 - EID079281 AJP002400 - AJP002404
D.4356	EID079309 - EID079348
D.4357	EID073131 AJP000744

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4358	EID080343 - EID080345 AJP000925 - AJP000927
D.4359	EID073226 - EID073251 AJP000845 - AJP000870
D.4360	MDL00062261 - MDL0062305
D.4361	015-0056-0000199
D.4362	EID165836 - EID165837
D.4363	EID602599 - EID602602
D.4364	EID300729 - EID300731
D.4365	EID190249 - EID190250
D.4366(R)	EID127582-94 RJZ009353-65
D.4367	RJZ009335-52 012-2009-00000640 - 657
D.4368	EID930056 RJZ001896
D.4369	EID127558 - EID127559
D.4370	EID127560 - EID127563 RJZ009331 - RJZ009334
D.4371	EID940859 - EID940868 RJZ018760 - RJZ018777
D.4372	EID940836 - EID940840 RJZ018745 - RJZ018749
D.4373	EID713634 - EID713637 DPL000079 - DPL000082
D.4374	EID221531 - EID221532
D.4375	EID951473 - EID951775
D.4376	EID939957 - EID939981 RJZ017732 - RJZ017756
D.4377	EID015218 - EID015223 RLR001141 - RLR001146
D.4378	EID029878 - EID029879 RLR001137 - RLR001138
D.4379	EID067277 - EID067278 RLR001134 - RLR001135

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4380	EID926527 - EID926528 RLR001132 - RLR001133
D.4381	EID924740 - EID924743
D.4382	EID939856 - EID939860 RJZ017627 - RJZ017631
D.4383	EID31821 - EID131825
D.4384	EID499611 - EID499613 CF035475 0 CF035477
D.4385	EID499615 - EID49622 CF035479 - CF035486
D.4386	EID925891 - EID925905 CS000528 - CS000542
D.4387	EID499637 - EID499638 CF035528 - CF035529
D.4388	EID499636 CF035527
D.4389	EID499091 - EID499097 AC009673 - AC009679
D.4390	EID160262 - EID160266
D.4391	EID515425 - EID515427
D.4392	EID311277 - EID311278
D.4393	DWB000146 - DWB000184
D.4394	EID604577 - EID604586 DDJ008807 - DDJ008816
D.4395	World Health Organization; Keeping our water clean: the case of water contamination in the Veneto Region, Italy
D.4396	H. Sung, R. Siegel, P. Rosenberg, A. Jemal; Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. <i>Lancet Public Health</i>
D.4397	Y. Zhang, S. Beeson, L. Zhu, J. Martin; Biomonitorin of Perfluoroalkyl Acids in Human Urine and Estimates of Biological Half-Life. <i>Environ. Sci. Technol.</i>
D.4398	J. Butenhoff, S. Chang, G. Olsen, P. Thomford; Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. <i>Toxicology</i> 293 (2012) 1-15
D.4399	LUB000515 - LUB000517
D.4400	LPSD104 - LPSD105

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4401	BJR000325
D.4402	LPSD080
D.4403	C8 Science Panel Quarterly Newsletter #1 - July, 2010
D.4404	C8 Science Panel Quarterly Newsletter #2 - October, 2010
D.4405	C8 Science Panel Quarterly Newsletter #3 - January, 2011
D.4406	C8 Science Panel Quarterly Newsletter #4 - May, 2011
D.4407	C8 Science Panel Quarterly Newsletter #5 - August, 2011
D.4408	C8 Science Panel Quarterly Newsletter #6 - October, 2011
D.4409	C8 Science Panel Quarterly Newsletter #7 - January, 2012
D.4410	C8 Science Panel Quarterly Newsletter #8 - May, 2012
D.4411	C8 Science Panel Quarterly Newsletter #9 - August, 2012
D.4412	C8 Science Panel Final Quarterly Newsletter - November, 2012
D.4413	C8 Science Panel Website Home Page (1st 3 pages)
D.4414	C8 Science Panel Probable Link News Conference Transcript
D.4415	Status Hearing Transcript in Leach
D.4416	Science Panel First Quarterly Report, covering the period up to June 30 2005
D.4417	Order Approving Final Settlement and Notice Plan and For Entry of Final Judgment - Leach
D.4418	Deitzler email to Aiello re Science Panel
D.4419	Bilott letter to M. Aiello supplementing info re initial submissions to the Science Panel
D.4420	C8 Science Panel Community Health Study - Outline Protocols
D.4421	S. Elmore, V. Carreira, C. Labriola, et al.; Proceedings of the 2018 National Toxicology Program Satellite Symposium. Toxicologic Pathology (2018) Vol. 46(8), 865-897
D.4422	National Institute of Environmental Health Sciences; Perfluorinated Chemicals (PFCs). July, 2016
D.4423	C. Begley, L. Ellis; Raise standards for preclinical cancer research - how methods, publications and incentives must change if patients are to benefit. Nature, Vol. 483, 531-533
D.4424	G. Begley; Six red flags for suspect work. Nature, Vol. 497, 433-434
D.4425	K. Dearfield, V. Thybaud, M. Cimino, et al.; Follow-up Actions from Positive Results of In Vitro Genetic Toxicity Testing. Environmental and Molecular Mutagenesis, 177-204

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4426	ESFA Committee T. Hardy, D. Benford, H. Halldorsson, et al.; Reflection on interpretation of some aspects related to genotoxicity assessment. ESFA Journal 2017; 15(12): 5133
D.4427	EFSA; Outcome of the public consultation on the draft opinion providing clarification of some aspects related to genotoxicity assessment.
D.4428	D. Kirkland, L. Reeve, D. Gatehouse, P. Vanparys; A core in vitro battery comprising the Ames test plus the in vitro micronucleus test is sufficient to detect rodent carcinogens and in vivo genotoxins. Mutation Research (2011)
D.4429	J. Ioannidis; Why Most Published Research Findings are False. PLoS Medicine Vol. 2, Issue 8, e124; 696-701
D.4430	M. Munafo, B. Nosek, D. Bishop, et al.; A manifesto for reproducible science. Nature
D.4431	F. Prinz, T. Schlange, K. Asadullah; Believe it or not: How much can we rely on published data on potential drug targets? Nature Rev. Drug Discov. 10(9); 712. Aug. 31, 2010
D.4432	S. Felter, J. Foreman, A. Boobis, et al.; Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. Regulatory Toxicology and Pharmacology 92 (2018) 1-7
D.4433	J. Corton, J. Peters, J. Klaunig; The PPAR $\alpha$ -dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Archives of Toxicology (2018) 92:83-119
D.4434	APFO Recovery from Process Air
D.4435	006-0009-0000675
D.4436	3M letter to EPA
D.4437	Final Report - Mortality Study of Workers Employed at the 3M Cottage Grove Facility, prepared by Bruce Alexander, University of Minnesota, 4/26/01
D.4438	EID012621
D.4439	EID217652-4
D.4440	EID150591-4
D.4441	EID024244-9
D.4442	IARC Table
D.4443	Periodic Table of the Elements
D.4444	AR26 Docket
D.4445	EID723018
D.4446	EID723019-29
D.4447	J. Gannon letter to D. Rurak
D.4448	A 2006 C-8 Physician Reference



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4449	EID573890-1
D.4450	ECHA, WS Human Relevance of Rodent Liver Tumors (2016)
D.4451	IARC Monographs, Vol. 110
D.4452	M. Christman letter to USEPA (1992)
D.4453	Chart re AR226 Studies
D.4454	3M Two Year Oral (Diet) Toxicity / Carcinogenicity Study of Fluorochemical FC-143 in Rats, Volume 2 of 4
D.4455	3M Two Year Oral (Diet) Toxicity / Carcinogenicity Study of Fluorochemical FC-143 in Rats, Volume 3 of 4
D.4456	3M Two Year Oral (Diet) Toxicity / Carcinogenicity Study of Fluorochemical FC-143 in Rats, Volume 4 of 4
D.4457	Legal Notice
D.4458	CV of Samuel Cohen, M.D., Ph.D.
D.4459	Ohio EPA Agenda
D.4460	B. Priestly; Literature Review and Report on the Potential Health Effects of Perfluoroalkyl Compounds, Mainly Perfluorooctane Sulfonate (PFOS) (2017)
D.4461	Food Standards Australia New Zealand; Hazard assessment report - Perfluorooctane Sulfonate (PFOS), Perfluorooctanoic Acid (PFOA), Perfluorohexane Sulfonate (PFHxS)
D.4462	S. Stalnecker letter to S. Hazen (2005)
D.4463	Potential National PFOA Stewardship Meeting Attendees (2005)
D.4464	US EPA Summary of PFOA Stewardship Program Meetings (2006)
D.4465	S. Stalnecker letter to S. Johnson (2006)
D.4466	P. Lindner letter to OPPT Document Control Office (2008)
D.4467	Meeting Sign-in Sheet PFOA Stewardship Program (2015)
D.4468	EPA's Summary Tableaus for 2010 Company Progress Reports
D.4469	S. Stalnecker letter to S. Johnson (2006)
D.4470	S. Doi letter to C. Auer (2006)
D.4471	P. Piringer, U. Wolfmeier letter to OPPT Document Control Office (2006)
D.4472	R. Evans email to NCIC OPPT (2007)
D.4473	R. Evans letter to S. Johnson (2007)
D.4474	E. Russell letter to OPPT Document Control Office (2007)
D.4475	Appendix E, Draft Company Report: Summary of Baseline Emissions and Product Content
D.4476	Expert Health Panel for Per- and Poly-Fluoroalkyl Substances (PFAS)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D.4477	K. Innes, J. Wimsatt, S. Frisbee, A. Ducatman; Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. <i>BMC Cancer</i> , 14: 45 (2014)
D.4478	S. Cohen, M. Meek, J. Klaunig, et al.; The Human Relevance of Information on Carcinogenic Modes of Action: Overview. <i>Critical Reviews in Toxicology</i> , 33(6): 581-589 (2003)
D.4479	M. Meek, J. Bucher, S. Cohen, et al.; A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action. <i>Critical Reviews in Toxicology</i> , 33(6): 591-653 (2003)
D.4480	DuPont Health Advisory Board 10/12/03
D.4481	DuPont Health Advisory Board Agenda 4/5/04
D.4482	DuPont Health Advisory Board Key Comments, Considerations, and Recommendations from HAB Participants 4/3/04
D.4483 - D.4500	RESERVED for photographs and Washington Works plant and facilities
D2.0006(R-TR2)	005-0167-0042761 - 81
D2.0007	Emmett study
D2.0008	Columbus Dispatch article: Water Utility's Contamination Warning Causing a Stir; Experts disagree on whether chemical C8 detected in wells poses health risk
D2.0018	Smith-Bindman, Lipson, et al., Radiation Dose Associated with Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer. <i>Arch Intern Med.</i> 2009; 169(22):2078-2086
D2.0019	Brenner, Hall, Computed Tomography - An Increasing Source of Radiation Exposure. <i>New Engl. J. Med</i> 2007; 357:2277-2284
D2.0020	de Gonzalez, Mahesh, et al., Projected Cancer Risks from Computed Tomographic Scans Performed in the United States in 2007. <i>Arch Intern Med.</i> 2009; 169(22):2071-2077
D2.0021	Carver, Al-Ahmadie, Sheinfeld; Adult and Pediatric Testicular Teratoma. <i>Urol Clin N Am</i> 34 (2007) 245-251
D2.0022	Leibovitch, Foster, et al., Adult Primary Pure Teratoma of the Testis. <i>CANCER</i> , May 1, 1995, Volume 75, No. 9, 2244-2250
D2.0023	American Cancer Society - What are the risk factors for testicular cancer?
D2.0024	May Clinic information on Testicular Cancer
D2.0025	Ahmad Shabsigh, MD on Testicular Cancer

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D2.0026	World Health Organization Classification of Testicular Tumors
D2.0027	Table 1 - Annual Average PFOA Concentration in Little Hocking Water Association from Figure 2, Shin 2011; Years Applicable to David Freeman are 1993 - 2005
D2.0028	C8 Science Panel's Probable Link Evaluation of Cancer
D2.0029	C8 Science Panel's Probable Link Evaluation of Cancer
D2.0030	Graph - Relative Risks v. Cumulative Serum Level
D2.0031	R. Bilott letter to Savitz & Fletcher C8 Science Panel report interpretation
D2.0033	American Cancer Society - Testicular Cancer Overview
D2.0035	Cancer of the Testis - SEER Stat Fact Sheets
D2.0039	Frisbee, Brooks, Maher, et al., The C8 Project: Design, Methods, and Participants. NIEHS, Environmental Health Perspectives
D2.0040	G. Sykes memo to C. Reinhardt - Two-Year Toxicity/Carcinogenicity Study of Fluorchemical FC-143 in Rats
D2.0041	3M MSDS for FC-118 Fluorad Brand Fluorchemical Surfactant
D2.0047	Shin, Vieira, Ryan, et al., Environmental Fate and Transport Modeling for Perfluorooctanoic Acid Emitted from the Washington Works Facility in West Virginia. Environ. Sci. Technol, 2011, 45, 1435-1442
D2.0048	Washburn MDL 23687 spreadsheet
D2.0050	MacIntosh / Environmental Health & Engineering blank interview form
D2.0051	Figure 1 - C8 Health Project study area
D2.0057	CV of Tony Luongo, MD, FRCSC, FACS (10/15)
D2.0058	R. Beranger, C. Le Cornet, J. Schuz, B. Fervers; Occupational and Environmental Exposures Associated with Testicular Germ Cell Tumours: Systematic Review fo Prenatal and Live-Long Exposures. PLOS ONE, Colume 8, Issue 10 e77120 (10/2013)
D2.0059	L. Biegel, M. Hurtt, S. Frame, et al.; Mechanisms of Extrahepatic Tumor Induction by Peroxisome Proliferators in Male CD Rats. Toxicological Sciences 60, 44-55 (2001)
D2.0060	L. Einhorn; Treatment of Testicular Cancer: A New and Improved Model. J. of Clin. Oncology, Vol. 8, No. 11 (November), 1990; pp 1777-1781.
D2.0061	S. Fossa, J. Chen, S. Schonfeld, K. McGlynn, et al.; Risk of Contralateral Testicular Cancer: A Population-based Study of 29515 U.S. Men. J. of the Natl. Cancer Inst., Vol. 97:1056-66 (2005)
D2.0062	Y. Huang, Z. Zhang, D. Tashkin, et al.; An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015 January; 24(1); 15-31.
D2.0063	S. Hussain, Y.T. Ma, D. Palmer, et al.; Biology of testicular germ cell tumors. Expert Review of Anticancer Therapy. 8.10 (Oct. 2008); p1659-73.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D2.0064	K.P. Dieckmann, N.E. Skakkebaek; Carcinoma <i>In Situ</i> of the Testis: Review of Biological and Clinical Features. <i>Int. J. Cancer</i> : 83,815-922 (1999)
D2.0065	L.H. Looijenga, A. Gillis, H. Stoop, et al.; Dissecting the molecular pathways of (testicular) germ cell tumor pathogenesis; from initiation to treatment-resistance. <i>Internal Journal of Andrology</i> , 34, e234-e251.
D2.0066	D. Lam, D. Larson, D. Eisenberg, et al.; Communicating Potential Radiation-Induced Cancer Risks from Medical Imaging Directly to Patients. <i>AJR</i> : 205; 962-970 (November 2015).
D2.0067	K. Litchfield, H. Thomsen, J. Mitchell, et al.; Quantifying the heritability of testicular germ cell tumor using both population-based and genomic approaches. <i>Sci. Rep.</i> 5:13889.
D2.0068	K. McGlynn, M. Cook; Etiologic factors in testicular germ cell tumors. <i>Future Oncol.</i> 2009 November; 5(9): 1389-1402.
D2.0069	K. McGlynn, S. Devesa, A. Sigurdson, et al.; Trends in the Incidence of Testicular Germ Cell Tumors in the United States. <i>Cancer</i> January 1; 97(1):63-70.
D2.0070	R. Montironi; Intratubular Germ Cell Neoplasia of the Testis: Testicular Intraepithelial Neoplasia. <i>European Urology</i> 41 (2002) 651-654.
D2.0071	J. Oldenburg, GC Alfsen, H. Waehre, SD Fossa; Late recurrences of germ cell malignancies: a population-based experience over three decades. <i>British J. of Cancer</i> (2006) 94, 820-827.
D2.0072	M. Purdue, S. Devesa, A. Sigurdson, K. McGlynn; International patterns and trends in testis cancer incidence. <i>Int. J. Cancer</i> : 115, 822-827 (2005).
D2.0073	E. Rajpert-De Meyts, C. Hoei-Hansen; From Gonocytes to Testicular Cancer The Role of Impaired Gonadal Development. <i>Ann. N.Y. Acad. Sci.</i> 1120: 168-180 (2007).
D2.0074	SEER Cancer Statistics Review 1975-2006.
D2.0075	SEER Cancer Statistics Review 1975-2012
D2.0076	R. Siegel, J. Ma, Z. Zou, A. Jemal; Cancer Statistics, 2014. <i>Ca Cancer J. Clin.</i> 2014; 64:9-29 (Jan./Feb. 2004)
D2.0077	S. Stevenson, W. Lowrance; Epidemiology and Diagnosis of Testis Cancer. <i>Urol Clin N Am</i> 42 (2015) 269-275.
D2.0078	C. Tomasetti, B. Vogelstein; Variation in cancer risk among tissues can be explained by the number of stem cell divisions. <i>Science Magazine</i> Vol 347 Issue 6217, 78-81.
D2.0079	C. Tomasetti, B. Vogelstein; Supplementary Materials for Variation in cancer incidences among tissues can be explained by the number of stem cell divisions. <i>Science Magazine</i> Vol. 347 Issue 6217. 78 Suppl./DC1.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D2.0080	C. Walraven, D. Fergusson, C. Earle, et al.; Association of Diagnostic Radiation Exposure and Second Abdominal-Pelvic Malignancies After Testicular Cancer. <i>J. Clin. Oncol</i> 29:2883-2888 (2011).
D2.0081	Y. Vergouwe, W. Steyerberg, M. Eijkemans, et al.; Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review. <i>J. Clin. Oncol.</i> 21:4092-4099 (2003).
D2.0082	A. Stephenson, T. Gilligan; Neoplasms of the Testis. <i>Campbell-Walsh Urology</i> , Eleventh Edition (2015).
D2.0084	CV of Mark Schoenberg, MD
D2.0085	P. Chieffi, S. Chieffi; An up-date on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors. <i>Histol Histopathol</i> (2014) 29: 999-1006.
D2.0086	D. Vizio, L. Cito, A. Boccia, et al.; Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. <i>Oncogene</i> (2005) 24, 1882-1894.
D2.0087	N. Hanna, L. Einhorn; Testicular Cancer - Discoveries and Updates. <i>N Engl J Med</i> 2014; 371:2005-6.
D2.0088	D. Harms, S. Zahn, U. Gobel, D.T. Schneider; Pathology and Molecular Biology of Teratomas in Childhood and Adolescence. <i>Klin Padiatr</i> 2006; 218: 296-302
D2.0089	M. Kier, J. Lauritsen, K. Almstrup, et al.; Screening for carcinoma <i>in situ</i> in the contralateral testicle in patients with testicular cancer: a population-based study. <i>Annals of Oncology</i> 26: 737-742 (2015).
D2.0090	T. Kimura, A. Suzuki, Y. Fujita, et al.; Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. <i>Development</i> 2003 130: 1691-1700.
D2.0091	M. Komarowska, A. Hermanowicz, W. Debek; Putting the pieces together: Cryptorchidism-do we know everything? <i>J Pediatr Endocrinol Metab</i> 2015; 28:1247-56.
D2.0092	K. Litchfield, J. Shipley, C. Turnbull; Common variants identified in genome-wide association studies of testicular germ cell tumor: an update, biological insights and clinical application. <i>Andrology</i> 2015;3:34-46.
D2.0093	G. Mikuz; Update on the Pathology of Testicular Tumors. <i>Anal Quant Cytopathol Histopathol</i> 2015;37:75-85.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D2.0094	N. Nicolai, A. Neccchi, D. Raggi, et al.; Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> 2015;85:402-6.
D2.0095	Ondrus, Ondrusova, Stastna; Bilateral Germ-Cell Testicular Cancer - Long Term Experience. <i>Klin Onkol</i> 2013;26:421-4.
D2.0096	Risk and prognostic significance of metachronous contraleateral testicular germ cell tumors. <i>British Journal of Cancer</i> (2012) 107, 1637-1643.
D2.0097	SEER Stat Fact Sheets 2015: Testis Cancer <a href="http://seer.cancer.gov/statfacts/html/testis.html">http://seer.cancer.gov/statfacts/html/testis.html</a>
D2.0098	S. Zequi, W. Henriques da Costa, T. Santana, et al; Bilateral testicular germ cell tumors: a systematic review. <i>BJUI</i> 2012;110:1102-9.
D2.0099	T. Tarin, G. Sonn, R. Shinghal; Estimating the Risk of Cancer Associated with Imaging Related Radiation During Surveillance for Stage I Testicular Cancer using Computerized Tomography. <i>The Journal of Urology</i> 2008;181:627-33.
D2.0100	J. Yamate, K. Gamou, K. Izawa-Ogata, et al.; Characterization of rat testicular teratoma and its derived cell lines, with particular reference to possible mesenchymal differentiations. <i>Histol Histopathol</i> (2014) 29: 1201-1216.
D2.0101	A.J. Stephenson; Neoplasms of the Testis. In: Wein AJ, ed. <i>Campbell-Walsh Urology</i> . 10th ed. Philadelphia, PA: Saunders; 2012:784-814.
D2.0102	Expert Report of Robert W. Rickard, PhD., DAPT
D2.0121	National Cancer Institute: Cancer Causing Substances in the Environment
D2.0122	National Cancer Institute: Environmental Carcinogens and Cancer Risk
D2.0123	National Cancer Institute: Risk Factors for Cancer
D2.0124	National Cancer Institute: Testicular Cancer - Health Professional Version
D2.0125	American Cancer Society: Testicular Cancer
D2.0126	National Institutes of Health: Testicular Cancer
D2.0123	National Cancer Institute: Risk Factors for Cancer
D2.0124	National Cancer Institute: Testicular Cancer - Health Professional Version
D2.0125	American Cancer Society: Testicular Cancer
D2.0126	National Institutes of Health: Testicular Cancer
D-Abbott.	
DP.1	005-0167-0042761 - 821
DP.10	EID072205-6
DP.11	EID136502-5; RCG0000104-17
DP.12	EID171605-34; RK000567-96



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
DP.13	Shin, et al.; Supplemental Material, Retrospective Exposure Estimation and Predicted versus Observed Serum Perfluorooctanoic Acid Concentrations for Participants in the C8 Health Project.
DP.14	West Virginia Department of Environmental Protection Final Decision and Response to Comments, July 2015
DP.2	001-0005-0001420 - 28
DP.3	WVDEP000609-12
DP.4	WVDEP Final Ammonium Perfluorooctanoate (C8) Assessment of Toxicity Team (CATT) Report, August 2002
DP.5	CATT report signature pages
DP.6	003-0230-0000062-66
DP.7	EID079096-100; RJZ009213-18
DP.8	EID951509; RJZ009907
DP.9	RJZ005098
D-Swartz.0002	Plaintiff's Responses to Defendant's Discovery Requests to Trial Plaintiff Angela Swartz
D-Swartz.0003	Plaintiff's Responses to Defendant's Discovery Requests to Trial Plaintiff Teddy Swartz
D-Swartz.0004	Plaintiff's Responses to Defendant's Third Discovery Requests to Trial Plaintiff Angela Swartz
D-Swartz.0005	Birth Certificate of Angela Swartz
D-Swartz.0006	Marriage License of Teddy Swartz and Angela Casto
D-Swartz.0007	2011 Swartz Tax Returns
D-Swartz.0008	2012 Swartz Tax Returns
D-Swartz.0009	2013 Swartz Tax Returns
D-Swartz.0010	2014 Swartz Tax Returns
D-Swartz.0011	2015 Swartz Tax Returns
D-Swartz.0012	796671-31SSA-00001 - 341
D-Swartz.0013	PFS
D-Swartz.0014	PFS
D-Swartz.0015	PFS
D-Swartz.0016	Employment Records - Big Ben Food Land
D-Swartz.0017	Employment Records - Big Ben Food Land
D-Swartz.0018	C8 Science Panel - C-8 Community Follow-Up to A. Swartz
D-Swartz.0019	Brookmar, Inc. - C8 Health Project Report for A. Swartz
D-Swartz.0020	Brookmar, Inc. - C8 Health Project Report for A. Swartz



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Swartz.0021	Pomeroy Water Affidavit for Big Ben Food Land location
D-Swartz.0022	Tuppers Plains-Chester Water District Proof of Water Service for Janet Oiler
D-Swartz.0023	2005 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0024	2005 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0025	2007 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0026	2008 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0027	2009 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0028	2010 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0029	2011 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0030	2012 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0031	2014 Tuppers Plains-Chester Water District Water Quality Report
D-Swartz.0032	Map - 312 Seigrist Rd.
D-Swartz.0033	Map - A. Swartz Mother's House
D-Swartz.0034	Map - Big Ben Food Land
D-Swartz.0035	Map - A. Swartz Sister's House
D-Swartz.0036	Map - 44192 Fores Run Road
D-Swartz.0037	Facebook Excerpts
D-Swartz.0038	Facebook photo of A. Swartz' Mother
D-Swartz.0039	Photo of Teddy Swartz
D-Swartz.0040	Photo of Teddy Swartz
D-Swartz.0041	Additional Billing Dr. Morabito
D-Swartz.0042	Billing Statements Holzer Clinic
D-Swartz.0043	Billing Statements St. Mary's Urology
D-Swartz.0044	Billing Statements St. Mary's Medical Center
D-Swartz.0045	Billing - Holzer Medical Center
D-Swartz.0046	Billing - Holzer Medical Clinic
D-Swartz.0047	Billing - Rocco Morabito
D-Swartz.0048	Billing - St. Mary's Medical Center
D-Swartz.0049	Dr. Morabito (Records)
D-Swartz.0050	Medical Records Holzer Clinic
D-Swartz.0051	Medical Records Holzer Medical
D-Swartz.0052	Medical Records St. Mary's Urology
D-Swartz.0053	Medical Records - CVS
D-Swartz.0054	Pharmacy Records - Express Scripts (MO)
D-Swartz.0055	Rocco Morabito (Records)
D-Swartz.0056	St. Mary Med Ctr 1

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Swartz.0057	St. Mary Med Ctr 2
D-Swartz.0058	St. Mary Med Ctr 3
D-Swartz.0059	Swartz - Nodule (Records)
D-Swartz.0060	Swartz Operative Report
D-Swartz.0061	Swartz Pathology Report
D-Swartz.0062	796671-6SMMC-00001
D-Swartz.0063	796671-7SMMC-00001 - 32
D-Swartz.0064	796671-9SMMC-00001 - 23
D-Swartz.0065	796671-10CVS-00001 - 6
D-Swartz.0066	796671-11HHS-00001 - 495
D-Swartz.0067	796671-12HHS-00001 - 500
D-Swartz.0068	796671-13HHS-00001 - 425
D-Swartz.0069	796671-14HHS-00001 - 500
D-Swartz.0070	796671-15HHS-00001 - 410
D-Swartz.0071	796671-16CVS-00001 - 6
D-Swartz.0072	796671-17SMCC-00001 - 32
D-Swartz.0073	796671-18SMCC-00001 - 23
D-Swartz.0074	796671-19HHS-00001 - 500
D-Swartz.0075	796671-20FPH-00001 - 10
D-Swartz.0076	796671-21HHS-00001 - 227
D-Swartz.0077	796671-22HHS-00001 - 227
D-Swartz.0078	796671-23FPH-00001 - 10
D-Swartz.0079	796671-24ESPO-00001 - 24
D-Swartz.0080	796671-25FPH-00001 - 10
D-Swartz.0081	796671-26ESPO-00001 - 24
D-Swartz.0082	796671-28OSUWMC-00001
D-Swartz.0083	796671-29OSUWMC-00001
D-Swartz.0084	796671-34 SMMC-00001 - 18
D-Swartz.0085	796671-38HHS-00001 - 17
D-Swartz.0086	Tab 39 - Swartz, Angela R. - Saint Mary's Medical Center (Pathology 2)
D-Swartz.0087	796671-41HHS-00001 - 4
D-Swartz.0088	Swartz Depo - Hysterectomy
D-Swartz.0089	Deposition of David L. MacIntosh in Swartz
D-Swartz.0090	MacIntosh Deposition Exhibit 1
D-Swartz.0091	MacIntosh Deposition Exhibit 2
D-Swartz.0092	MacIntosh Deposition Exhibit 3

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Swartz.0093	MacIntosh Deposition Exhibit 4
D-Swartz.0094	MacIntosh Deposition Exhibit 5
D-Swartz.0095	MacIntosh Deposition Exhibit 6
D-Swartz.0096	Deposition of James Cox (Vol. 1)
D-Swartz.0097	Deposition of James Cox (Vol. 2)
D-Swartz.0098	Expert Report of David MacIntosh (Swartz)
D-Swartz.0099	ATSDR - Toxicological Profile for Perfluoroalkyls - Draft for Public Comment
D-Swartz.0100	R. Avanası, H. Shin, V. Vieira, D. Savitz, S. Bartell; Impact of Exposure Uncertainty on the Association between Perfluorooctanoate and Preeclampsia in the C8 Health Project Population. <i>Environ Health Perspect</i> 124:126-132
D-Swartz.0101	L. Begnudelli, B. Sanders; Unstructured Grid Finite-Volume Algorithm for Shallow-Water Flow and Scalar Transport with Wetting and Drying. <i>Journal of Hydraulic Engineering- asce - J HYDRAUL ENG-ASCE</i> . 132. (2006)10.1061/(ASCE)0733-9429(2006)132:4(371).
D-Swartz.0102	L. Begnudelli, A. Valiani, B. Sanders; A balanced treatment of secondary currents, turbulence and dispersion in a depth-integrated hydrodynamic and bed deformation model for channel bends; <i>Advances in Water Resources</i> 33 (2010) 17-33
D-Swartz.0103	Betts KS. PFOA and high cholesterol: basis for the finding of a probable link. <i>Environ Health Perspect</i> . 2014;122(12): A338
D-Swartz.0104	Franko, Jennifer & J Meade, B & Frasc, H & M Barbero, Ana & Anderson, Stacey. (2012). Dermal Penetration Potential of Perfluorooctanoic Acid (PFOA) in Human and Mouse Skin. <i>Journal of toxicology and environmental health. Part A</i> . 75. 50-62
D-Swartz.0105	Gleason, et al. Health-based Maximum Contaminant Level Support Document: Perfluorooctanoic Acid (PFOA). New Jersey Drinking Water Quality Institute. Health Effects Subcommittee. (2016)
D-Swartz.0106	Grandjean P, Andersen EW, Budtz-Jørgensen E, et al. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds [published correction appears in JAMA. 2012 Mar 21;307(11):1142]. <i>JAMA</i> . 2012;307(4):391–397
D-Swartz.0107	Higgins, Christopher & Luthy, Richard. (2007). Sorption of Perfluorinated Surfactants on Sediments †. <i>Environmental science &amp; technology</i> . 40. 7251-6. 10.1021/es061000n.

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Swartz.0108	Hu XC, Andrews DQ, Lindstrom AB, et al. Detection of Poly- and Perfluoroalkyl Substances (PFASs) in U.S. Drinking Water Linked to Industrial Sites, Military Fire Training Areas, and Wastewater Treatment Plants. <i>Environ Sci Technol Lett.</i> 2016;3(10):344–350
D-Swartz.0109	Jing P, Rodgers PJ, Amemiya S. High lipophilicity of perfluoroalkyl carboxylate and sulfonate: implications for their membrane permeability. <i>J Am Chem Soc.</i> 2009;131(6):2290–2296
D-Swartz.0110	Lorber, M., Egeghy, P.; Simple Intake and Pharmacokinetic Modeling to Characterize Exposure of Americans to Perfluorooctanoic Acid, PFOA. <i>Environmental Science &amp; Technology</i> 2011 45 (19), 8006-8014
D-Swartz.0111	Looker C, Luster MI, Calafat AM, et al. Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate. <i>Toxicol Sci.</i> 2014;138(1)
D-Swartz.0112	Mondal D, Lopez-Espinosa MJ, Armstrong B, Stein CR, Fletcher T. Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between mother-child pairs in a population with perfluorooctanoate exposure from drinking water. <i>Environ Health Perspect.</i> 2012;120(5)
D-Swartz.0113	Nguyen, P.B., Thorstensen, A.R., Sorooshian, S., Hsu, K., Aghakouchak, A., Sanders, B.F., Koren, V., Cui, Z., & Smith, M. (2016). A high resolution coupled hydrologic–hydraulic model (HiResFlood-UCI) for flash flood modeling.
D-Swartz.0114	Stemmler, Irene & Lammel, G. (2010). Pathways of PFOA to the Arctic: Variabilities and contributions of oceanic currents and atmospheric transport and chemistry sources. <i>Atmospheric Chemistry and Physics</i> , v.10, 9965-9980 (2010).
D-Swartz.0115	Tsafnat G, Glasziou P, Choong MK, Dunn A, Galgani F, Coiera E. Systematic review automation technologies. <i>Syst Rev.</i> 2014;3:74
D-Swartz.0116	Yamashita, Nobuyoshi et al. "Perfluorinated acids as novel chemical tracers of global circulation of ocean waters." <i>Chemosphere</i> 70 7 (2008): 1247-55
D-Swartz.0117	Morrison; Actionable level for PFOA in drinking water lowered, <i>Chemical &amp; Engineering News</i> , January 16, 2017, Volume 95, Issue 3, pp. 13
D-Swartz.0118	Deposition of Vitaly Margulis (Swartz)
D-Swartz.0119	Margulis Deposition Exhibit 1
D-Swartz.0120	Margulis Deposition Exhibit 2
D-Swartz.0121	Margulis Deposition Exhibit 3
D-Swartz.0122	Margulis Deposition Exhibit 4
D-Swartz.0123	Margulis Deposition Exhibit 5
D-Swartz.0124	Expert report of Vitaly Margulis (Swartz)
D-Swartz.0125	Cancer.org – Kidney Cancer Adult Risk Factors

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Swartz.0126	Cancer.gov – Stat Facts: Kidney and Renal Pelvis Cancer
D-Swartz.0127	Cancer.gov – Psychological Stress and Cancer
D-Swartz.0128	Cancer.org – Anxiety, Fear and Depression - Having cancer affects your emotional health
D-Swartz.0129	Gofrit ON, Yutkin V, Zorn KC, et al. The growth rate of "clinically significant" renal cancer. Springerplus. 2015;4:580
D-Swartz.0130	Jewett, MA. et al. Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. Eur Urol (2011) 60:39-44
D-Swartz.0131	Nerli R, Devaraju S, Hiremath MB, Guntaka AK, Patne P, Dixit N. Tumor doubling time of renal cell carcinoma measured by CT. Indian J Urol. 2014;30(2):153–157
D-Swartz.0132	NRDC letter - Setting a Maximum Contaminant Level for PFOA and PFOS
D-Swartz.0133	Expert report of Marie Tobin (Swartz)
D-Swartz.0134	Expert report of Stephen Washburn (Swartz)
D-Swartz.0135	Deposition of Angela Swartz
D-Swartz.0136	Deposition of Teddy Swartz
D-Swartz.0137	Deposition of Ashok Dayal
D-Swartz.0138	Dayal Deposition Exhibit 3
D-Swartz.0139	Dayal Deposition Exhibit 4
D-Swartz.0140	Dayal Deposition Exhibit 11
D-Swartz.0141	Deposition of Rocco Morabito
D-Swartz.0142	Morabito Deposition Exhibit 16
D-Swartz.0143	Deposition of Jennifer Olson
D-Swartz.0144	Olson Deposition Exhibit 20
D-Swartz.0145	Information on Travis L. Swartz
D-Swartz.0146	Information on Travis L. Swartz
D-Abbott.0001	Deposition of Travis Abbott, dated April 4, 2019
D-Abbott.0002	Travis Abbott Deposition Exhibit 1
D-Abbott.0003	Travis Abbott Deposition Exhibit 2
D-Abbott.0004	Travis Abbott Deposition Exhibit 3
D-Abbott.0005	Travis Abbott Deposition Exhibit 4
D-Abbott.0006	Travis Abbott Deposition Exhibit 5
D-Abbott.0007	Travis Abbott Deposition Exhibit 6
D-Abbott.0008	Travis Abbott Deposition Exhibit 7
D-Abbott.0009	Travis Abbott Deposition Exhibit 8
D-Abbott.0010	Travis Abbott Deposition Exhibit 9
D-Abbott.0011	Travis Abbott Deposition Exhibit 10

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0012	Travis Abbott Deposition Exhibit 11
D-Abbott.0013	Travis Abbott Deposition Exhibit 12
D-Abbott.0014	Travis Abbott Deposition Exhibit 13
D-Abbott.0015	Travis Abbott Deposition Exhibit 14
D-Abbott.0016	Travis Abbott Deposition Exhibit 15
D-Abbott.0017	Travis Abbott Deposition Exhibit 16
D-Abbott.0018	Travis Abbott Deposition Exhibit 17
D-Abbott.0019	Travis Abbott Deposition Exhibit 18
D-Abbott.0020	Travis Abbott Deposition Exhibit 19
D-Abbott.0021	Travis Abbott Deposition Exhibit 20
D-Abbott.0022	Travis Abbott Deposition Exhibit 21
D-Abbott.0023	Travis Abbott Complaint (SDOH), filed November 14, 2017
D-Abbott.0024	Travis Abbott 1st Amended Complaint (SDOH), filed February 21, 2019
D-Abbott.0025	Travis Abbott Brookmar, Inc. - C8 Health Project Report
D-Abbott.0026	Travis Abbott Brookmar, Inc. - C8 Health Project Report
D-Abbott.0027	Travis Abbott PFS
D-Abbott.0028	Travis Abbott 1st Amended PFS
D-Abbott.0029	Travis Abbott 2nd Amended PFS
D-Abbott.0030	2019-2020 Meigs High School Principal's Message
D-Abbott.0031	Board Approves Abbott as new Meigs Principal
D-Abbott.0032	MDL-T_Abbott-000001-27
D-Abbott.0033	MDL-T_Abbott-000028-32
D-Abbott.0034	Pomeroy Water Affidavit - High Street
D-Abbott.0035	Pomeroy Water Affidavit - Wehe Terrace
D-Abbott.0036	Water User's Agreement, Tuppens Plains-Chester Water District
D-Abbott.0037	March 2, 2002 article, Parkersburg News: "C8 found in Belpre, Tuppens Plains"
D-Abbott.0038	June 18, 2004 article, Pomeroy Daily Sentinel: "Engineer questions DuPont C8 claims"
D-Abbott.0039	June 22, 2004 article, Pomeroy Daily Sentinel: "TP-C shows dwindling C8 levels"
D-Abbott.0040	September 13, 2004 article, Pomeroy Daily Sentinel: "DuPont settlement includes new water treatment systems"
D-Abbott.0041	November 24, 2004 article, Pomeroy Daily Sentinel: "Judge OKs terms of C8 settlement"
D-Abbott.0042	December 12, 2004 article, Pomeroy Sentinel: "Customers learn C8 settlement details"



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0043	March 18, 2005 article, Pomeroy Daily Sentinel: "DuPont to cut amount of chemical used to make Teflon"
D-Abbott.0044	April 23, 2010 article, Pomeroy Daily Sentine: "More C8 health studies planned in W.Va., Ohio"
D-Abbott.0045	April 17, 2012 article, Pomeroy Daily Sentinel: "C8 Science Panel links C8 to testicular, kidney cancer"
D-Abbott.0046	May 13, 2012 article, Pomeroy Daily Sentinel: "EPA orders nationwide monitoring of C8 in water supply"
D-Abbott.0047	January 15, 2013 notice, Pomeroy Daily Sentinel: "Legal Notice to People Who Have Consumed Certain Water for at Least One Year in Certain Locations in West Virginia and Ohio"
D-Abbott.0048	December 6, 2013, article, Pomeroy Daily Sentinel: "DuPont to phase out C8 by 2014"
D-Abbott.0049 - D-Abbott.0050 RESERVED	
D-Abbott.0051	IU Simon Cancer Center Records
D-Abbott.0052	Abbott, Travis Medical Records
D-Abbott.0053	Clarian North Medical Center Records
D-Abbott.0054	Albany, Costantine Medical Records
D-Abbott.0055	Weisman, Keith Medical Records
D-Abbott.0056	Marietta Memorial Hospital Records (117 pages)
D-Abbott.0057	Vu, Khai Medical Records
D-Abbott.0058	Marietta Memorial Hospital Records (4 pages)
D-Abbott.0059	Rite Aid Pharmacy Records
D-Abbott.0060	Masterson, Timothy - IU Labs
D-Abbott.0061	Timothy Masterson medical records
D-Abbott.0062	Abbott, Travis Meigs Highschool Records
D-Abbott.0063	Billing--Costantine Albany
D-Abbott.0064	Billing records Dr. Masterson
D-Abbott.0065	Billing Records-IU Simon Cancer Center
D-Abbott.0066	Billing Records-Masterson, Dr. Timothy
D-Abbott.0067	Billing Records-Vu, Dr. Khai
D-Abbott.0068	Billing Statements_Holzer Medical Center_1020360
D-Abbott.0069	Billing Statements_Zyromski , Dr. Nicholas_1020362
D-Abbott.0070	Billing--Clarian North Medical Center



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0071	Billing--Kenneth Weisman
D-Abbott.0072	Billing--Marietta Memorial Hospital
D-Abbott.0073	Billing--Nationwide Children's Hospital-Columbus
D-Abbott.0074	Children's Hospital-Columbus
D-Abbott.0075	Medical Billing IU Simon Cancer
D-Abbott.0076	Medical Records - Abbott, Travis
D-Abbott.0077	Medical Records - Any and All_Holzer Clinic_1045766
D-Abbott.0078	Medical Records - Any and All_Holzer Medical Center_1020359
D-Abbott.0079	Medical Records - Any and All_Meigs Local School District_1117209
D-Abbott.0080	Medical Records - Any and All_Meigs Local School District_1117210
D-Abbott.0081	Medical Records - Any and All_Midwest Fertility Specialists_1063297
D-Abbott.0082	Medical Records - Any and All_Nationwide Children's Hospital_1045767
D-Abbott.0083	Medical Records - Any and All_Zyromski , Dr. Nicholas_1020361
D-Abbott.0084	Medical records--IU Simon Cancer Center
D-Abbott.0085	Medical Records-Nationwide Children's Hospital-Columbus
D-Abbott.0086	Meigs Local School District Subpoena Index
D-Abbott.0087	Meigs Local Subpoena - Categories 2, 7
D-Abbott.0088	Meigs Local Subpoena - Category 1
D-Abbott.0089	Meigs Local Subpoena - Category 8
D-Abbott.0090	Meigs Local Subpoena - Redactions to Categories 2,7
D-Abbott.0091	Meigs Local Subpoena - Redactions to Category 8
D-Abbott.0092	Part 2 billing records Dr. Albany
D-Abbott.0093	Tab_4_-_Abbott,_Travis_-_Marietta_Memorial_Hospital_-_Medical_-_64_-_Bates_-_a083900000sL2aLAAS_-_20181008100017
D-Abbott.0094	Tab_5_-_Abbott,_Travis_-_IU_Simon_Cancer_Center_-_Billing_-_3_-_Bates_-_a083900000sL5eEAAS_-_20181022100012
D-Abbott.0095	Tab_6_-_Abbott,_Travis_-_Marietta_Memorial_Hospital_-_Billing_-_7_-_Bates_-_a083900000sL6LJAA0_-_20181024154512
D-Abbott.0096	Tab_8_-_Abbott,_Travis_-_IU_Simon_Cancer_Center_-_Billing_-_12_-_Bates_-_a083900000sL73VAAS_-_20181026190029
D-Abbott.0097	Tab_9_-_Abbott,_Travis_-_IU_Simon_Cancer_Center_-_Medical_-_288_-_Bates_-_a083900000sLFbpAAG_-_20181129151553
D-Abbott.0098	Tab_10_-_Abbott,_Travis_-_Marietta_Memorial_Hospital_-_Medical_-_64_-_Bates_-_a083900000sLFgzAAG_-_20181130113015
D-Abbott.0099	Tab_11_-_Abbott,_Travis_-_IU_Simon_Cancer_Center_-_Billing_-_12_-_Bates_-_a083900000sLFh9AAG_-_20181130123113

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0100	Tab_12_-_Abbott,_Travis_-_Marietta_Memorial_Hospital_-_Billing_-_7_-_Bates_-_a083900000sLFh4AAG_-_20181130123120
D-Abbott.0101	Tab_14_-_Abbott,_Travis_-_Holzer_Health_System_-_Billing_-_103_-_Bates_-_a083900000sLHa4AAG_-_20181206164511
D-Abbott.0102	Tab_15_-_Abbott,_Travis_-_Holzer_Health_System_-_Medical_-_308_-_Bates_-_a083900000sLHZzAAO_-_20181206170010
D-Abbott.0103	Tab_16_-_Abbott,_Travis_-_Holzer_Health_System_-_Billing_-_103_-_Bates_-_a083900000sLIhuAAG_-_20181213064509
D-Abbott.0104	Tab_17_-_Abbott,_Travis_-_Holzer_Health_System_-_Medical_-_308_-_Bates_-_a083900000sLIj7AAG_-_20181213064513
D-Abbott.0105	Tab_18_-_Abbott,_Travis_-_Rite_Aid_Corporation_-_Pharmacy_-_2_-_Bates_-_a083900000sLJ16AAG_-_20181214131537
D-Abbott.0106	Tab_19_-_Abbott,_Travis_-_Rite_Aid_Corporation_-_Pharmacy_-_6_-_Bates_-_a083900000sLJWuAAO_-_20181218103023
D-Abbott.0107	Tab_20_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Medical_-_259_-_Bates_-_a083900000sLNaHAAW_-_20190107123225
D-Abbott.0108	Tab_21_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Billing_-_41_-_Bates_-_a083900000sLNrSAAW_-_20190108153020
D-Abbott.0109	Tab_22_-_Abbott,_Travis_-_Rite_Aid_Corporation_-_Pharmacy_-_6_-_Bates_-_a083900000sLOiYAAW_-_20190109134524
D-Abbott.0110	Tab_23_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Medical_-_258_-_Bates_-_a083900000sLOiTAAW_-_20190109140017
D-Abbott.0111	Tab_24_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Medical_-_2_-_Bates_-_a083900000sLQWVAA4_-_20190118083009
D-Abbott.0112	Tab_25_-_Abbott,_Travis_-_Timothy_A._Masterson,_M.D._-_Medical_-_2_-_Bates_-_a081000000zmTeDQAU_-_20190409094518
D-Abbott.0113	Tab_26_-_Abbott,_Travis_-_IU_Simon_Cancer_Center_-_Medical_-_288_-_Bates_-_a081000000zpYpkQAE_-_20190410103104
D-Abbott.0114	Tab_27_-_Abbott,_Travis_-_Timothy_A._Masterson,_M.D._-_Medical_-_53_-_Bates_-_a081000000zseVIQAI_-_20190415133409
D-Abbott.0115	Tab_29_-_Abbott,_Travis_-_Midwest_Fertility_Specialist_-_Medical_-_4_-_Bates_-_a08100000109klpQAI_-_20190418134539
D-Abbott.0116	Tab_30_-_Abbott,_Travis_-_Timothy_A._Masterson,_M.D._-_Medical_-_53_-_Bates_-_a0810000010No0hQAC_-_20190429090017
D-Abbott.0117	Tab_31_-_Abbott,_Travis_-_Midwest_Fertility_Specialist_-_Medical_-_4_-_Bates_-_a0810000010No1BQAS_-_20190429090023

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0118	Tab_32_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_2_-_Bates_-_a081O000010di2xQAA_-_20190502083107
D-Abbott.0119	Tab_33_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_52_-_Bates_-_a081O000010dmi9QAA_-_20190502083110
D-Abbott.0120	Tab_34_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_2_-_Bates_-_a081O000010f8xeQAA_-_20190506101717
D-Abbott.0121	Tab_35_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_52_-_Bates_-_a081O000010iyZSQAY_-_20190507141557
D-Abbott.0122	Tab_36_-_Abbott,_Travis_-_Kenneth_M._Weisman,_M.D._-_Medical_-_7_-_Bates_-_a081O0000118qlpQAA_-_20190523150041
D-Abbott.0123	Tab_37_-_Abbott,_Travis_-_Urology_of_Indiana_-_Billing_-_2_-_Bates_-_a081O0000118qZeQAI_-_20190525144525
D-Abbott.0124	Tab_38_-_Abbott,_Travis_-_Urology_of_Indiana_-_Medical_-_2_-_Bates_-_a081O000011BvnyQAC_-_20190525150012
D-Abbott.0125	Tab_39_-_Abbott,_Travis_-_Urology_of_Indiana_-_Billing_-_2_-_Bates_-_a081O000011Bvo3QAC_-_20190525150015
D-Abbott.0126	Tab_40_-_Abbott,_Travis_-_Urology_of_Indiana_-_Medical_-_36_-_Bates_-_a081O0000118qZjQAI_-_20190525151513
D-Abbott.0127	Tab_42_-_Abbott,_Travis_-_Kenneth_M._Weisman,_M.D._-_Medical_-_8_-_Bates_-_a081O000011NqDjQAK_-_20190531101525
D-Abbott.0128	Tab_43_-_Abbott,_Travis_-_Urology_of_Indiana_-_Medical_-_36_-_Bates_-_a081O000011NqDoQAK_-_20190531101528
D-Abbott.0129	Tab_44_-_Abbott,_Travis_-_Urology_of_Indiana_-_Billing_-_2_-_Bates_-_a081O000011NqDtQAK_-_20190531101530
D-Abbott.0130	Tab_45_-_Abbott,_Travis_-_Kenneth_M._Weisman,_M.D._-_Medical_-_7_-_Bates_-_a081O000011NqDyQAK_-_20190531103020
D-Abbott.0131	Tab_46_-_Abbott,_Travis_-_Midwest_Fertility_Specialist_-_Billing_-_2_-_Bates_-_a081O000011diaWQAO_-_20190611081657
D-Abbott.0132	Tab_47_-_Abbott,_Travis_-_Zyromski,_Nicholas_J._M.D._-_Medical_-_25_-_Bates_-_a081O000011izKSQAY_-_20190611083047
D-Abbott.0133	Tab_48_-_Abbott,_Travis_-_Indiana_University_Health_North_Hospital_-_Billing_-_Billing_-_2_-_Bates_-_a081O000011m57JQAO_-_20190613164631
D-Abbott.0134	Tab_50_-_Abbott,_Travis_-_Indiana_University_Health_North_Hospital_-_Billing_-_Billing_-_3_-_Bates_-_a081O000011sLibQAE_-_20190618100053
D-Abbott.0135	Tab_51_-_Abbott,_Travis_-_Zyromski,_Nicholas_J._M.D._-_Medical_-_25_-_Bates_-_a081O000011sLiMQAU_-_20190618090028

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0136	Tab_52_-_Abbott,_Travis_-_Indiana_University_Health_North_Hospital_-_Medical_-_88_-_Bates_-_a081O000012L07iQAC_-_20190708073026
D-Abbott.0137	Tab_53_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Pathology_-_2_-_Bates_-_a081O000012hKA7QAM_-_20190718154557
D-Abbott.0138	Tab_54_-_Abbott,_Travis_-_Indiana_University_Health_North_Hospital_-_Medical_-_88_-_Bates_-_a081O000012hKM8QAM_-_20190719100020
D-Abbott.0139	Tab_55_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Pathology_-_2_-_Bates_-_a081O000012kPutQAE_-_20190719154530
D-Abbott.0140	Tab_57_-_Abbott,_Travis_-_Nationwide_Children's_Hospital_-_Pathology_-_6_-_Bates_-_a081O0000130QmmQAE_-_20190801113042
D-Abbott.0141	Tab_58_-_Abbott,_Travis_-_IU_Health_Pathology_Laboratory_-_Pathology_Reports_and_Inventory_-_17_-_Bates_-_a081O000013nVeSQAU_-_20190823080014
D-Abbott.0142	Tab_59_-_Abbott,_Travis_-_IU_Health_Pathology_Laboratory_-_Pathology_Reports_and_Inventory_-_17_-_Bates_-_a081O000013vuxRQAO_-_20190828230019
D-Abbott.0143	Tab_60_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Billing_-_4_-_Bates_-_a081O000013xT0jQAE_-_20190828230021
D-Abbott.0144	Tab_61_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_489_-_Bates_-_a081O000013xRegQAE_-_20190828231514
D-Abbott.0145	Tab_62_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_501_-_Bates_-_a081O000013xRftQAE_-_20190828231522 (1)
D-Abbott.0146	Tab_63_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_480_-_Bates_-_a081O000013xRfyQAE_-_20190828231530
D-Abbott.0147	Tab_64_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_2_-_Bates_-_a081O000014Gzo0QAC_-_20190910094521
D-Abbott.0148	Tab_65_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_7_-_Bates_-_a081O000014H0hwQAC_-_20190910094523
D-Abbott.0149	Tab_66_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_489_-_Bates_-_a081O0000149j0sQAA_-_20190910100018
D-Abbott.0150	Tab_67_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_501_-_Bates_-_a081O0000149j0xQAA_-_20190910100026
D-Abbott.0151	Tab_68_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Medical_-_480_-_Bates_-_a081O0000149j17QAA_-_20190910101514
D-Abbott.0152	Tab_69_-_Abbott,_Travis_-_Indiana_University_Medical_Center_-_Billing_-_4_-_Bates_-_a081O0000149j0iQAA_-_20190910100031

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0153	Tab_70_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_2_-_Bates_-_a081O000014HOLsQAO_-_20190911124526
D-Abbott.0154	Tab_71_-_Abbott,_Travis_-_Indiana_University_Health_Methodist_Hospital_-_Radiology_-_7_-_Bates_-_a081O000014mTLPOA2_-_20190926061511
D-Abbott.0155	Deposition of Julie Abbott, dated April 4, 2019
D-Abbott.0156	Julie Abbott Facebook Photo 20111119
D-Abbott.0157	Julie Abbott Facebook Photo 20171111
D-Abbott.0158	Julie Abbott Facebook Photo 20180901
D-Abbott.0159	Julie Abbott FB Friends with L. Haggy
D-Abbott.0160	Picture of 36950 Rocksprings Road, Pomeroy Ohio
D-Abbott.0162	Roger Abbott Deposition Exhibit 1
D-Abbott.0163	Deposition of Susie Abbott, dated May 29, 2019
D-Abbott.0164	Susie Abbott Deposition Exhibit 1
D-Abbott.0165	Deposition of Leila Haggy, dated May 28, 2019
D-Abbott.0166	Leila Haggy Deposition Exhibit 1
D-Abbott.0167	Leila Haggy Deposition Exhibit 2
D-Abbott.0168	Leila Haggy Deposition Exhibit 3
D-Abbott.0169	Leila Haggy Deposition Exhibit 4
D-Abbott.0170	Leila Haggy Deposition Exhibit 5
D-Abbott.0171	Leila Haggy Deposition Exhibit 6
D-Abbott.0172	Deposition of Constantine Albany, dated May 8, 2019
D-Abbott.0173	Constantine Albany Deposition Exhibit 1
D-Abbott.0174	Constantine Albany Deposition Exhibit 2
D-Abbott.0175	Constantine Albany Deposition Exhibit 3
D-Abbott.0176	Constantine Albany Deposition Exhibit 4
D-Abbott.0177	Constantine Albany Deposition Exhibit 5
D-Abbott.0178	Constantine Albany Deposition Exhibit 6
D-Abbott.0179	Constantine Albany Deposition Exhibit 7
D-Abbott.0180	Constantine Albany Deposition Exhibit 8
D-Abbott.0181	Constantine Albany Deposition Exhibit 9
D-Abbott.0182	Constantine Albany Deposition Exhibit 10
D-Abbott.0183	Constantine Albany Deposition Exhibit 11
D-Abbott.0184	Deposition of Epiq 30(b)(6) Designee, dated October 25, 2019
D-Abbott.0185	Epiq 30(b)(6) Deposition Exhibit 1
D-Abbott.0186	Epiq 30(b)(6) Deposition Exhibit 2
D-Abbott.0187	Epiq 30(b)(6) Deposition Exhibit 3

**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0188	Epiq 30(b)(6) Deposition Exhibit 4
D-Abbott.0189	Deposition of Barry Levy, MD, dated July 3, 2019
D-Abbott.0190	Barry Levy, MD Deposition Exhibit 1
D-Abbott.0191	Barry Levy, MD Deposition Exhibit 2
D-Abbott.0192	Barry Levy, MD Deposition Exhibit 3
D-Abbott.0193	Barry Levy, MD Deposition Exhibit 4
D-Abbott.0194	Barry Levy, MD Deposition Exhibit 5
D-Abbott.0195	Barry Levy, MD Deposition Exhibit 6
D-Abbott.0196 - RESERVED	Barry Levy, MD Deposition Exhibit 7
D-Abbott.0197	Barry Levy, MD Deposition Exhibit 8
D-Abbott.0198	Barry Levy, MD Deposition Exhibit 9
D-Abbott.0199	Barry Levy, MD Deposition Exhibit 10
D-Abbott.0200	Barry Levy, MD Deposition Exhibit 11
D-Abbott.0201	Barry Levy, MD Deposition Exhibit 12
D-Abbott.0202	Barry Levy, MD Deposition Exhibit 13
D-Abbott.0203	Barry Levy, MD Deposition Exhibit 14
D-Abbott.0204	Deposition of David MacIntosh, Jr., Sc.D., C.I.H., dated June 10, 2019
D-Abbott.0205	David MacIntosh, Jr., Sc.D., C.I.H. Deposition Exhibit 1
D-Abbott.0206	David MacIntosh, Jr., Sc.D., C.I.H. Deposition Exhibit 2
D-Abbott.0207	David MacIntosh, Jr., Sc.D., C.I.H. Deposition Exhibit 3
D-Abbott.0208	David MacIntosh, Jr., Sc.D., C.I.H. Deposition Exhibit 4
D-Abbott.0209	David MacIntosh, Jr., Sc.D., C.I.H. Deposition Exhibit 5
D-Abbott.0210	Deposition of Timothy Masterson, MD, dated May 7, 2019
D-Abbott.0211	Timothy Masterson, MD Deposition Exhibit 1
D-Abbott.0212	Timothy Masterson, MD Deposition Exhibit 2
D-Abbott.0213	Timothy Masterson, MD Deposition Exhibit 3
D-Abbott.0214	Timothy Masterson, MD Deposition Exhibit 4
D-Abbott.0215	Timothy Masterson, MD Deposition Exhibit 5
D-Abbott.0216	Timothy Masterson, MD Deposition Exhibit 6
D-Abbott.0217	Timothy Masterson, MD Deposition Exhibit 7
D-Abbott.0218	Timothy Masterson, MD Deposition Exhibit 8
D-Abbott.0219	Timothy Masterson, MD Deposition Exhibit 9
D-Abbott.0220	Timothy Masterson, MD Deposition Exhibit 10
D-Abbott.0221	Timothy Masterson, MD Deposition Exhibit 11
D-Abbott.0222	Timothy Masterson, MD Deposition Exhibit 12



**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0223	Timothy Masterson, MD Deposition Exhibit 13
D-Abbott.0224	Deposition of Kamal Pohar, MD, dated June 14, 2019
D-Abbott.0225	Kamal Pohar, MD Deposition Exhibit 1
D-Abbott.0226	Kamal Pohar, MD Deposition Exhibit 2
D-Abbott.0227	Kamal Pohar, MD Deposition Exhibit 3
D-Abbott.0228	Kamal Pohar, MD Deposition Exhibit 4
D-Abbott.0229	Kamal Pohar, MD Deposition Exhibit 5
D-Abbott.0230	Kamal Pohar, MD Deposition Exhibit 6
D-Abbott.0231	Kamal Pohar, MD Deposition Exhibit 7
D-Abbott.0232	Kamal Pohar, MD Deposition Exhibit 8
D-Abbott.0233	Kamal Pohar, MD Deposition Exhibit 9
D-Abbott.0234	Kamal Pohar, MD Deposition Exhibit 10
D-Abbott.0235	Kamal Pohar, MD Deposition Exhibit 11
D-Abbott.0236	Kamal Pohar, MD Deposition Exhibit 12
D-Abbott.0237	Kamal Pohar, MD Deposition Exhibit 13
D-Abbott.0238	Kamal Pohar, MD Deposition Exhibit 14
D-Abbott.0239	Kamal Pohar, MD Deposition Exhibit 15
D-Abbott.0240	Kamal Pohar, MD Deposition Exhibit 16
D-Abbott.0241	Kamal Pohar, MD Deposition Exhibit 17
D-Abbott.0242	Kamal Pohar, MD Deposition Exhibit 18
D-Abbott.0243	Kamal Pohar, MD Deposition Exhibit 19
D-Abbott.0244	Kamal Pohar, MD Deposition Exhibit 20
D-Abbott.0245	Kamal Pohar, MD Deposition Exhibit 21
D-Abbott.0246	Deposition of Kenneth Weisman, MD, dated May 13, 2019
D-Abbott.0247	Kenneth Weisman, MD Deposition Exhibit 1
D-Abbott.0248	Kenneth Weisman, MD Deposition Exhibit 2
D-Abbott.0249	Kenneth Weisman, MD Deposition Exhibit 3
D-Abbott.0250	Kenneth Weisman, MD Deposition Exhibit 4
D-Abbott.0251	Kenneth Weisman, MD Deposition Exhibit 5
D-Abbott.0252	Kenneth Weisman, MD Deposition Exhibit 6
D-Abbott.0253	Kenneth Weisman, MD Deposition Exhibit 7
D-Abbott.0254	Kenneth Weisman, MD Deposition Exhibit 8
D-Abbott.0255	Kenneth Weisman, MD Deposition Exhibit 9
D-Abbott.0256	Kenneth Weisman, MD Deposition Exhibit 10
D-Abbott.0257	DuPont's Notice of Adoption of Expert Reports, including all materials referenced and considered - dated May 31, 2019



**Exhibit A**

*Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998  
*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136  
 DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0258	Expert Report and CV of Teresa L. Deshields, Ph.D., ABPP, FAPOS, including all materials referenced and considered - dated July 3, 2019
D-Abbott.0259	Deposition Transcript of Teresa L. Deshields, Ph.D., dated August 19, 2019
D-Abbott.0260	Teresa Deshields, Ph.D. Deposition Ex. 1
D-Abbott.0261	Teresa Deshields, Ph.D. Deposition Ex. 2
D-Abbott.0262	Teresa Deshields, Ph.D. Deposition Ex. 3
D-Abbott.0263	Teresa Deshields, Ph.D. Deposition Ex. 4
D-Abbott.0264	Teresa Deshields, Ph.D. Deposition Ex. 5
D-Abbott.0265	Teresa Deshields, Ph.D. Deposition Ex. 6
D-Abbott.0266	Teresa Deshields, Ph.D. Deposition Ex. 7
D-Abbott.0267	Expert Report and CV of Craig R. Nichols, MD, FASCO, FACP, including all materials referenced and considered - dated September 16, 2016
D-Abbott.0268	Expert Report and CV of Craig R. Nichols, MD, FASCO, FACP, including all materials referenced and considered - dated December 22, 2016 (Beckner, Boso, McClain)
D-Abbott.0269	Expert Report and CV of Craig R. Nichols, MD, FASCO, FACP, including all materials referenced and considered - dated December 22, 2016 (Huffman)
D-Abbott.0270	Expert Report and CV of Craig R. Nichols, MD, FASCO, FACP, including all materials referenced and considered - December 22, 2016 (Rizer)
D-Abbott.0271	Expert Report and CV of Craig R. Nichols, MD, FASCO, FACP, including all materials referenced and considered - dated May 31, 2019
D-Abbott.0272	Deposition Transcript of Craig R. Nichols, MD, FASCO, FACP, dated June 20, 2019
D-Abbott.0273	Craig Nichols, MD Deposition Ex. 1
D-Abbott.0274	Craig Nichols, MD Deposition Ex. 2
D-Abbott.0275	Craig Nichols, MD Deposition Ex. 3
D-Abbott.0276	Craig Nichols, MD Deposition Ex. 4
D-Abbott.0277	Craig Nichols, MD Deposition Ex. 5
D-Abbott.0278	Expert Report of Kamal S. Pohar, MD, FRCSC, dated May 21, 2019
D-Abbott.0279	Expert Report and CV of Stephen T. Washburn, including all materials referenced and considered - dated May 31, 2019 (Abbott)
D-Abbott.0280	Deposition Transcript of Stephen T. Washburn, dated July 3, 2019 (Abbott)
D-Abbott.0281	Washburn Deposition Ex. 1
D-Abbott.0282	Washburn Deposition Ex. 2
D-Abbott.0283	Washburn Deposition Ex. 3
D-Abbott.0284	Washburn Deposition Ex. 4
D-Abbott.0285	Washburn Deposition Ex. 5

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0286	Expert Report and CV of Thomas M. Wheeler, MD, including all materials referenced and considered - dated August 22, 2019
D-Abbott.0287 - D.0304 RESERVED	1994 Pathology Slides
D-Abbott.0305	Commission on Cancer - Program Standards 2012: Ensuring Patient-Centered Care
D-Abbott.0306	S. Gonzalez-Fernandez, C. Fernandez-Rodriguez; Acceptance and Commitment Therapy in Cancer: Review of Applications and Findings. <i>Behavioral Medicine</i> , 45:3, 255-269 (3/20/19)
D-Abbott.0307	K. Darabos, M. Hoyt; Cancer-Related Worry and Physical Well-Being in the Context of Perceived Stress in Young Adults with Testicular Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 6(2), 363-366 (11/2/17)
D-Abbott.0308	N-N. Lu, A. Hansen, P. Bedard, et al.; Excellent outcomes in bilateral testicular germ cell tumors over four decades; <i>Journal of Clinical Oncology</i> , 37.3, Suppl. 523 (2019)
D-Abbott.0309	S. Lebel, G. Ozankinci, G. Humphris, et al.; From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. DOI 10.1997/s00520-016-32772-5 (5/5/16)
D-Abbott.0310	A. Pedersen, P. Rossen, F. Olesen, et al.; Fear of recurrence and casual attributions in long-term survivors of testicular cancer. <i>Psycho-Oncology</i> 21: 1222-1229 (2012)
D-Abbott.0311	A. Pitman, S. Suleman, N. Hyde, et al.; Depression and anxiety in patients with cancer. <i>BMJ</i> 2018;361 :k1415 doi: 1136/bmj.k1415 (4/25/18)
D-Abbott.0312	W. Strohsnitter; Prenatal Diethylstilbestrol Exposure: A Harbinger for Future Testicular Cancer Incidence? <i>JNCI Cancer Spectrum</i> (6/13/19) 3(3): pkz046
D-Abbott.0313	P. Rossen, A. Pedersen, R. Zachariae, H. vonder Maase; Health-Related Quality of Life in Long-Term Survivors of Testicular Cancer. <i>Journal of Clinical Oncology</i> , 27(35), 5993-5999 (12/20/09)
D-Abbott.0314	A. Smith, P. Butow, I. Oliver, T. Lockett, et al.; The prevalence, severity,, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <a href="http://www.researchgate.net/publication/280121098">http://www.researchgate.net/publication/280121098</a> (2015)
D-Abbott.0315	L. Traeger, J. Greer, C. Fernandez-Robles, J. Temel, W. Pirl; Evidence-Based Treatment of Anxiety in Patients with Cancer. <i>Journal of Clinical Oncology</i> 30(11), 1197-1205 (4/10/12)
D-Abbott.0316	C. Hoei-Hansen, E. Rajpert-De Meyts, G. Daugaard, N. Skakkebaek; Carcinoma <i>in situ</i> testis, the progenitor of testicular germ cell tumors: a clinical review; <i>Annals of Oncology</i> 16: 863-868 (2005)

**Exhibit A***Abbott v. E. I. du Pont de Nemours and Company*, Case No. 2:17-cv-00998*Swartz v. E. I. du Pont de Nemours and Company*, Case No. 2:18-cv-00136

## DuPont's Trial Exhibit List

<b>Exhibit Number</b>	<b>Description</b>
D-Abbott.0317	C. Loveday, P. Law, K. Litchfield, et al.; Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. <i>European Urology</i> 74, 248-252 (2002)
D-Abbott.0318	C. Nichols, B. Roth, S. Williams, et al.; No Evidence of Acute Cardiovascular Complications of Chemotherapy for Testicular Cancer: An Analysis of the Testicular Cancer Intergroup Study. <i>Journal of Clinical Oncology</i> 10(5); 760-765 (May, 1992)
D-Abbott.0319	K. Litchfield, M. Levy, R. Huddart, J. Shipley, C. Turnbull; The genomic landscape of testicular germ cell tumors: from susceptibility to treatment. <i>Nature Reviews / Urology</i> , 33; 409-419 (July 2016)
D-Abbott.0320	K. Litchfield, M. Levy, G. Orlando, et al.; Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. <i>Nature Genetics</i> , 49; 1133-1143 (July 2017)
D-Abbott.0321	N. Skakkebaek, E. Rajpert-De Meyts, G. Louis, et al; Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. <i>Physiol Rev</i> 96: 55-97 (2016)
D-Abbott.0322	L. Pyle, K. Nathanson; Genetic changes associated with testicular cancer susceptibility. <i>Seminars in Oncology</i> 43; 575-581 (2016)
D-Abbott.0323	N. Skakkebaek; Testicular dysgenesis syndrome: clinical and environmental aspects. <i>Endocrine Abstracts</i> 15 S3 (2008)
D-Abbott.0324	R. Kopp, M. Chevinsky, M. Bernstein, et al; Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 103; 154-160 (2017)
D-Abbott.0325	C. Nichols; Mediastinal Germ Cell Tumors. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 4(1); 45-50 (1992)
D-Abbott.0326	C. Nichols; Treatment of Recurrent Germ Cell Tumors. <i>Seminars in Surgical Oncology</i> , 17: 268-274 (1999)
D-Abbott.0327	C. Nichols, E. Broun; Chapter 60 Germ-cell Cancer. 802-813
D-Abbott.0328	Holland - Fei; <i>Cancer Medicine</i> 7 (2006)
D-Abbott.0329	M. Garzotto, C. Nichols; Current Concepts in Risk Factor Assessment for Advanced Germ Cell Cancer. <i>Seminars in Urologic Oncology</i> , 19(3); 165-169 (2001)
RESERVED	Travis Abbot Phone Records (Pending discovery)
RESERVED	Abbott Tax Records or Stipulation (Pending discovery)
RESERVED	Records of Dr. Grant (Pending discovery authorization and request)
RESERVED	Records of Kathy Brown (Pending discovery)
RESERVED	Abbott Property Deeds (Pending discovery)
RESERVED	Travis Abbott Retention Agreement with Counsel (Pending discovery)
RESERVED	Pre-orchietomy birth control medical records (Pending discovery)